

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
001 ALAN AMINO	ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE	20 %									
2023-001	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	120.857	3.681	3.05	97.000	145.000				
2023-001	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	125.200	3.919	3.13	100.000	150.000				
2023-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	88	130.814	3.737	2.86	105.000	157.000				
2023-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	22	116.619	2.919	2.50	93.000	140.000				
2023-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	107.552	3.212	2.99	86.000	129.000				
2023-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	39	129.333	10.965	8.48	103.000	155.000				
2023-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	39	134.421	9.072	6.75	108.000	161.000				
2023-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	34	118.848	2.244	1.89	95.000	143.000				
2023-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	11	141.727	11.841	8.35	113.000	170.000				
2023-001	12 IFCC witho	203 ROCHE	93 ROCHE	11	119.818	2.516	2.10	96.000	144.000				
2023-001	13 ALA &aKETO	165 VITROS	155 ALTV	131	113.527	3.184	2.81	91.000	136.000				
2023-002	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	78.364	3.038	3.88	63.000	94.000				
2023-002	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	84.200	1.887	2.24	67.000	101.000				
2023-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	88	85.713	2.791	3.26	69.000	103.000				
2023-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	22	75.500	2.726	3.61	60.000	91.000				
2023-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	69.655	2.022	2.90	56.000	84.000				
2023-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	39	87.605	5.284	6.03	70.000	105.000				
2023-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	39	83.667	5.793	6.92	67.000	100.000				
2023-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	34	76.941	2.071	2.69	62.000	92.000				
2023-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	11	89.455	3.394	3.79	72.000	107.000				
2023-002	12 IFCC witho	203 ROCHE	93 ROCHE	11	77.909	1.975	2.54	62.000	93.000				
2023-002	13 ALA &aKETO	165 VITROS	155 ALTV	131	73.713	2.186	2.97	59.000	88.000				
2023-003	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	22	405.682	15.446	3.81	325.000	487.000				
2023-003	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	380.000	13.221	3.48	304.000	456.000				
2023-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	88	416.747	12.835	3.08	333.000	500.000				
2023-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	22	381.409	13.422	3.52	305.000	458.000				
2023-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	29	357.414	12.280	3.44	286.000	429.000				

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	439.667	40.664	9.25	352.000	528.000	
2023-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	432.684	32.374	7.48	346.000	519.000	
2023-003	11 MOD. IFCC	203 ROCHE	93 ROCHE		34	392.545	10.299	2.62	314.000	471.000	
2023-003	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	450.000	19.240	4.28	360.000	540.000	
2023-003	12 IFCC witho	203 ROCHE	93 ROCHE		11	407.636	37.395	9.17	326.000	489.000	
2023-003	13 ALA &aKETO	165 VITROS	155 ALTV		131	361.391	12.088	3.34	289.000	434.000	
001 ALAN AMINO ALT/SGPT		CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 20 %								
2023-004	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT		22	217.682	7.394	3.40	174.000	261.000	
2023-004	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	217.700	5.533	2.54	174.000	261.000	
2023-004	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS		88	231.070	7.039	3.05	185.000	277.000	
2023-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE		22	209.773	7.160	3.41	168.000	252.000	
2023-004	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	193.655	7.023	3.63	155.000	232.000	
2023-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	242.947	16.080	6.62	194.000	292.000	
2023-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	235.667	22.867	9.70	189.000	283.000	
2023-004	11 MOD. IFCC	203 ROCHE	93 ROCHE		34	214.091	5.160	2.41	171.000	257.000	
2023-004	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	248.091	9.010	3.63	198.000	298.000	
2023-004	12 IFCC witho	203 ROCHE	93 ROCHE		11	215.091	5.501	2.56	172.000	258.000	
2023-004	13 ALA &aKETO	165 VITROS	155 ALTV		131	202.515	5.800	2.86	162.000	243.000	
2023-005	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT		22	295.000	10.518	3.57	236.000	354.000	
2023-005	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	289.300	6.388	2.21	231.000	347.000	
2023-005	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS		88	310.284	9.113	2.94	248.000	372.000	
2023-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE		22	282.500	11.614	4.11	226.000	339.000	
2023-005	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	261.607	8.886	3.40	209.000	314.000	
2023-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	315.000	27.857	8.84	252.000	378.000	
2023-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		39	330.132	22.472	6.81	264.000	396.000	
2023-005	11 MOD. IFCC	203 ROCHE	93 ROCHE		34	287.794	6.182	2.15	230.000	345.000	
2023-005	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	333.000	11.809	3.55	266.000	400.000	
2023-005	12 IFCC witho	203 ROCHE	93 ROCHE		11	290.545	9.375	3.23	232.000	349.000	
2023-005	13 ALA &aKETO	165 VITROS	155 ALTV		131	270.031	6.643	2.46	216.000	324.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %					
2023-001	3 DYE BI-B.G	165 VITROS	63 KODAK		147	2.926	0.106	3.61	2.600	3.200	
2023-001	3 DYE BI-B.G	184 INTEGRA	93 ROCHE		32	2.958	0.101	3.41	2.700	3.300	
2023-001	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN		29	2.834	0.084	2.97	2.600	3.100	
2023-001	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX		40	2.960	0.086	2.91	2.700	3.300	
2023-001	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT		14	2.793	0.110	3.94	2.500	3.100	
2023-001	3 DYE BI-B.G	203 ROCHE	93 ROCHE		45	3.016	0.103	3.42	2.700	3.300	
2023-001	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS		11	2.873	0.062	2.15	2.600	3.200	
2023-001	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS		92	2.626	0.082	3.12	2.400	2.900	
2023-001	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT		10	2.710	0.137	5.07	2.400	3.000	
2023-002	3 DYE BI-B.G	165 VITROS	63 KODAK		147	2.533	0.082	3.23	2.300	2.800	
2023-002	3 DYE BI-B.G	184 INTEGRA	93 ROCHE		32	2.584	0.083	3.22	2.300	2.800	
2023-002	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN		29	2.486	0.073	2.94	2.200	2.700	
2023-002	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX		40	2.620	0.075	2.86	2.400	2.900	
2023-002	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT		14	2.450	0.073	2.99	2.200	2.700	
2023-002	3 DYE BI-B.G	203 ROCHE	93 ROCHE		45	2.671	0.102	3.84	2.400	2.900	
2023-002	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS		11	2.482	0.039	1.55	2.200	2.700	
2023-002	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS		92	2.273	0.074	3.27	2.000	2.500	
2023-002	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT		10	2.360	0.120	5.08	2.100	2.600	
2023-003	3 DYE BI-B.G	165 VITROS	63 KODAK		147	5.849	0.164	2.80	5.300	6.400	
2023-003	3 DYE BI-B.G	184 INTEGRA	93 ROCHE		32	5.378	0.139	2.58	4.800	5.900	
2023-003	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN		29	5.238	0.142	2.72	4.700	5.800	
2023-003	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX		40	5.253	0.140	2.66	4.700	5.800	
2023-003	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT		14	5.200	0.068	1.31	4.700	5.700	
2023-003	3 DYE BI-B.G	203 ROCHE	93 ROCHE		45	5.557	0.200	3.61	5.000	6.100	
2023-003	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS		11	5.391	0.100	1.85	4.900	5.900	
2023-003	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS		92	5.093	0.162	3.17	4.600	5.600	
2023-003	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT		10	5.050	0.201	3.99	4.500	5.600	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
002	ALBUMIN	CLIA TEST ID #: 265				EVALUATION CRITERIA: TARGET VALUE 10 %					
2023-004	3 DYE BI-B.G	165 VITROS	63 KODAK	147	3.951	0.144	3.64	3.600	4.300		
2023-004	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	32	3.852	0.091	2.37	3.500	4.200		
2023-004	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	29	3.700	0.095	2.56	3.300	4.100		
2023-004	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	40	3.810	0.102	2.68	3.400	4.200		
2023-004	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	14	3.700	0.065	1.77	3.300	4.100		
2023-004	3 DYE BI-B.G	203 ROCHE	93 ROCHE	45	3.964	0.161	4.06	3.600	4.400		
2023-004	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	11	3.791	0.090	2.37	3.400	4.200		
2023-004	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	92	3.496	0.126	3.59	3.100	3.800		
2023-004	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT	10	3.550	0.175	4.92	3.200	3.900		
2023-005	3 DYE BI-B.G	165 VITROS	63 KODAK	147	4.796	0.175	3.64	4.300	5.300		
2023-005	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	32	4.491	0.153	3.40	4.000	4.900		
2023-005	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	29	4.348	0.122	2.81	3.900	4.800		
2023-005	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	40	4.433	0.129	2.91	4.000	4.900		
2023-005	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	14	4.321	0.101	2.34	3.900	4.800		
2023-005	3 DYE BI-B.G	203 ROCHE	93 ROCHE	45	4.640	0.154	3.32	4.200	5.100		
2023-005	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	11	4.473	0.105	2.35	4.000	4.900		
2023-005	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	92	4.179	0.124	2.98	3.800	4.600		
2023-005	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT	10	4.190	0.192	4.58	3.800	4.600		
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %					
2023-001	3 COLORIMET.	184 INTEGRA	93 ROCHE	28	103.571	4.716	4.55	73.000	135.000		
2023-001	3 COLORIMET.	203 ROCHE	93 ROCHE	31	101.129	5.229	5.17	71.000	131.000		
2023-001	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	93.100	4.784	5.14	65.000	121.000		
2023-001	6 KINETIC 37	165 VITROS	63 KODAK	147	104.459	6.240	5.97	73.000	136.000		
2023-001	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	82.900	4.415	5.33	58.000	108.000		
2023-001	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	28	85.214	6.971	8.18	60.000	111.000		
2023-001	10 IFCC	219 ATELLICA	143 SIEMENS	11	100.636	2.603	2.59	70.000	131.000		
2023-001	11 Modified I	38 SIEMENS DI	143 SIEMENS	84	106.952	6.816	6.37	75.000	139.000		
2023-001	11 Modified I	191 RX-SERIES	126 RANDOX	31	89.677	11.485	12.81	63.000	117.000		

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
2023-001	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	12	92.000	5.627	6.12	64.000	120.000				
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE	30	%								
2023-002	3 COLORIMET.	184 INTEGRA	93 ROCHE	28	70.786	3.266	4.61	50.000	92.000				
2023-002	3 COLORIMET.	203 ROCHE	93 ROCHE	31	69.226	3.678	5.31	48.000	90.000				
2023-002	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	64.455	3.652	5.67	45.000	84.000				
2023-002	6 KINETIC 37	165 VITROS	63 KODAK	147	80.226	4.664	5.81	56.000	104.000				
2023-002	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	56.500	2.655	4.70	40.000	73.000				
2023-002	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	28	58.143	4.756	8.18	41.000	76.000				
2023-002	10 IFCC	219 ATELLICA	143 SIEMENS	11	68.636	3.199	4.66	48.000	89.000				
2023-002	11 Modified I	38 SIEMENS DI	143 SIEMENS	84	73.439	5.063	6.89	51.000	95.000				
2023-002	11 Modified I	191 RX-SERIES	126 RANDOX	31	61.677	8.173	13.25	43.000	80.000				
2023-002	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	12	62.833	3.738	5.95	44.000	82.000				
2023-003	3 COLORIMET.	184 INTEGRA	93 ROCHE	28	337.259	10.807	3.20	236.000	438.000				
2023-003	3 COLORIMET.	203 ROCHE	93 ROCHE	31	326.194	14.740	4.52	228.000	424.000				
2023-003	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	306.273	19.744	6.45	214.000	398.000				
2023-003	6 KINETIC 37	165 VITROS	63 KODAK	147	177.483	11.864	6.68	124.000	231.000				
2023-003	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	270.400	13.071	4.83	189.000	352.000				
2023-003	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	28	279.607	24.427	8.74	196.000	363.000				
2023-003	10 IFCC	219 ATELLICA	143 SIEMENS	11	324.727	7.875	2.43	227.000	422.000				
2023-003	11 Modified I	38 SIEMENS DI	143 SIEMENS	84	347.634	12.700	3.65	243.000	452.000				
2023-003	11 Modified I	191 RX-SERIES	126 RANDOX	31	270.806	29.761	10.99	190.000	352.000				
2023-003	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	12	300.750	18.462	6.14	211.000	391.000				
2023-004	3 COLORIMET.	184 INTEGRA	93 ROCHE	28	182.259	6.028	3.31	128.000	237.000				
2023-004	3 COLORIMET.	203 ROCHE	93 ROCHE	31	176.833	9.011	5.10	124.000	230.000				
2023-004	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	165.000	8.644	5.24	116.000	215.000				
2023-004	6 KINETIC 37	165 VITROS	63 KODAK	147	145.320	8.730	6.01	102.000	189.000				
2023-004	6 KINETIC 37	215 B.C DXC	134 BECKM.COUL	10	148.100	6.379	4.31	104.000	193.000				
2023-004	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	28	150.429	11.682	7.77	105.000	196.000				

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2023-004	10 IFCC	219 ATELLICA	143	SIEMENS	11	177.545	4.229	2.38	124.000	231.000		
2023-004	11 Modified I	38 SIEMENS DI	143	SIEMENS	84	189.366	8.540	4.51	133.000	246.000		
2023-004	11 Modified I	191 RX-SERIES	126	RANDOX	31	153.516	18.658	12.15	107.000	200.000		
2023-004	12 P NITRO PH	197 ARCHITECT	1	ABBOTT	12	162.250	7.595	4.68	114.000	211.000		
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE 30 %									
2023-005	3 COLORIMET.	184 INTEGRA	93	ROCHE	28	245.185	8.161	3.33	172.000	319.000		
2023-005	3 COLORIMET.	203 ROCHE	93	ROCHE	31	237.839	10.836	4.56	166.000	309.000		
2023-005	5 KINETIC 30	197 ARCHITECT	1	ABBOTT	11	220.818	11.496	5.21	155.000	287.000		
2023-005	6 KINETIC 37	165 VITROS	63	KODAK	147	165.333	10.501	6.35	116.000	215.000		
2023-005	6 KINETIC 37	215 B.C DXC	134	BECKM.COUL	10	200.000	9.306	4.65	140.000	260.000		
2023-005	8 BOW. MC-37	186 BECK. COUL	76	AU-BECKMAN	28	203.143	16.649	8.20	142.000	264.000		
2023-005	10 IFCC	219 ATELLICA	143	SIEMENS	11	240.000	7.186	2.99	168.000	312.000		
2023-005	11 Modified I	38 SIEMENS DI	143	SIEMENS	84	254.952	9.292	3.64	178.000	331.000		
2023-005	11 Modified I	191 RX-SERIES	126	RANDOX	31	202.419	22.772	11.25	142.000	263.000		
2023-005	12 P NITRO PH	197 ARCHITECT	1	ABBOTT	12	217.417	12.176	5.60	152.000	283.000		
004	AMYLASE	CLIA TEST ID #: 285										
2023-001	3 ENZYM. 37C	165 VITROS	63	KODAK	85	72.250	4.399	6.09	51.000	94.000		
2023-001	3 ENZYM. 37C	215 B.C DXC	134	BECKM.COUL	10	105.800	2.088	1.97	74.000	138.000		
2023-001	4 HYDRO ACT.	38 SIEMENS DI	143	SIEMENS	27	96.704	2.069	2.14	68.000	126.000		
2023-001	9 ENZ/COL.37	184 INTEGRA	93	ROCHE	11	99.800	1.249	1.25	70.000	130.000		
2023-001	9 ENZ/COL.37	203 ROCHE	93	ROCHE	23	98.522	1.716	1.74	69.000	128.000		
2023-001	10 CNPG3	186 BECK. COUL	76	AU-BECKMAN	16	76.438	3.020	3.95	54.000	99.000		
2023-002	3 ENZYM. 37C	165 VITROS	63	KODAK	85	51.337	4.221	8.22	36.000	67.000		
2023-002	3 ENZYM. 37C	215 B.C DXC	134	BECKM.COUL	10	72.900	1.640	2.25	51.000	95.000		
2023-002	4 HYDRO ACT.	38 SIEMENS DI	143	SIEMENS	27	66.185	1.700	2.57	46.000	86.000		
2023-002	9 ENZ/COL.37	184 INTEGRA	93	ROCHE	11	69.091	2.466	3.57	48.000	90.000		
2023-002	9 ENZ/COL.37	203 ROCHE	93	ROCHE	23	68.739	1.621	2.36	48.000	89.000		
2023-002	10 CNPG3	186 BECK. COUL	76	AU-BECKMAN	16	52.063	2.277	4.37	36.000	68.000		

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
004	AMYLASE		CLIA TEST ID #: 285			EVALUATION CRITERIA: TARGET VALUE	30 %				
2023-003	3 ENZYM. 37C	165 VITROS	63 KODAK		85	216.964	8.950	4.13	152.000	282.000	
2023-003	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL		10	327.000	6.826	2.09	229.000	425.000	
2023-003	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS		27	301.370	8.097	2.69	211.000	392.000	
2023-003	9 ENZ/COL.37	184 INTEGRA	93 ROCHE		11	304.545	9.365	3.08	213.000	396.000	
2023-003	9 ENZ/COL.37	203 ROCHE	93 ROCHE		23	306.087	6.310	2.06	214.000	398.000	
2023-003	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN		16	238.500	9.192	3.85	167.000	310.000	
2023-004	3 ENZYM. 37C	165 VITROS	63 KODAK		85	123.690	5.477	4.43	87.000	161.000	
2023-004	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL		10	182.400	4.565	2.50	128.000	237.000	
2023-004	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS		27	167.037	3.024	1.81	117.000	217.000	
2023-004	9 ENZ/COL.37	184 INTEGRA	93 ROCHE		11	167.909	5.334	3.18	118.000	218.000	
2023-004	9 ENZ/COL.37	203 ROCHE	93 ROCHE		23	168.273	3.018	1.79	118.000	219.000	
2023-004	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN		16	131.563	5.788	4.40	92.000	171.000	
2023-005	3 ENZYM. 37C	165 VITROS	63 KODAK		85	164.750	6.945	4.22	115.000	214.000	
2023-005	3 ENZYM. 37C	215 B.C DXC	134 BECKM.COUL		10	244.000	6.957	2.85	171.000	317.000	
2023-005	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS		27	223.889	4.237	1.89	157.000	291.000	
2023-005	9 ENZ/COL.37	184 INTEGRA	93 ROCHE		11	223.727	8.302	3.71	157.000	291.000	
2023-005	9 ENZ/COL.37	203 ROCHE	93 ROCHE		23	225.043	3.917	1.74	158.000	293.000	
2023-005	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN		16	174.188	7.493	4.30	122.000	226.000	
005	ASP. AMINO AST/SGOT		CLIA TEST ID #: 295			EVALUATION CRITERIA: TARGET VALUE	20 %				
2023-001	1 ASPAR&KETO	165 VITROS	63 KODAK		145	160.069	5.951	3.72	128.000	192.000	
2023-001	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS		92	144.207	4.437	3.08	115.000	173.000	
2023-001	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	142.600	3.323	2.33	114.000	171.000	
2023-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE		24	144.750	6.716	4.64	116.000	174.000	
2023-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	126.759	5.934	4.68	101.000	152.000	
2023-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	165.750	5.356	3.23	133.000	199.000	
2023-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	165.100	8.800	5.33	132.000	198.000	
2023-001	11 MOD. IFCC	203 ROCHE	93 ROCHE		32	145.875	4.547	3.12	117.000	175.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	163.300	2.685	1.64	131.000	196.000	
2023-001	12 IFCC witho	203 ROCHE	93 ROCHE		11	144.091	7.077	4.91	115.000	173.000	
2023-001	13 NADH wo P5	197 ARCHITECT	1 ABBOTT		14	137.143	6.896	5.03	110.000	165.000	
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 20 %							
2023-002	1 ASPAR&KETO	165 VITROS	63 KODAK		145	112.106	3.482	3.11	90.000	135.000	
2023-002	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS		92	102.374	3.314	3.24	82.000	123.000	
2023-002	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	102.600	2.458	2.40	82.000	123.000	
2023-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE		24	103.000	4.528	4.40	82.000	124.000	
2023-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	90.000	3.391	3.77	72.000	108.000	
2023-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	117.450	6.387	5.44	94.000	141.000	
2023-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	120.000	4.301	3.58	96.000	144.000	
2023-002	11 MOD. IFCC	203 ROCHE	93 ROCHE		32	103.656	3.294	3.18	83.000	124.000	
2023-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	117.636	4.118	3.50	94.000	141.000	
2023-002	12 IFCC witho	203 ROCHE	93 ROCHE		11	101.727	4.712	4.63	81.000	122.000	
2023-002	13 NADH wo P5	197 ARCHITECT	1 ABBOTT		14	97.786	3.967	4.06	78.000	117.000	
2023-003	1 ASPAR&KETO	165 VITROS	63 KODAK		145	560.014	26.365	4.71	448.000	672.000	
2023-003	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS		92	426.363	13.831	3.24	341.000	512.000	
2023-003	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	394.700	11.498	2.91	316.000	474.000	
2023-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE		24	413.375	16.805	4.07	331.000	496.000	
2023-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	363.000	18.892	5.20	290.000	436.000	
2023-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	444.500	8.292	1.87	356.000	533.000	
2023-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	464.125	48.226	10.39	371.000	557.000	
2023-003	11 MOD. IFCC	203 ROCHE	93 ROCHE		32	419.548	13.385	3.19	336.000	503.000	
2023-003	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	468.091	11.642	2.49	374.000	562.000	
2023-003	12 IFCC witho	203 ROCHE	93 ROCHE		11	427.182	33.645	7.88	342.000	513.000	
2023-003	13 NADH wo P5	197 ARCHITECT	1 ABBOTT		14	394.786	18.040	4.57	316.000	474.000	
2023-004	1 ASPAR&KETO	165 VITROS	63 KODAK		145	281.806	10.462	3.71	225.000	338.000	
2023-004	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS		92	241.451	7.425	3.08	193.000	290.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-004	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	233.900	7.063	3.02	187.000	281.000	
2023-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE		24	239.750	10.051	4.19	192.000	288.000	
2023-004	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	208.821	9.079	4.35	167.000	251.000	
2023-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	273.600	15.570	5.69	219.000	328.000	
2023-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	274.750	16.161	5.88	220.000	330.000	
2023-004	11 MOD. IFCC	203 ROCHE	93 ROCHE		32	241.871	7.308	3.02	193.000	290.000	
2023-004	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	273.200	6.337	2.32	219.000	328.000	
2023-004	12 IFCC witho	203 ROCHE	93 ROCHE		11	238.273	11.553	4.85	191.000	286.000	
2023-004	13 NADH wo P5	197 ARCHITECT	1 ABBOTT		14	229.143	6.988	3.05	183.000	275.000	
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 20 %							
2023-005	1 ASPAR&KETO	165 VITROS	63 KODAK		145	393.583	15.531	3.95	315.000	472.000	
2023-005	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS		92	319.837	8.775	2.74	256.000	384.000	
2023-005	10 KINETIC 37	215 B.C DXC	134 BECKM.COUL		10	304.500	7.103	2.33	244.000	365.000	
2023-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE		24	312.375	12.835	4.11	250.000	375.000	
2023-005	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN		29	272.107	12.913	4.75	218.000	327.000	
2023-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	353.500	10.235	2.90	283.000	424.000	
2023-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX		41	356.950	27.085	7.59	286.000	428.000	
2023-005	11 MOD. IFCC	203 ROCHE	93 ROCHE		32	316.750	8.828	2.79	253.000	380.000	
2023-005	11 MOD. IFCC	219 ATELLICA	143 SIEMENS		11	355.909	7.204	2.02	285.000	427.000	
2023-005	12 IFCC witho	203 ROCHE	93 ROCHE		11	311.727	18.489	5.93	249.000	374.000	
2023-005	13 NADH wo P5	197 ARCHITECT	1 ABBOTT		14	298.929	12.291	4.11	239.000	359.000	
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305									
2023-001	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		89	1.733	0.029	1.65	1.390	2.080	
2023-001	4 J-G WITH B	38 SIEMENS DI	143 SIEMENS		89	1.766	0.105	5.96	1.410	2.120	
2023-001	4 J-G WITH B	186 BECK. COUL	76 AU-BECKMAN		28	1.820	0.056	3.07	1.460	2.180	
2023-001	4 J-G WITH B	191 RX-SERIES	126 RANDOX		30	1.762	0.112	6.37	1.410	2.110	
2023-001	4 J-G WITH B	191 RX-SERIES	126 RANDOX		30	1.762	0.097	5.52	1.410	2.110	
2023-001	5 J-G NO BK.	215 B.C DXC	134 BECKM.COUL		10	1.996	0.133	6.64	1.600	2.400	
2023-001	7 DIAZO-DYPH	165 VITROS	63 KODAK		144	1.704	0.114	6.70	1.360	2.050	
2023-001	13 AZOBIL.	184 INTEGRA	93 ROCHE		14	1.554	0.058	3.73	1.240	1.860	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-001	13	AZOBIL.	203	ROCHE	93	ROCHE	30	1.567	0.055	3.53	1.250	1.880
2023-001	14	VANADATE	219	ATELLICA	143	SIEMENS	11	1.876	0.121	6.47	1.500	2.250
2023-001	14	VANADATE	219	ATELLICA	143	SIEMENS	11	2.140	0.097	4.52	1.710	2.570
2023-001	18	COLORIMETR	184	INTEGRA	93	ROCHE	11	1.558	0.098	6.29	1.250	1.870
2023-001	18	COLORIMETR	203	ROCHE	93	ROCHE	14	1.566	0.073	4.66	1.250	1.880
2023-001	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	1.869	0.092	4.94	1.500	2.240
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 %								
2023-002	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	1.024	0.071	6.91	0.820	1.230
2023-002	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	1.013	0.024	2.33	0.810	1.220
2023-002	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	1.091	0.032	2.92	0.870	1.310
2023-002	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	1.033	0.094	9.13	0.830	1.240
2023-002	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	1.018	0.050	4.91	0.810	1.220
2023-002	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	1.296	0.117	9.02	1.040	1.560
2023-002	7	DIAZO-DYPH	165	VITROS	63	KODAK	144	1.037	0.086	8.26	0.830	1.240
2023-002	13	AZOBIL.	184	INTEGRA	93	ROCHE	14	0.908	0.046	5.05	0.730	1.090
2023-002	13	AZOBIL.	203	ROCHE	93	ROCHE	30	0.916	0.036	3.94	0.730	1.100
2023-002	14	VANADATE	219	ATELLICA	143	SIEMENS	11	1.096	0.075	6.87	0.880	1.320
2023-002	14	VANADATE	219	ATELLICA	143	SIEMENS	11	1.273	0.086	6.77	1.020	1.530
2023-002	18	COLORIMETR	184	INTEGRA	93	ROCHE	11	0.902	0.068	7.59	0.720	1.080
2023-002	18	COLORIMETR	203	ROCHE	93	ROCHE	14	0.917	0.039	4.27	0.730	1.100
2023-002	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	1.129	0.050	4.45	0.900	1.350
2023-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	6.667	0.050	0.75	5.330	8.000
2023-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	6.780	0.410	6.05	5.420	8.140
2023-003	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	6.525	0.174	2.66	5.220	7.830
2023-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	6.861	0.488	7.12	5.490	8.230
2023-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	6.888	0.584	8.47	5.510	8.270
2023-003	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	7.226	0.182	2.52	5.780	8.670
2023-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	144	6.335	0.289	4.56	5.070	7.600
2023-003	13	AZOBIL.	184	INTEGRA	93	ROCHE	14	5.975	0.219	3.67	4.780	7.170

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-003	13	AZOBIL.	203	ROCHE	93	ROCHE	30	6.092	0.324	5.31	4.870	7.310
2023-003	14	VANADATE	219	ATELLICA	143	SIEMENS	11	7.199	0.479	6.66	5.760	8.640
2023-003	14	VANADATE	219	ATELLICA	143	SIEMENS	11	7.910	0.445	5.63	6.330	9.490
2023-003	18	COLORIMETR	184	INTEGRA	93	ROCHE	11	6.067	0.365	6.01	4.850	7.280
2023-003	18	COLORIMETR	203	ROCHE	93	ROCHE	14	6.068	0.256	4.21	4.850	7.280
2023-003	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	6.854	0.270	3.94	5.480	8.220
006 BILIRUBIN, TOTAL			CLIA TEST ID #: 305		EVALUATION CRITERIA: TARGET VALUE 20 %							
2023-004	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	3.383	0.062	1.84	2.710	4.060
2023-004	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	3.452	0.261	7.55	2.760	4.140
2023-004	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	3.436	0.089	2.60	2.750	4.120
2023-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	3.444	0.226	6.55	2.760	4.130
2023-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	3.459	0.222	6.41	2.770	4.150
2023-004	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	3.704	0.091	2.45	2.960	4.440
2023-004	7	DIAZO-DYPH	165	VITROS	63	KODAK	144	3.225	0.166	5.14	2.580	3.870
2023-004	13	AZOBIL.	184	INTEGRA	93	ROCHE	14	3.038	0.082	2.71	2.430	3.650
2023-004	13	AZOBIL.	203	ROCHE	93	ROCHE	30	3.090	0.131	4.25	2.470	3.710
2023-004	14	VANADATE	219	ATELLICA	143	SIEMENS	11	4.159	0.246	5.91	3.330	4.990
2023-004	14	VANADATE	219	ATELLICA	143	SIEMENS	11	3.685	0.273	7.40	2.950	4.420
2023-004	18	COLORIMETR	184	INTEGRA	93	ROCHE	11	3.070	0.206	6.69	2.460	3.680
2023-004	18	COLORIMETR	203	ROCHE	93	ROCHE	14	3.081	0.159	5.15	2.470	3.700
2023-004	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	3.550	0.103	2.91	2.840	4.260
2023-005	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	4.841	0.295	6.09	3.870	5.810
2023-005	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	89	4.713	0.050	1.06	3.770	5.660
2023-005	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	28	4.710	0.123	2.61	3.770	5.650
2023-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	4.851	0.370	7.63	3.880	5.820
2023-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	30	4.806	0.397	8.25	3.840	5.770
2023-005	5	J-G NO BK.	215	B.C DXC	134	BECKM.COUL	10	5.194	0.204	3.93	4.160	6.230
2023-005	7	DIAZO-DYPH	165	VITROS	63	KODAK	144	4.493	0.241	5.36	3.590	5.390
2023-005	13	AZOBIL.	184	INTEGRA	93	ROCHE	14	4.226	0.157	3.72	3.380	5.070

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-005	13	AZOBIL.	203	ROCHE	93	ROCHE	30	4.330	0.162	3.74	3.460	5.200
2023-005	14	VANADATE	219	ATELLICA	143	SIEMENS	11	5.126	0.369	7.21	4.100	6.150
2023-005	14	VANADATE	219	ATELLICA	143	SIEMENS	11	5.661	0.254	4.49	4.530	6.790
2023-005	18	COLORIMETR	184	INTEGRA	93	ROCHE	11	4.294	0.272	6.33	3.430	5.150
2023-005	18	COLORIMETR	203	ROCHE	93	ROCHE	14	4.335	0.151	3.47	3.470	5.200
2023-005	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	4.854	0.125	2.57	3.880	5.820
010	CALCIUM, TOTAL	CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00								
2023-001	3	ARSEN.-III	165	VITROS	63	KODAK	161	7.353	0.183	2.49	6.400	8.400
2023-001	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	31	7.619	0.169	2.22	6.600	8.600
2023-001	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	41	8.222	0.305	3.71	7.200	9.200
2023-001	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	41	7.858	0.284	3.61	6.900	8.900
2023-001	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	14	7.593	0.139	1.83	6.600	8.600
2023-001	3	ARSEN.-III	220	Medica E.	99	STAMBIO	10	7.560	0.233	3.09	6.600	8.600
2023-001	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	93	7.500	0.219	2.92	6.500	8.500
2023-001	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	16	7.638	0.218	2.85	6.600	8.600
2023-001	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.760	0.242	3.11	6.800	8.800
2023-001	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	11	7.382	0.217	2.94	6.400	8.400
2023-001	14	ELECTRODE	215	B.C DXC	134	BECKM.COUL	10	7.700	0.118	1.54	6.700	8.700
2023-001	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	17	7.700	0.150	1.95	6.700	8.700
2023-001	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	34	7.824	0.197	2.52	6.800	8.800
2023-002	3	ARSEN.-III	165	VITROS	63	KODAK	161	6.699	0.151	2.25	5.700	7.700
2023-002	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	31	6.926	0.127	1.83	5.900	7.900
2023-002	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	41	7.422	0.266	3.58	6.400	8.400
2023-002	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	41	7.249	0.333	4.59	6.200	8.200
2023-002	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	14	6.936	0.172	2.47	5.900	7.900
2023-002	3	ARSEN.-III	220	Medica E.	99	STAMBIO	10	6.950	0.297	4.28	6.000	8.000
2023-002	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	93	6.908	0.222	3.22	5.900	7.900
2023-002	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	16	7.025	0.164	2.33	6.000	8.000
2023-002	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.150	0.175	2.44	6.200	8.200

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2023-002	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	11	6.709	0.219	3.27	5.700	7.700
2023-002	14	ELECTRODE	215 B.C DXC	134	BECKM.COUL	10	7.050	0.102	1.45	6.100	8.100
2023-002	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	17	7.053	0.179	2.53	6.100	8.100
2023-002	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	34	7.170	0.178	2.49	6.200	8.200
010	CALCIUM, TOTAL	CLIA TEST ID #: 345		EVALUATION CRITERIA: TARGET VALUE 1.00							
2023-003	3	ARSEN.-III	165 VITROS	63	KODAK	161	11.940	0.228	1.91	10.900	12.900
2023-003	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	31	12.877	0.294	2.28	11.900	13.900
2023-003	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	41	12.663	0.442	3.49	11.700	13.700
2023-003	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	41	12.856	0.320	2.49	11.900	13.900
2023-003	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	14	12.521	0.384	3.07	11.500	13.500
2023-003	3	ARSEN.-III	220 Medica E.	99	STAMBIO	10	12.560	0.578	4.60	11.600	13.600
2023-003	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	93	12.321	0.396	3.21	11.300	13.300
2023-003	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	16	12.681	0.376	2.97	11.700	13.700
2023-003	8	CRESOLPHT.	203 ROCHE	93	ROCHE	10	12.660	0.380	3.00	11.700	13.700
2023-003	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	11	12.682	0.276	2.17	11.700	13.700
2023-003	14	ELECTRODE	215 B.C DXC	134	BECKM.COUL	10	12.230	0.185	1.51	11.200	13.200
2023-003	15	CA-NM-BAPT	184 INTEGRA	93	ROCHE	17	12.629	0.284	2.25	11.600	13.600
2023-003	15	CA-NM-BAPT	203 ROCHE	93	ROCHE	34	12.806	0.345	2.69	11.800	13.800
2023-004	3	ARSEN.-III	165 VITROS	63	KODAK	161	9.078	0.221	2.43	8.100	10.100
2023-004	3	ARSEN.-III	186 BECK. COUL	76	AU-BECKMAN	31	9.452	0.193	2.04	8.500	10.500
2023-004	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	41	9.778	0.294	3.00	8.800	10.800
2023-004	3	ARSEN.-III	191 RX-SERIES	126	RANDOX	41	9.590	0.319	3.33	8.600	10.600
2023-004	3	ARSEN.-III	197 ARCHITECT	1	ABBOTT	14	9.350	0.226	2.42	8.400	10.400
2023-004	3	ARSEN.-III	220 Medica E.	99	STAMBIO	10	9.550	0.307	3.22	8.600	10.600
2023-004	8	CRESOLPHT.	38 SIEMENS DI	143	SIEMENS	93	9.217	0.278	3.02	8.200	10.200
2023-004	8	CRESOLPHT.	184 INTEGRA	93	ROCHE	16	9.506	0.282	2.96	8.500	10.500
2023-004	8	CRESOLPHT.	203 ROCHE	93	ROCHE	10	9.830	1.017	10.34	8.800	10.800
2023-004	8	CRESOLPHT.	219 ATELLICA	143	SIEMENS	11	9.373	0.196	2.09	8.400	10.400
2023-004	14	ELECTRODE	215 B.C DXC	134	BECKM.COUL	10	9.360	0.150	1.60	8.400	10.400

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE	SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2023-004	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	17	9.494	0.213	2.24	8.500	10.500
	2023-004	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	34	9.632	0.236	2.45	8.600	10.600
010 CALCIUM, TOTAL			CLIA TEST ID #: 345	EVALUATION CRITERIA: TARGET VALUE 1.00						
	2023-005	3 ARSEN.-III	165 VITROS	63 KODAK	161	10.364	0.253	2.44	9.400	11.400
	2023-005	3 ARSEN.-III	186 BECK. COUL	76 AU-BECKMAN	31	10.861	0.250	2.30	9.900	11.900
	2023-005	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	41	10.939	0.381	3.48	9.900	11.900
	2023-005	3 ARSEN.-III	191 RX-SERIES	126 RANDOX	41	11.233	0.353	3.14	10.200	12.200
	2023-005	3 ARSEN.-III	197 ARCHITECT	1 ABBOTT	14	10.657	0.258	2.42	9.700	11.700
	2023-005	3 ARSEN.-III	220 Medica E.	99 STAMBIO	10	10.860	0.380	3.50	9.900	11.900
	2023-005	8 CRESOLPHT.	38 SIEMENS DI	143 SIEMENS	93	10.490	0.279	2.66	9.500	11.500
	2023-005	8 CRESOLPHT.	184 INTEGRA	93 ROCHE	16	10.738	0.296	2.75	9.700	11.700
	2023-005	8 CRESOLPHT.	203 ROCHE	93 ROCHE	10	10.830	0.168	1.55	9.800	11.800
	2023-005	8 CRESOLPHT.	219 ATELLICA	143 SIEMENS	11	10.755	0.268	2.49	9.800	11.800
	2023-005	14 ELECTRODE	215 B.C DXC	134 BECKM.COUL	10	10.590	0.164	1.55	9.600	11.600
	2023-005	15 CA-NM-BAPT	184 INTEGRA	93 ROCHE	17	10.706	0.425	3.97	9.700	11.700
	2023-005	15 CA-NM-BAPT	203 ROCHE	93 ROCHE	34	10.974	0.283	2.58	10.000	12.000
011 CHLORIDE			CLIA TEST ID #: 355	EVALUATION CRITERIA: TARGET VALUE 5 %						
	2023-001	3 ISE DILUTE	184 INTEGRA	93 ROCHE	35	92.343	2.828	3.06	88.000	97.000
	2023-001	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	29	90.552	1.714	1.89	86.000	95.000
	2023-001	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	17	93.353	1.185	1.27	89.000	98.000
	2023-001	3 ISE DILUTE	203 ROCHE	93 ROCHE	47	88.565	1.837	2.07	84.000	93.000
	2023-001	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	92.600	1.497	1.62	88.000	97.000
	2023-001	4 ISE UND-DI	165 VITROS	63 KODAK	86	92.233	2.004	2.17	88.000	97.000
	2023-001	4 ISE UND-DI	165 VITROS	156 Kit 32	73	93.000	2.014	2.17	88.000	98.000
	2023-001	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	40	92.778	3.047	3.28	88.000	97.000
	2023-001	4 ISE UND-DI	191 RX-SERIES	126 RANDOX	40	90.590	2.638	2.91	86.000	95.000
	2023-001	4 ISE UND-DI	220 Medica E.	130 MEDICA	10	90.600	1.497	1.65	86.000	95.000
	2023-001	8 IMT	219 ATELLICA	143 SIEMENS	11	93.091	2.151	2.31	88.000	98.000
	2023-001	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	90	92.000	1.581	1.72	87.000	97.000
	2023-001	9 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	90	91.156	2.097	2.30	87.000	96.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2023-002	3	ISE DILUTE	184 INTEGRA	93	ROCHE	35	89.735	1.975	2.20	85.000	94.000	
2023-002	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	29	89.000	1.414	1.59	85.000	93.000	
2023-002	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	17	91.412	1.942	2.12	87.000	96.000	
2023-002	3	ISE DILUTE	203 ROCHE	93	ROCHE	47	87.130	2.163	2.48	83.000	91.000	
2023-002	3	ISE DILUTE	215 B.C DXC	134	BECKM.COUL	10	90.900	1.375	1.51	86.000	95.000	
2023-002	4	ISE UND-DI	165 VITROS	63	KODAK	86	91.035	1.701	1.87	86.000	96.000	
2023-002	4	ISE UND-DI	165 VITROS	156	Kit 32	73	91.616	1.610	1.76	87.000	96.000	
2023-002	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	40	88.175	2.719	3.08	84.000	93.000	
2023-002	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	40	91.333	3.432	3.76	87.000	96.000	
2023-002	4	ISE UND-DI	220 Medica E.	130	MEDICA	10	88.200	1.600	1.81	84.000	93.000	
2023-002	8	IMT	219 ATELLICA	143	SIEMENS	11	90.545	1.827	2.02	86.000	95.000	
2023-002	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	90	88.567	1.620	1.83	84.000	93.000	
2023-002	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	90	89.000	0.707	0.79	85.000	93.000	
2023-003	3	ISE DILUTE	184 INTEGRA	93	ROCHE	35	113.912	4.300	3.78	108.000	120.000	
2023-003	3	ISE DILUTE	186 BECK. COUL	76	AU-BECKMAN	29	107.103	1.788	1.67	102.000	112.000	
2023-003	3	ISE DILUTE	197 ARCHITECT	1	ABBOTT	17	109.875	1.654	1.50	104.000	115.000	
2023-003	3	ISE DILUTE	203 ROCHE	93	ROCHE	47	108.587	2.102	1.94	103.000	114.000	
2023-003	3	ISE DILUTE	215 B.C DXC	134	BECKM.COUL	10	109.100	1.578	1.45	104.000	115.000	
2023-003	4	ISE UND-DI	165 VITROS	63	KODAK	86	110.365	1.969	1.78	105.000	116.000	
2023-003	4	ISE UND-DI	165 VITROS	156	Kit 32	73	110.822	1.947	1.76	105.000	116.000	
2023-003	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	40	112.000	3.055	2.73	106.000	118.000	
2023-003	4	ISE UND-DI	191 RX-SERIES	126	RANDOX	40	112.375	3.014	2.68	107.000	118.000	
2023-003	4	ISE UND-DI	220 Medica E.	130	MEDICA	10	115.300	1.735	1.50	110.000	121.000	
2023-003	8	IMT	219 ATELLICA	143	SIEMENS	11	111.636	1.967	1.76	106.000	117.000	
2023-003	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	90	115.000	1.732	1.51	109.000	121.000	
2023-003	9	QUICK LYTE	38 SIEMENS DI	143	SIEMENS	90	113.663	2.203	1.94	108.000	119.000	
2023-004	3	ISE DILUTE	184 INTEGRA	93	ROCHE	35	100.794	3.479	3.45	96.000	106.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	97.069	1.837	1.89	92.000	102.000
2023-004	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	17	100.353	2.027	2.02	95.000	105.000
2023-004	3	ISE DILUTE	203	ROCHE	93	ROCHE	47	97.022	2.633	2.71	92.000	102.000
2023-004	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	99.900	1.972	1.97	95.000	105.000
2023-004	4	ISE UND-DI	165	VITROS	63	KODAK	86	99.372	2.046	2.06	94.000	104.000
2023-004	4	ISE UND-DI	165	VITROS	156	Kit 32	73	99.877	1.944	1.95	95.000	105.000
2023-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	40	98.308	2.642	2.69	93.000	103.000
2023-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	40	100.556	5.909	5.88	96.000	106.000
2023-004	4	ISE UND-DI	220	Medica E.	130	MEDICA	10	100.600	2.154	2.14	96.000	106.000
2023-004	8	IMT	219	ATELLICA	143	SIEMENS	11	100.364	0.979	0.98	95.000	105.000
2023-004	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	99.809	1.999	2.00	95.000	105.000
2023-004	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	99.250	2.278	2.29	94.000	104.000
011	CHLORIDE	CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2023-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	35	105.971	4.301	4.06	101.000	111.000
2023-005	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	29	101.345	2.439	2.41	96.000	106.000
2023-005	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	17	103.353	2.400	2.32	98.000	109.000
2023-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	47	101.511	1.845	1.82	96.000	107.000
2023-005	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	103.600	1.855	1.79	98.000	109.000
2023-005	4	ISE UND-DI	165	VITROS	63	KODAK	86	103.814	2.132	2.05	99.000	109.000
2023-005	4	ISE UND-DI	165	VITROS	156	Kit 32	73	104.569	1.884	1.80	99.000	110.000
2023-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	40	105.667	2.494	2.36	100.000	111.000
2023-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	40	103.925	3.274	3.15	99.000	109.000
2023-005	4	ISE UND-DI	220	Medica E.	130	MEDICA	10	106.300	1.616	1.52	101.000	112.000
2023-005	8	IMT	219	ATELLICA	143	SIEMENS	11	104.909	1.311	1.25	100.000	110.000
2023-005	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	107.250	2.278	2.12	102.000	113.000
2023-005	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	105.330	1.743	1.66	100.000	111.000
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %						
2023-001	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	145.500	4.610	3.17	131.000	160.000
2023-001	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	149.258	5.135	3.44	134.000	164.000
2023-001	1	ENZYMATIC	165	VITROS	63	KODAK	148	150.405	4.382	2.91	135.000	165.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-001	1	ENZYMATIC	184	INTEGRA	93	ROCHE	14	147.429	5.513	3.74	133.000	162.000
2023-001	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	159.000	3.559	2.24	143.000	175.000
2023-001	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	162.295	7.298	4.50	146.000	179.000
2023-001	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	153.333	2.779	1.81	138.000	169.000
2023-001	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	155.762	3.407	2.19	140.000	171.000
2023-001	1	ENZYMATIC	215	B.C DXC	134	BECKM.COUL	10	153.900	5.029	3.27	139.000	169.000
2023-001	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	157.636	4.270	2.71	142.000	173.000
2023-001	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	153.300	4.428	2.89	138.000	169.000
2023-001	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	145.500	4.610	3.17	131.000	160.000
2023-001	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	150.000	4.624	3.08	135.000	165.000
2023-001	8	ENZYMATIC	203	ROCHE	93	ROCHE	10	158.200	4.490	2.84	142.000	174.000
2023-001	9	ENZYMATIC	203	ROCHE	93	ROCHE	11	153.909	6.082	3.95	139.000	169.000
2023-001	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	11	154.182	2.037	1.32	139.000	170.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2023-002	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	138.678	4.479	3.23	125.000	153.000
2023-002	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	134.500	3.571	2.65	121.000	148.000
2023-002	1	ENZYMATIC	165	VITROS	63	KODAK	148	137.456	3.888	2.83	124.000	151.000
2023-002	1	ENZYMATIC	184	INTEGRA	93	ROCHE	14	137.857	5.410	3.92	124.000	152.000
2023-002	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	151.070	6.886	4.56	136.000	166.000
2023-002	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	150.667	2.867	1.90	136.000	166.000
2023-002	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	141.846	1.875	1.32	128.000	156.000
2023-002	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	144.238	3.598	2.49	130.000	159.000
2023-002	1	ENZYMATIC	215	B.C DXC	134	BECKM.COUL	10	142.100	3.239	2.28	128.000	156.000
2023-002	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	147.364	4.598	3.12	133.000	162.000
2023-002	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	140.800	4.956	3.52	127.000	155.000
2023-002	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	134.500	3.571	2.65	121.000	148.000
2023-002	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	137.731	3.536	2.57	124.000	152.000
2023-002	8	ENZYMATIC	203	ROCHE	93	ROCHE	10	146.100	5.319	3.64	131.000	161.000
2023-002	9	ENZYMATIC	203	ROCHE	93	ROCHE	11	142.364	5.515	3.87	128.000	157.000
2023-002	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	11	142.364	3.083	2.17	128.000	157.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
012	CHOLESTEROL, TOTAL	CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %					
2023-003	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		90	226.250	3.562	1.57	204.000	249.000	
2023-003	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		90	230.416	6.251	2.71	207.000	253.000	
2023-003	1 ENZYMATI	165 VITROS	63 KODAK		148	256.405	8.352	3.26	231.000	282.000	
2023-003	1 ENZYMATI	184 INTEGRA	93 ROCHE		14	231.143	9.365	4.05	208.000	254.000	
2023-003	1 ENZYMATI	191 RX-SERIES	126 RANDOX		44	238.000	3.559	1.50	214.000	262.000	
2023-003	1 ENZYMATI	191 RX-SERIES	126 RANDOX		44	256.465	11.226	4.38	231.000	282.000	
2023-003	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		13	240.538	3.587	1.49	216.000	265.000	
2023-003	1 ENZYMATI	203 ROCHE	93 ROCHE		21	243.190	8.942	3.68	219.000	268.000	
2023-003	1 ENZYMATI	215 B.C DXC	134 BECKM.COUL		10	244.700	8.149	3.33	220.000	269.000	
2023-003	1 ENZYMATI	220 Medica E.	130 MEDICA		11	244.727	6.982	2.85	220.000	269.000	
2023-003	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT		10	240.500	12.452	5.18	216.000	265.000	
2023-003	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		27	234.577	6.103	2.60	211.000	258.000	
2023-003	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		27	226.250	3.562	1.57	204.000	249.000	
2023-003	8 ENZYMATI	203 ROCHE	93 ROCHE		10	247.000	7.308	2.96	222.000	272.000	
2023-003	9 ENZYMATI	203 ROCHE	93 ROCHE		11	249.818	17.071	6.83	225.000	275.000	
2023-003	9 ENZYMATI	219 ATELLICA	143 SIEMENS		11	245.727	3.744	1.52	221.000	270.000	
2023-004	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		90	177.852	5.620	3.16	160.000	196.000	
2023-004	1 ENZYMATI	38 SIEMENS DI	143 SIEMENS		90	170.750	4.603	2.70	154.000	188.000	
2023-004	1 ENZYMATI	165 VITROS	63 KODAK		148	188.696	5.650	2.99	170.000	208.000	
2023-004	1 ENZYMATI	184 INTEGRA	93 ROCHE		14	179.429	5.766	3.21	161.000	197.000	
2023-004	1 ENZYMATI	191 RX-SERIES	126 RANDOX		44	198.659	10.088	5.08	179.000	219.000	
2023-004	1 ENZYMATI	191 RX-SERIES	126 RANDOX		44	196.000	9.416	4.80	176.000	216.000	
2023-004	1 ENZYMATI	197 ARCHITECT	1 ABBOTT		13	184.462	2.818	1.53	166.000	203.000	
2023-004	1 ENZYMATI	203 ROCHE	93 ROCHE		21	187.100	4.134	2.21	168.000	206.000	
2023-004	1 ENZYMATI	215 B.C DXC	134 BECKM.COUL		10	187.900	6.057	3.22	169.000	207.000	
2023-004	1 ENZYMATI	220 Medica E.	130 MEDICA		11	188.000	5.689	3.03	169.000	207.000	
2023-004	5 FE-SALTS-N	197 ARCHITECT	1 ABBOTT		10	182.600	5.953	3.26	164.000	201.000	
2023-004	8 ENZYMATI	186 BECK. COUL	76 AU-BECKMAN		27	170.750	4.603	2.70	154.000	188.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	179.577	4.448	2.48	162.000	198.000
2023-004	8	ENZYMATIC	203	ROCHE	93	ROCHE	10	190.300	7.308	3.84	171.000	209.000
2023-004	9	ENZYMATIC	203	ROCHE	93	ROCHE	11	184.545	6.330	3.43	166.000	203.000
2023-004	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	11	188.273	2.666	1.42	169.000	207.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2023-005	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	195.000	4.528	2.32	176.000	215.000
2023-005	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	90	200.584	5.846	2.91	181.000	221.000
2023-005	1	ENZYMATIC	165	VITROS	63	KODAK	148	218.129	7.032	3.22	196.000	240.000
2023-005	1	ENZYMATIC	184	INTEGRA	93	ROCHE	14	199.571	8.252	4.14	180.000	220.000
2023-005	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	214.333	7.134	3.33	193.000	236.000
2023-005	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	44	224.591	13.388	5.96	202.000	247.000
2023-005	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	13	205.923	3.474	1.69	185.000	227.000
2023-005	1	ENZYMATIC	203	ROCHE	93	ROCHE	21	210.190	4.136	1.97	189.000	231.000
2023-005	1	ENZYMATIC	215	B.C DXC	134	BECKM.COUL	10	211.900	8.514	4.02	191.000	233.000
2023-005	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	211.000	4.632	2.20	190.000	232.000
2023-005	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	10	204.700	8.235	4.02	184.000	225.000
2023-005	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	202.154	5.238	2.59	182.000	222.000
2023-005	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	27	195.000	4.528	2.32	176.000	215.000
2023-005	8	ENZYMATIC	203	ROCHE	93	ROCHE	10	214.500	7.606	3.55	193.000	236.000
2023-005	9	ENZYMATIC	203	ROCHE	93	ROCHE	11	209.091	9.405	4.50	188.000	230.000
2023-005	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	11	211.909	2.391	1.13	191.000	233.000
013 CHOLESTEROL, (HDL)			CLIA TEST ID #: 375			EVALUATION CRITERIA: TARGET VALUE 30 %						
2023-001	11	ENC.-COLO.	165	VITROS	63	KODAK	145	52.266	2.131	4.08	36.600	67.900
2023-001	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	32	52.742	2.161	4.10	36.900	68.600
2023-001	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	28	55.329	2.692	4.87	38.700	71.900
2023-001	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	44	49.041	4.950	10.09	34.300	63.800
2023-001	11	ENC.-COLO.	203	ROCHE	93	ROCHE	37	51.839	2.403	4.64	36.300	67.400
2023-001	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	11	50.818	4.771	9.39	35.600	66.100
2023-001	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	16	54.088	2.705	5.00	37.900	70.300
2023-001	12	HOM-LQ.S.D	215	B.C DXC	134	BECKM.COUL	10	56.530	1.558	2.76	39.600	73.500

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2023-001	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	87	55.273	2.770	5.01	38.700	71.900
013 CHOLESTEROL, (HDL)													
CLIA TEST ID #: 375													
EVALUATION CRITERIA: TARGET VALUE 30 %													
2023-002	11	ENC.-COLO.		165	VITROS	63	KODAK	145	49.299	1.993	4.04	34.500	64.100
2023-002	11	ENC.-COLO.		184	INTEGRA	93	ROCHE	32	50.791	2.199	4.33	35.600	66.000
2023-002	11	ENC.-COLO.		186	BECK. COUL	76	AU-BECKMAN	28	51.325	2.523	4.92	35.900	66.700
2023-002	11	ENC.-COLO.		191	RX-SERIES	126	RANDOX	44	45.848	5.478	11.95	32.100	59.600
2023-002	11	ENC.-COLO.		203	ROCHE	93	ROCHE	37	49.911	2.113	4.23	34.900	64.900
2023-002	11	ENC.-COLO.		219	ATELLICA	143	SIEMENS	11	46.973	4.946	10.53	32.900	61.100
2023-002	12	HOM-LQ.S.D		197	ARCHITECT	1	ABBOTT	16	50.813	2.214	4.36	35.600	66.100
2023-002	12	HOM-LQ.S.D		215	B.C DXC	134	BECKM.COUL	10	53.280	1.628	3.06	37.300	69.300
2023-002	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	87	54.441	2.696	4.95	38.100	70.800
2023-003	11	ENC.-COLO.		165	VITROS	63	KODAK	145	83.523	4.057	4.86	58.500	108.600
2023-003	11	ENC.-COLO.		184	INTEGRA	93	ROCHE	32	68.000	3.313	4.87	47.600	88.400
2023-003	11	ENC.-COLO.		186	BECK. COUL	76	AU-BECKMAN	28	86.864	4.243	4.88	60.800	112.900
2023-003	11	ENC.-COLO.		191	RX-SERIES	126	RANDOX	44	73.280	7.348	10.03	51.300	95.300
2023-003	11	ENC.-COLO.		203	ROCHE	93	ROCHE	37	66.870	3.663	5.48	46.800	86.900
2023-003	11	ENC.-COLO.		219	ATELLICA	143	SIEMENS	11	78.918	7.412	9.39	55.200	102.600
2023-003	12	HOM-LQ.S.D		197	ARCHITECT	1	ABBOTT	16	83.213	4.181	5.02	58.200	108.200
2023-003	12	HOM-LQ.S.D		215	B.C DXC	134	BECKM.COUL	10	85.140	7.543	8.86	59.600	110.700
2023-003	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	87	60.929	3.696	6.07	42.700	79.200
2023-004	11	ENC.-COLO.		165	VITROS	63	KODAK	145	61.436	2.679	4.36	43.000	79.900
2023-004	11	ENC.-COLO.		184	INTEGRA	93	ROCHE	32	58.591	3.031	5.17	41.000	76.200
2023-004	11	ENC.-COLO.		186	BECK. COUL	76	AU-BECKMAN	28	66.014	3.459	5.24	46.200	85.800
2023-004	11	ENC.-COLO.		191	RX-SERIES	126	RANDOX	44	58.723	6.235	10.62	41.100	76.300
2023-004	11	ENC.-COLO.		203	ROCHE	93	ROCHE	37	57.547	2.716	4.72	40.300	74.800
2023-004	11	ENC.-COLO.		219	ATELLICA	143	SIEMENS	11	61.036	5.660	9.27	42.700	79.300
2023-004	12	HOM-LQ.S.D		197	ARCHITECT	1	ABBOTT	16	64.631	3.119	4.83	45.200	84.000
2023-004	12	HOM-LQ.S.D		215	B.C DXC	134	BECKM.COUL	10	67.730	1.720	2.54	47.400	88.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2023-004	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	87	58.326	3.293	5.65	40.800	75.800
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 30 %							
2023-005	11	ENC.-COLO.		165	VITROS	63	KODAK	145	70.148	3.290	4.69	49.100	91.200
2023-005	11	ENC.-COLO.		184	INTEGRA	93	ROCHE	32	61.947	2.779	4.49	43.400	80.500
2023-005	11	ENC.-COLO.		186	BECK. COUL	76	AU-BECKMAN	28	73.954	3.711	5.02	51.800	96.100
2023-005	11	ENC.-COLO.		191	RX-SERIES	126	RANDOX	44	64.836	6.636	10.23	45.400	84.300
2023-005	11	ENC.-COLO.		203	ROCHE	93	ROCHE	37	61.861	2.740	4.43	43.300	80.400
2023-005	11	ENC.-COLO.		219	ATELLICA	143	SIEMENS	11	70.327	10.542	14.99	49.200	91.400
2023-005	12	HOM-LQ.S.D		197	ARCHITECT	1	ABBOTT	16	71.713	3.334	4.65	50.200	93.200
2023-005	12	HOM-LQ.S.D		215	B.C DXC	134	BECKM.COUL	10	75.160	2.552	3.40	52.600	97.700
2023-005	13	AMIN.W.E.Q		38	SIEMENS DI	143	SIEMENS	87	60.039	2.920	4.86	42.000	78.100
014 CREATINE KINASE (CK)		CLIA TEST ID #: 385											
2023-001	3	KINETIC 37		165	VITROS	63	KODAK	72	168.597	11.547	6.85	118.000	219.000
2023-001	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	19	176.895	11.706	6.62	124.000	230.000
2023-001	4	OLIVER ROS		215	B.C DXC	134	BECKM.COUL	10	203.500	2.579	1.27	142.000	265.000
2023-001	8	Hexokinase		184	INTEGRA	93	ROCHE	11	204.545	5.598	2.74	143.000	266.000
2023-001	8	Hexokinase		203	ROCHE	93	ROCHE	11	206.909	6.986	3.38	145.000	269.000
2023-001	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	30	204.862	5.090	2.48	143.000	266.000
2023-002	3	KINETIC 37		165	VITROS	63	KODAK	72	113.431	7.688	6.78	79.000	147.000
2023-002	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	19	115.474	7.735	6.70	81.000	150.000
2023-002	4	OLIVER ROS		215	B.C DXC	134	BECKM.COUL	10	134.200	3.156	2.35	94.000	174.000
2023-002	8	Hexokinase		184	INTEGRA	93	ROCHE	11	136.364	3.365	2.47	95.000	177.000
2023-002	8	Hexokinase		203	ROCHE	93	ROCHE	11	135.727	5.344	3.94	95.000	176.000
2023-002	9	SIEMENS		38	SIEMENS DI	143	SIEMENS	30	134.069	3.039	2.27	94.000	174.000
2023-003	3	KINETIC 37		165	VITROS	63	KODAK	72	411.194	27.034	6.57	288.000	535.000
2023-003	3	KINETIC 37		186	BECK. COUL	76	AU-BECKMAN	19	591.000	42.250	7.15	414.000	768.000
2023-003	4	OLIVER ROS		215	B.C DXC	134	BECKM.COUL	10	644.900	15.372	2.38	451.000	838.000
2023-003	8	Hexokinase		184	INTEGRA	93	ROCHE	11	660.727	16.080	2.43	463.000	859.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE	SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
	2023-003	8 Hexokinase	203 ROCHE	93 ROCHE	11	667.545	40.297	6.04	467.000	868.000
	2023-003	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	30	664.633	27.917	4.20	465.000	864.000
014 CREATINE KINASE (CK)			CLIA TEST ID #: 385	EVALUATION CRITERIA: TARGET VALUE 30 %						
	2023-004	3 KINETIC 37	165 VITROS	63 KODAK	72	275.361	16.440	5.97	193.000	358.000
	2023-004	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	19	316.526	22.668	7.16	222.000	411.000
	2023-004	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL	10	360.900	6.978	1.93	253.000	469.000
	2023-004	8 Hexokinase	184 INTEGRA	93 ROCHE	11	359.636	11.276	3.14	252.000	468.000
	2023-004	8 Hexokinase	203 ROCHE	93 ROCHE	11	380.545	37.691	9.90	266.000	495.000
	2023-004	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	30	367.310	9.552	2.60	257.000	478.000
	2023-005	3 KINETIC 37	165 VITROS	63 KODAK	72	345.000	23.257	6.74	242.000	449.000
	2023-005	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	19	425.579	33.020	7.76	298.000	553.000
	2023-005	4 OLIVER ROS	215 B.C DXC	134 BECKM.COUL	10	484.800	10.591	2.18	339.000	630.000
	2023-005	8 Hexokinase	184 INTEGRA	93 ROCHE	11	487.727	16.712	3.43	341.000	634.000
	2023-005	8 Hexokinase	203 ROCHE	93 ROCHE	11	496.273	14.985	3.02	347.000	645.000
	2023-005	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	30	496.138	11.073	2.23	347.000	645.000
016 CREATININE			CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
	2023-001	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	31	2.333	0.164	7.03	2.030	2.630
	2023-001	4 ENZYMATIC	220 Medica E.	130 MEDICA	11	2.637	0.065	2.46	2.340	2.940
	2023-001	6 KIN. ALK P	184 INTEGRA	93 ROCHE	19	2.599	0.087	3.34	2.300	2.900
	2023-001	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	31	2.552	0.103	4.04	2.250	2.850
	2023-001	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	20	2.579	0.109	4.24	2.280	2.880
	2023-001	6 KIN. ALK P	203 ROCHE	93 ROCHE	25	2.567	0.153	5.94	2.270	2.870
	2023-001	6 KIN. ALK P	215 B.C DXC	134 BECKM.COUL	10	2.633	0.087	3.32	2.330	2.930
	2023-001	8 IDMS-CREA	165 VITROS	63 KODAK	158	2.247	0.079	3.50	1.950	2.550
	2023-001	9 MODIFIED	219 ATELLICA	143 SIEMENS	11	2.488	0.060	2.42	2.190	2.790
	2023-001	10 JAFFE COMP	184 INTEGRA	93 ROCHE	10	2.575	0.104	4.03	2.280	2.880
	2023-001	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	85	2.682	0.086	3.21	2.380	2.980
	2023-002	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	31	1.799	0.111	6.17	1.500	2.100

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-002	4	ENZYMATIC	220	Medica E.	130	MEDICA	11	1.933	0.040	2.09	1.630	2.230
2023-002	6	KIN. ALK P	184	INTEGRA	93	ROCHE	19	1.941	0.079	4.06	1.640	2.240
2023-002	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	1.890	0.064	3.39	1.590	2.190
2023-002	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	20	1.848	0.058	3.15	1.550	2.150
2023-002	6	KIN. ALK P	203	ROCHE	93	ROCHE	25	1.908	0.084	4.41	1.610	2.210
2023-002	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	1.950	0.063	3.25	1.650	2.250
2023-002	8	IDMS-CREA	165	VITROS	63	KODAK	158	1.672	0.058	3.46	1.370	1.970
2023-002	9	MODIFIED	219	ATELLICA	143	SIEMENS	11	1.832	0.051	2.79	1.530	2.130
2023-002	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	1.919	0.070	3.67	1.620	2.220
2023-002	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	85	1.965	0.062	3.14	1.670	2.270
016 CREATININE			CLIA TEST ID #: 405			EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2023-003	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	31	5.986	0.362	6.04	5.390	6.580
2023-003	4	ENZYMATIC	220	Medica E.	130	MEDICA	11	7.284	0.154	2.11	6.560	8.010
2023-003	6	KIN. ALK P	184	INTEGRA	93	ROCHE	19	6.557	0.223	3.41	5.900	7.210
2023-003	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	6.809	0.371	5.45	6.130	7.490
2023-003	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	20	7.715	0.349	4.53	6.940	8.490
2023-003	6	KIN. ALK P	203	ROCHE	93	ROCHE	25	6.679	0.298	4.45	6.010	7.350
2023-003	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	7.139	0.303	4.25	6.430	7.850
2023-003	8	IDMS-CREA	165	VITROS	63	KODAK	158	5.735	0.204	3.55	5.160	6.310
2023-003	9	MODIFIED	219	ATELLICA	143	SIEMENS	11	6.906	0.162	2.35	6.220	7.600
2023-003	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	6.424	0.208	3.24	5.780	7.070
2023-003	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	85	7.265	0.201	2.77	6.540	7.990
2023-004	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	31	3.567	0.235	6.58	3.210	3.920
2023-004	4	ENZYMATIC	220	Medica E.	130	MEDICA	11	4.240	0.100	2.35	3.820	4.660
2023-004	6	KIN. ALK P	184	INTEGRA	93	ROCHE	19	4.021	0.110	2.74	3.620	4.420
2023-004	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	4.045	0.199	4.91	3.640	4.450
2023-004	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	20	4.357	0.126	2.89	3.920	4.790
2023-004	6	KIN. ALK P	203	ROCHE	93	ROCHE	25	4.051	0.167	4.13	3.650	4.460
2023-004	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	4.231	0.163	3.85	3.810	4.650

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	8	IDMS-CREA	165	VITROS	63	KODAK	158	3.533	0.155	4.37	3.180	3.890
2023-004	9	MODIFIED	219	ATELLICA	143	SIEMENS	11	4.035	0.093	2.30	3.630	4.440
2023-004	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	3.950	0.158	3.99	3.560	4.350
2023-004	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	85	4.200	0.125	2.99	3.780	4.620
016	CREATININE	CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2023-005	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	31	4.587	0.284	6.18	4.130	5.050
2023-005	4	ENZYMATIC	220	Medica E.	130	MEDICA	11	5.495	0.133	2.43	4.950	6.050
2023-005	6	KIN. ALK P	184	INTEGRA	93	ROCHE	19	5.116	0.155	3.02	4.600	5.630
2023-005	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	31	5.209	0.239	4.59	4.690	5.730
2023-005	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	20	5.765	0.157	2.72	5.190	6.340
2023-005	6	KIN. ALK P	203	ROCHE	93	ROCHE	25	5.184	0.254	4.90	4.670	5.700
2023-005	6	KIN. ALK P	215	B.C DXC	134	BECKM.COUL	10	5.465	0.238	4.35	4.920	6.010
2023-005	8	IDMS-CREA	165	VITROS	63	KODAK	158	4.495	0.198	4.40	4.050	4.940
2023-005	9	MODIFIED	219	ATELLICA	143	SIEMENS	11	5.247	0.139	2.64	4.720	5.770
2023-005	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	4.987	0.203	4.08	4.490	5.490
2023-005	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	85	5.504	0.146	2.66	4.950	6.050
017	GLUCOSE	CLIA TEST ID #: 415		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}								
2023-001	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	65.000	2.490	3.83	59.000	72.000
2023-001	3	GL. OXI. C	165	VITROS	63	KODAK	163	67.528	1.895	2.81	61.000	74.000
2023-001	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	71.872	2.275	3.17	65.000	79.000
2023-001	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	68.100	2.879	4.23	61.000	75.000
2023-001	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	66.452	2.045	3.08	60.000	73.000
2023-001	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	70.706	2.844	4.02	64.000	78.000
2023-001	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	71.000	1.897	2.67	64.000	78.000
2023-001	5	HEXOKINASE	203	ROCHE	93	ROCHE	27	68.111	1.892	2.78	61.000	75.000
2023-001	6	HEXOKI. CO	220	Medica E.	130	MEDICA	10	70.700	1.418	2.01	64.000	78.000
2023-001	12	HEXOKINASE	184	INTEGRA	93	ROCHE	24	67.958	2.111	3.11	61.000	75.000
2023-001	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	16	65.200	0.980	1.50	59.000	72.000
2023-001	12	HEXOKINASE	203	ROCHE	93	ROCHE	19	67.158	1.694	2.52	60.000	74.000
2023-001	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	11	67.091	1.881	2.80	60.000	74.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
017	GLUCOSE	CLIA TEST ID #: 415			EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2023-002	2 GL. OXI. E	215 B.C DXC	134 BECKM.COUL		10	50.600	1.281	2.53	45.000	57.000	
2023-002	3 GL. OXI. C	165 VITROS	63 KODAK		163	50.708	1.490	2.94	45.000	57.000	
2023-002	5 HEXOKINASE	38 SIEMENS DI	143 SIEMENS		94	56.717	1.777	3.13	51.000	63.000	
2023-002	5 HEXOKINASE	184 INTEGRA	93 ROCHE		10	53.000	1.483	2.80	47.000	59.000	
2023-002	5 HEXOKINASE	186 BECK. COUL	76 AU-BECKMAN		31	51.935	1.777	3.42	46.000	58.000	
2023-002	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		35	58.800	2.315	3.94	53.000	65.000	
2023-002	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		35	56.059	2.612	4.66	50.000	62.000	
2023-002	5 HEXOKINASE	203 ROCHE	93 ROCHE		27	53.519	1.398	2.61	48.000	60.000	
2023-002	6 HEXOKI. CO	220 Medica E.	130 MEDICA		10	55.700	1.676	3.01	50.000	62.000	
2023-002	12 HEXOKINASE	184 INTEGRA	93 ROCHE		24	53.333	1.404	2.63	47.000	59.000	
2023-002	12 HEXOKINASE	197 ARCHITECT	1 ABBOTT		16	50.625	1.615	3.19	45.000	57.000	
2023-002	12 HEXOKINASE	203 ROCHE	93 ROCHE		19	52.526	1.313	2.50	47.000	59.000	
2023-002	12 HEXOKINASE	219 ATELLICA	143 SIEMENS		11	53.000	1.595	3.01	47.000	59.000	
2023-003	2 GL. OXI. E	215 B.C DXC	134 BECKM.COUL		10	164.100	3.936	2.40	148.000	181.000	
2023-003	3 GL. OXI. C	165 VITROS	63 KODAK		163	175.469	4.187	2.39	158.000	193.000	
2023-003	5 HEXOKINASE	38 SIEMENS DI	143 SIEMENS		94	174.484	5.423	3.11	157.000	192.000	
2023-003	5 HEXOKINASE	184 INTEGRA	93 ROCHE		10	168.400	5.499	3.27	152.000	185.000	
2023-003	5 HEXOKINASE	186 BECK. COUL	76 AU-BECKMAN		31	164.200	3.781	2.30	148.000	181.000	
2023-003	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		35	167.543	7.244	4.32	151.000	184.000	
2023-003	5 HEXOKINASE	191 RX-SERIES	126 RANDOX		35	162.600	4.800	2.95	146.000	179.000	
2023-003	5 HEXOKINASE	203 ROCHE	93 ROCHE		27	170.846	4.356	2.55	154.000	188.000	
2023-003	6 HEXOKI. CO	220 Medica E.	130 MEDICA		10	176.700	4.337	2.45	159.000	194.000	
2023-003	12 HEXOKINASE	184 INTEGRA	93 ROCHE		24	168.833	4.696	2.78	152.000	186.000	
2023-003	12 HEXOKINASE	197 ARCHITECT	1 ABBOTT		16	163.867	3.096	1.89	147.000	180.000	
2023-003	12 HEXOKINASE	203 ROCHE	93 ROCHE		19	168.833	5.449	3.23	152.000	186.000	
2023-003	12 HEXOKINASE	219 ATELLICA	143 SIEMENS		11	165.000	4.533	2.75	149.000	182.000	
2023-004	2 GL. OXI. E	215 B.C DXC	134 BECKM.COUL		10	99.300	3.100	3.12	89.000	109.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	3	GL. OXI. C	165	VITROS	63	KODAK	163	104.340	2.802	2.69	94.000	115.000
2023-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	107.298	3.614	3.37	97.000	118.000
2023-004	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	102.100	3.081	3.02	92.000	112.000
2023-004	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	100.290	2.920	2.91	90.000	110.000
2023-004	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	107.000	2.828	2.64	96.000	118.000
2023-004	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	103.941	4.608	4.43	94.000	114.000
2023-004	5	HEXOKINASE	203	ROCHE	93	ROCHE	27	103.333	2.841	2.75	93.000	114.000
2023-004	6	HEXOKI. CO	220	Medica E.	130	MEDICA	10	107.700	1.676	1.56	97.000	118.000
2023-004	12	HEXOKINASE	184	INTEGRA	93	ROCHE	24	103.042	3.867	3.75	93.000	113.000
2023-004	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	16	99.188	2.351	2.37	89.000	109.000
2023-004	12	HEXOKINASE	203	ROCHE	93	ROCHE	19	102.222	2.973	2.91	92.000	112.000
2023-004	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	11	101.727	2.831	2.78	92.000	112.000
017	GLUCOSE		CLIA TEST ID #: 415			EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2023-005	2	GL. OXI. E	215	B.C DXC	134	BECKM.COUL	10	126.600	3.852	3.04	114.000	139.000
2023-005	3	GL. OXI. C	165	VITROS	63	KODAK	163	133.500	3.405	2.55	120.000	147.000
2023-005	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	94	135.484	3.775	2.79	122.000	149.000
2023-005	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	129.100	4.036	3.13	116.000	142.000
2023-005	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	31	126.133	3.528	2.80	114.000	139.000
2023-005	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	132.257	6.771	5.12	119.000	145.000
2023-005	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	35	130.600	3.611	2.77	118.000	144.000
2023-005	5	HEXOKINASE	203	ROCHE	93	ROCHE	27	131.615	2.910	2.21	118.000	145.000
2023-005	6	HEXOKI. CO	220	Medica E.	130	MEDICA	10	138.000	3.661	2.65	124.000	152.000
2023-005	12	HEXOKINASE	184	INTEGRA	93	ROCHE	24	129.708	3.878	2.99	117.000	143.000
2023-005	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	16	125.813	2.766	2.20	113.000	138.000
2023-005	12	HEXOKINASE	203	ROCHE	93	ROCHE	19	128.842	2.943	2.28	116.000	142.000
2023-005	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	11	127.636	3.650	2.86	115.000	140.000
018	IRON, TOTAL		CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 20 %						
2023-001	4	COULOMETR.	165	VITROS	63	KODAK	15	121.667	8.844	7.27	97.000	146.000
2023-002	4	COULOMETR.	165	VITROS	63	KODAK	15	89.800	6.892	7.67	72.000	108.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
018	IRON, TOTAL	CLIA TEST ID #: 425				EVALUATION CRITERIA: TARGET VALUE 20 %						
2023-003	4 COULOMETR.	165	VITROS	63	KODAK	15	412.400	26.971	6.54	330.000	495.000	
2023-004	4 COULOMETR.	165	VITROS	63	KODAK	15	209.333	11.441	5.47	167.000	251.000	
2023-005	4 COULOMETR.	165	VITROS	63	KODAK	15	286.667	17.184	5.99	229.000	344.000	
019	LACTASE DEHY. (LDH)	CLIA TEST ID #: 435										
2023-001	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	21	202.381	14.381	7.11	162.000	243.000	
2023-001	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	205.300	5.832	2.84	164.000	246.000	
2023-001	6 NADH	184	INTEGRA	93	ROCHE	11	261.545	7.451	2.85	209.000	314.000	
2023-001	6 NADH	203	ROCHE	93	ROCHE	23	253.478	12.254	4.83	203.000	304.000	
2023-001	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	35	239.343	7.848	3.28	191.000	287.000	
2023-001	9 LDH1	165	VITROS	63	KODAK	68	292.015	7.601	2.60	234.000	350.000	
2023-002	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	21	139.952	10.265	7.33	112.000	168.000	
2023-002	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	143.000	3.578	2.50	114.000	172.000	
2023-002	6 NADH	184	INTEGRA	93	ROCHE	11	184.364	5.227	2.84	147.000	221.000	
2023-002	6 NADH	203	ROCHE	93	ROCHE	23	175.091	5.999	3.43	140.000	210.000	
2023-002	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	35	166.571	7.007	4.21	133.000	200.000	
2023-002	9 LDH1	165	VITROS	63	KODAK	68	205.515	5.362	2.61	164.000	247.000	
2023-003	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	21	620.571	41.615	6.71	496.000	745.000	
2023-003	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	590.500	9.351	1.58	472.000	709.000	
2023-003	6 NADH	184	INTEGRA	93	ROCHE	11	757.818	19.418	2.56	606.000	909.000	
2023-003	6 NADH	203	ROCHE	93	ROCHE	23	756.696	40.277	5.32	605.000	908.000	
2023-003	7 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	35	732.257	24.371	3.33	586.000	879.000	
2023-003	9 LDH1	165	VITROS	63	KODAK	68	832.882	44.182	5.30	666.000	999.000	
2023-004	3 KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	21	344.714	23.608	6.85	276.000	414.000	
2023-004	3 KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	346.800	7.897	2.28	277.000	416.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	6	NADH	184	INTEGRA	93	ROCHE	11	434.636	13.268	3.05	348.000	522.000
2023-004	6	NADH	203	ROCHE	93	ROCHE	23	430.591	23.579	5.48	344.000	517.000
2023-004	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	35	410.086	12.408	3.03	328.000	492.000
2023-004	9	LDH1	165	VITROS	63	KODAK	68	486.761	14.759	3.03	389.000	584.000
019	LACTASE DEHY. (LDH)		CLIA TEST ID #: 435			EVALUATION CRITERIA: TARGET VALUE 20 %						
2023-005	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	21	455.619	28.676	6.29	364.000	547.000
2023-005	3	KINETIC-37	215	B.C DXC	134	BECKM.COUL	10	452.800	10.713	2.37	362.000	543.000
2023-005	6	NADH	184	INTEGRA	93	ROCHE	11	570.545	16.323	2.86	456.000	685.000
2023-005	6	NADH	203	ROCHE	93	ROCHE	23	566.000	26.405	4.67	453.000	679.000
2023-005	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	35	546.543	14.829	2.71	437.000	656.000
2023-005	9	LDH1	165	VITROS	63	KODAK	68	646.119	33.844	5.24	517.000	775.000
021	MAGNESIUM		CLIA TEST ID #: 455			EVALUATION CRITERIA: TARGET VALUE 25 %						
2023-001	5	COLOR./K E	165	VITROS	63	KODAK	26	2.692	0.062	2.29	2.000	3.400
2023-002	5	COLOR./K E	165	VITROS	63	KODAK	26	2.146	0.063	2.96	1.600	2.700
2023-003	5	COLOR./K E	165	VITROS	63	KODAK	26	6.156	0.113	1.84	4.600	7.700
2023-004	5	COLOR./K E	165	VITROS	63	KODAK	26	3.931	0.072	1.84	2.900	4.900
2023-005	5	COLOR./K E	165	VITROS	63	KODAK	26	4.873	0.081	1.66	3.700	6.100
022	POTASSIUM		CLIA TEST ID #: 465			EVALUATION CRITERIA: TARGET VALUE 1.00						
2023-001	3	ISE DILUT.	184	INTEGRA	93	ROCHE	33	3.213	0.065	2.02	2.200	4.200
2023-001	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	3.200	0.058	1.80	2.200	4.200
2023-001	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	3.212	0.090	2.80	2.200	4.200
2023-001	3	ISE DILUT.	203	ROCHE	93	ROCHE	48	3.269	0.071	2.18	2.300	4.300
2023-001	3	ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	3.180	0.060	1.89	2.200	4.200
2023-001	4	ISE UNDIL.	165	VITROS	63	KODAK	84	3.224	0.067	2.07	2.200	4.200
2023-001	4	ISE UNDIL.	165	VITROS	156	Kit 32	76	3.212	0.056	1.76	2.200	4.200
2023-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDEX	39	3.256	0.143	4.39	2.300	4.300

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	3.100	0.045	1.44	2.100	4.100
2023-001	5	IMT	219	ATELLICA	143	SIEMENS	11	3.182	0.057	1.81	2.200	4.200
2023-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	3.174	0.074	2.34	2.200	4.200
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 1.00						
2023-002	3	ISE DILUT.	184	INTEGRA	93	ROCHE	33	2.766	0.059	2.14	1.800	3.800
2023-002	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	2.770	0.046	1.65	1.800	3.800
2023-002	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	2.759	0.069	2.50	1.800	3.800
2023-002	3	ISE DILUT.	203	ROCHE	93	ROCHE	48	2.831	0.079	2.81	1.800	3.800
2023-002	3	ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	2.720	0.040	1.47	1.700	3.700
2023-002	4	ISE UNLIL.	165	VITROS	63	KODAK	84	2.762	0.063	2.30	1.800	3.800
2023-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	2.776	0.049	1.76	1.800	3.800
2023-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	39	2.836	0.139	4.89	1.800	3.800
2023-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	2.680	0.040	1.49	1.700	3.700
2023-002	5	IMT	219	ATELLICA	143	SIEMENS	11	2.736	0.064	2.35	1.700	3.700
2023-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	2.706	0.069	2.55	1.700	3.700
2023-003	3	ISE DILUT.	184	INTEGRA	93	ROCHE	33	6.427	0.096	1.50	5.400	7.400
2023-003	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	6.377	0.096	1.50	5.400	7.400
2023-003	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	6.506	0.094	1.44	5.500	7.500
2023-003	3	ISE DILUT.	203	ROCHE	93	ROCHE	48	6.551	0.132	2.01	5.600	7.600
2023-003	3	ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	6.570	0.100	1.53	5.600	7.600
2023-003	4	ISE UNLIL.	165	VITROS	63	KODAK	84	6.570	0.126	1.92	5.600	7.600
2023-003	4	ISE UNLIL.	165	VITROS	156	Kit 32	76	6.584	0.101	1.53	5.600	7.600
2023-003	4	ISE UNLIL.	191	RX-SERIES	126	RANLIX	39	6.321	0.188	2.98	5.300	7.300
2023-003	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	6.460	0.191	2.95	5.500	7.500
2023-003	5	IMT	219	ATELLICA	143	SIEMENS	11	6.373	0.114	1.78	5.400	7.400
2023-003	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	6.434	0.120	1.86	5.400	7.400
2023-004	3	ISE DILUT.	184	INTEGRA	93	ROCHE	33	4.319	0.085	1.96	3.300	5.300
2023-004	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	4.303	0.080	1.85	3.300	5.300

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	4.359	0.109	2.50	3.400	5.400
2023-004	3	ISE DILUT.	203	ROCHE	93	ROCHE	48	4.404	0.109	2.48	3.400	5.400
2023-004	3	ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	4.350	0.092	2.12	3.400	5.400
2023-004	4	ISE UNDIL.	165	VITROS	63	KODAK	84	4.375	0.089	2.03	3.400	5.400
2023-004	4	ISE UNDIL.	165	VITROS	156	Kit 32	76	4.359	0.069	1.59	3.400	5.400
2023-004	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	39	4.287	0.122	2.85	3.300	5.300
2023-004	4	ISE UNDIL.	220	Medica E.	130	MEDICA	10	4.250	0.081	1.90	3.300	5.300
2023-004	5	IMT	219	ATELLICA	143	SIEMENS	11	4.309	0.079	1.84	3.300	5.300
2023-004	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	4.299	0.080	1.87	3.300	5.300
022 POTASSIUM		CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 1.00						
2023-005	3	ISE DILUT.	184	INTEGRA	93	ROCHE	33	5.172	0.091	1.76	4.200	6.200
2023-005	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	30	5.157	0.120	2.33	4.200	6.200
2023-005	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	17	5.194	0.126	2.42	4.200	6.200
2023-005	3	ISE DILUT.	203	ROCHE	93	ROCHE	48	5.294	0.106	2.00	4.300	6.300
2023-005	3	ISE DILUT.	215	B.C DXC	134	BECKM.COUL	10	5.260	0.111	2.12	4.300	6.300
2023-005	4	ISE UNDIL.	165	VITROS	63	KODAK	84	5.286	0.114	2.16	4.300	6.300
2023-005	4	ISE UNDIL.	165	VITROS	156	Kit 32	76	5.287	0.094	1.77	4.300	6.300
2023-005	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	39	5.131	0.160	3.13	4.100	6.100
2023-005	4	ISE UNDIL.	220	Medica E.	130	MEDICA	10	5.130	0.127	2.47	4.100	6.100
2023-005	5	IMT	219	ATELLICA	143	SIEMENS	11	5.155	0.108	2.09	4.200	6.200
2023-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	90	5.182	0.092	1.78	4.200	6.200
023 SODIUM		CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00						
2023-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	127.655	2.072	1.62	124.000	132.000
2023-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	130.429	1.761	1.35	126.000	134.000
2023-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	128.367	2.057	1.60	124.000	132.000
2023-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	129.083	3.040	2.36	125.000	133.000
2023-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	130.429	1.761	1.35	126.000	134.000
2023-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	129.098	1.948	1.51	125.000	133.000
2023-001	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	129.333	2.055	1.59	125.000	133.000
2023-001	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	128.600	2.107	1.64	125.000	133.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-001	4	ISE UNLIL.	165	VITROS	63	KODAK	77	129.000	2.140	1.66	125.000	133.000
2023-001	4	ISE UNLIL.	165	VITROS	63	KODAK	77	129.333	2.055	1.59	125.000	133.000
2023-001	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	129.225	1.884	1.46	125.000	133.000
2023-001	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	129.333	2.055	1.59	125.000	133.000
2023-001	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	130.500	1.803	1.38	127.000	135.000
2023-001	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	129.056	2.494	1.93	125.000	133.000
2023-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	128.900	1.578	1.22	125.000	133.000
2023-001	5	IMT	197	ARCHITECT	1	ABBOTT	12	128.333	3.965	3.09	124.000	132.000
2023-001	5	IMT	219	ATELLICA	143	SIEMENS	11	128.636	2.012	1.56	125.000	133.000
2023-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	128.000	1.225	0.96	124.000	132.000
2023-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	130.489	2.320	1.78	126.000	134.000
023 SODIUM			CLIA TEST ID #: 475			EVALUATION CRITERIA: TARGET VALUE 4.00						
2023-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	124.200	1.759	1.42	120.000	128.000
2023-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	126.571	3.375	2.67	123.000	131.000
2023-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	125.267	1.711	1.37	121.000	129.000
2023-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	125.667	1.700	1.35	122.000	130.000
2023-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	125.951	2.241	1.78	122.000	130.000
2023-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	126.571	3.375	2.67	123.000	131.000
2023-002	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	124.400	1.428	1.15	120.000	128.000
2023-002	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	124.000	1.633	1.32	120.000	128.000
2023-002	4	ISE UNLIL.	165	VITROS	63	KODAK	77	125.632	1.986	1.58	122.000	130.000
2023-002	4	ISE UNLIL.	165	VITROS	63	KODAK	77	124.000	1.633	1.32	120.000	128.000
2023-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	124.000	1.633	1.32	120.000	128.000
2023-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	125.407	1.669	1.33	121.000	129.000
2023-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	125.811	2.958	2.35	122.000	130.000
2023-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	126.000	2.000	1.59	122.000	130.000
2023-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	125.500	2.110	1.68	122.000	130.000
2023-002	5	IMT	197	ARCHITECT	1	ABBOTT	12	126.000	1.528	1.21	122.000	130.000
2023-002	5	IMT	219	ATELLICA	143	SIEMENS	11	125.636	2.307	1.84	122.000	130.000
2023-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	126.844	2.144	1.69	123.000	131.000
2023-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	125.000	1.225	0.98	121.000	129.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
023	SODIUM	CLIA TEST ID #: 475		EVALUATION CRITERIA: TARGET VALUE 4.00								
2023-003	3 ISE DILUTE	184 INTEGRA	93 ROCHE	30	161.714	1.829	1.13	158.000	166.000			
2023-003	3 ISE DILUTE	184 INTEGRA	93 ROCHE	30	158.733	2.421	1.53	155.000	163.000			
2023-003	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	30	160.533	2.500	1.56	157.000	165.000			
2023-003	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	12	163.000	1.414	0.87	159.000	167.000			
2023-003	3 ISE DILUTE	203 ROCHE	93 ROCHE	42	161.714	1.829	1.13	158.000	166.000			
2023-003	3 ISE DILUTE	203 ROCHE	93 ROCHE	42	161.951	3.200	1.98	158.000	166.000			
2023-003	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	166.667	1.247	0.75	163.000	171.000			
2023-003	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	162.300	3.035	1.87	158.000	166.000			
2023-003	4 ISE UNDIL.	165 VITROS	63 KODAK	77	166.667	1.247	0.75	163.000	171.000			
2023-003	4 ISE UNDIL.	165 VITROS	63 KODAK	77	167.066	2.582	1.55	163.000	171.000			
2023-003	4 ISE UNDIL.	165 VITROS	156 Kit 32	81	166.667	1.247	0.75	163.000	171.000			
2023-003	4 ISE UNDIL.	165 VITROS	156 Kit 32	81	166.620	1.951	1.17	163.000	171.000			
2023-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	37	161.750	0.829	0.51	158.000	166.000			
2023-003	4 ISE UNDIL.	191 RX-SERIES	126 RANDOX	37	161.865	3.112	1.92	158.000	166.000			
2023-003	4 ISE UNDIL.	220 Medica E.	130 MEDICA	10	163.600	2.939	1.80	160.000	168.000			
2023-003	5 IMT	197 ARCHITECT	1 ABBOTT	12	164.583	5.992	3.64	161.000	169.000			
2023-003	5 IMT	219 ATELLICA	143 SIEMENS	11	157.818	2.587	1.64	154.000	162.000			
2023-003	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	91	153.250	0.433	0.28	149.000	157.000			
2023-003	6 QUICK LYTE	38 SIEMENS DI	143 SIEMENS	91	159.833	2.892	1.81	156.000	164.000			
2023-004	3 ISE DILUTE	184 INTEGRA	93 ROCHE	30	139.690	2.654	1.90	136.000	144.000			
2023-004	3 ISE DILUTE	184 INTEGRA	93 ROCHE	30	148.571	17.162	11.55	145.000	153.000			
2023-004	3 ISE DILUTE	186 BECK. COUL	76 AU-BECKMAN	30	140.967	2.258	1.60	137.000	145.000			
2023-004	3 ISE DILUTE	197 ARCHITECT	1 ABBOTT	12	142.917	2.691	1.88	139.000	147.000			
2023-004	3 ISE DILUTE	203 ROCHE	93 ROCHE	42	141.857	3.314	2.34	138.000	146.000			
2023-004	3 ISE DILUTE	203 ROCHE	93 ROCHE	42	148.571	17.162	11.55	145.000	153.000			
2023-004	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	141.900	2.809	1.98	138.000	146.000			
2023-004	3 ISE DILUTE	215 B.C DXC	134 BECKM.COUL	10	142.667	2.055	1.44	139.000	147.000			
2023-004	4 ISE UNDIL.	165 VITROS	63 KODAK	77	142.667	2.055	1.44	139.000	147.000			

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	4	ISE UNLIL.	165	VITROS	63	KODAK	77	143.211	2.451	1.71	139.000 147.000	
2023-004	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	143.049	2.072	1.45	139.000 147.000	
2023-004	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	142.667	2.055	1.44	139.000 147.000	
2023-004	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	142.750	4.548	3.19	139.000 147.000	
2023-004	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	141.054	3.279	2.32	137.000 145.000	
2023-004	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	142.600	2.245	1.57	139.000 147.000	
2023-004	5	IMT	197	ARCHITECT	1	ABBOTT	12	141.750	2.521	1.78	138.000 146.000	
2023-004	5	IMT	219	ATELLICA	143	SIEMENS	11	140.182	1.946	1.39	136.000 144.000	
2023-004	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	141.484	2.504	1.77	137.000 145.000	
2023-004	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	136.250	1.479	1.09	132.000 140.000	
023 SODIUM		CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00						
2023-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	147.034	2.236	1.52	143.000 151.000	
2023-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	30	150.571	2.718	1.81	147.000 155.000	
2023-005	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	30	149.267	3.425	2.29	145.000 153.000	
2023-005	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	149.583	2.985	2.00	146.000 154.000	
2023-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	150.571	2.718	1.81	147.000 155.000	
2023-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	42	150.244	2.809	1.87	146.000 154.000	
2023-005	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	150.400	3.747	2.49	146.000 154.000	
2023-005	3	ISE DILUTE	215	B.C DXC	134	BECKM.COUL	10	152.000	2.160	1.42	148.000 156.000	
2023-005	4	ISE UNLIL.	165	VITROS	63	KODAK	77	152.961	2.741	1.79	149.000 157.000	
2023-005	4	ISE UNLIL.	165	VITROS	63	KODAK	77	152.000	2.160	1.42	148.000 156.000	
2023-005	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	152.000	2.160	1.42	148.000 156.000	
2023-005	4	ISE UNLIL.	165	VITROS	156	Kit 32	81	152.988	2.502	1.64	149.000 157.000	
2023-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	149.892	3.177	2.12	146.000 154.000	
2023-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLIL	37	150.500	2.693	1.79	147.000 155.000	
2023-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	10	150.400	2.538	1.69	146.000 154.000	
2023-005	5	IMT	197	ARCHITECT	1	ABBOTT	12	150.083	2.660	1.77	146.000 154.000	
2023-005	5	IMT	219	ATELLICA	143	SIEMENS	11	147.182	2.081	1.41	143.000 151.000	
2023-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	145.000	2.121	1.46	141.000 149.000	
2023-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	91	149.022	2.288	1.54	145.000 153.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
024 TOTAL PROTEIN		CLIA TEST ID #: 485		EVALUATION CRITERIA: TARGET VALUE 10 %								
2023-001	1	BIURET	38 SIEMENS DI	143	SIEMENS	91	4.674	0.119	2.55	4.200	5.100	
2023-001	1	BIURET	165 VITROS	63	KODAK	146	4.406	0.116	2.64	4.000	4.800	
2023-001	1	BIURET	184 INTEGRA	93	ROCHE	22	4.327	0.142	3.28	3.900	4.800	
2023-001	1	BIURET	186 BECK. COUL	76	AU-BECKMAN	28	4.461	0.118	2.63	4.000	4.900	
2023-001	1	BIURET	191 RX-SERIES	126	RANDOX	40	4.375	0.349	7.98	3.900	4.800	
2023-001	1	BIURET	191 RX-SERIES	126	RANDOX	40	4.487	0.170	3.78	4.000	4.900	
2023-001	1	BIURET	197 ARCHITECT	1	ABBOTT	23	4.400	0.164	3.73	4.000	4.800	
2023-001	1	BIURET	203 ROCHE	93	ROCHE	38	4.511	0.113	2.51	4.100	5.000	
2023-001	1	BIURET	215 B.C DXC	134	BECKM.COUL	10	4.490	0.164	3.65	4.000	4.900	
2023-001	1	BIURET	219 ATELLICA	143	SIEMENS	11	4.509	0.124	2.75	4.100	5.000	
2023-001	1	BIURET	220 Medica E.	130	MEDICA	10	4.350	0.112	2.57	3.900	4.800	
2023-001	3	BIURET COL	203 ROCHE	93	ROCHE	10	4.480	0.133	2.96	4.000	4.900	
2023-002	1	BIURET	38 SIEMENS DI	143	SIEMENS	91	4.104	0.124	3.02	3.700	4.500	
2023-002	1	BIURET	165 VITROS	63	KODAK	146	3.906	0.110	2.82	3.500	4.300	
2023-002	1	BIURET	184 INTEGRA	93	ROCHE	22	3.805	0.119	3.12	3.400	4.200	
2023-002	1	BIURET	186 BECK. COUL	76	AU-BECKMAN	28	3.904	0.074	1.91	3.500	4.300	
2023-002	1	BIURET	191 RX-SERIES	126	RANDOX	40	3.935	0.167	4.24	3.500	4.300	
2023-002	1	BIURET	191 RX-SERIES	126	RANDOX	40	3.825	0.249	6.50	3.400	4.200	
2023-002	1	BIURET	197 ARCHITECT	1	ABBOTT	23	3.835	0.117	3.04	3.500	4.200	
2023-002	1	BIURET	203 ROCHE	93	ROCHE	38	3.974	0.116	2.93	3.600	4.400	
2023-002	1	BIURET	215 B.C DXC	134	BECKM.COUL	10	3.940	0.156	3.96	3.500	4.300	
2023-002	1	BIURET	219 ATELLICA	143	SIEMENS	11	3.955	0.144	3.63	3.600	4.400	
2023-002	1	BIURET	220 Medica E.	130	MEDICA	10	3.810	0.130	3.41	3.400	4.200	
2023-002	3	BIURET COL	203 ROCHE	93	ROCHE	10	3.980	0.117	2.93	3.600	4.400	
2023-003	1	BIURET	38 SIEMENS DI	143	SIEMENS	91	8.788	0.258	2.94	7.900	9.700	
2023-003	1	BIURET	165 VITROS	63	KODAK	146	8.174	0.207	2.53	7.400	9.000	
2023-003	1	BIURET	184 INTEGRA	93	ROCHE	22	8.014	0.214	2.67	7.200	8.800	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	28	8.378	0.145	1.73	7.500	9.200
2023-003	1	BIURET	191	RX-SERIES	126	RANDOX	40	8.225	0.377	4.58	7.400	9.000
2023-003	1	BIURET	191	RX-SERIES	126	RANDOX	40	8.387	0.354	4.22	7.500	9.200
2023-003	1	BIURET	197	ARCHITECT	1	ABBOTT	23	8.596	0.197	2.29	7.700	9.500
2023-003	1	BIURET	203	ROCHE	93	ROCHE	38	8.292	0.329	3.96	7.500	9.100
2023-003	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	8.580	0.268	3.12	7.700	9.400
2023-003	1	BIURET	219	APELLICA	143	SIEMENS	11	8.718	0.262	3.01	7.800	9.600
2023-003	1	BIURET	220	Medica E.	130	MEDICA	10	8.120	0.172	2.12	7.300	8.900
2023-003	3	BIURET COL	203	ROCHE	93	ROCHE	10	8.640	0.780	9.03	7.800	9.500
024 TOTAL PROTEIN			CLIA TEST ID #: 485			EVALUATION CRITERIA: TARGET VALUE 10 %						
2023-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	91	6.116	0.181	2.96	5.500	6.700
2023-004	1	BIURET	165	VITROS	63	KODAK	146	5.699	0.141	2.47	5.100	6.300
2023-004	1	BIURET	184	INTEGRA	93	ROCHE	22	5.632	0.166	2.95	5.100	6.200
2023-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	28	5.825	0.135	2.32	5.200	6.400
2023-004	1	BIURET	191	RX-SERIES	126	RANDOX	40	5.877	0.258	4.38	5.300	6.500
2023-004	1	BIURET	191	RX-SERIES	126	RANDOX	40	5.750	0.384	6.68	5.200	6.300
2023-004	1	BIURET	197	ARCHITECT	1	ABBOTT	23	5.870	0.146	2.48	5.300	6.500
2023-004	1	BIURET	203	ROCHE	93	ROCHE	38	5.865	0.203	3.46	5.300	6.500
2023-004	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	5.930	0.210	3.54	5.300	6.500
2023-004	1	BIURET	219	APELLICA	143	SIEMENS	11	6.009	0.150	2.50	5.400	6.600
2023-004	1	BIURET	220	Medica E.	130	MEDICA	10	5.680	0.108	1.90	5.100	6.200
2023-004	3	BIURET COL	203	ROCHE	93	ROCHE	10	5.890	0.130	2.21	5.300	6.500
2023-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	91	7.232	0.204	2.82	6.500	8.000
2023-005	1	BIURET	165	VITROS	63	KODAK	146	6.713	0.187	2.78	6.000	7.400
2023-005	1	BIURET	184	INTEGRA	93	ROCHE	22	6.659	0.197	2.96	6.000	7.300
2023-005	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	28	6.882	0.139	2.02	6.200	7.600
2023-005	1	BIURET	191	RX-SERIES	126	RANDOX	40	6.750	0.335	4.97	6.100	7.400
2023-005	1	BIURET	191	RX-SERIES	126	RANDOX	40	6.888	0.309	4.49	6.200	7.600
2023-005	1	BIURET	197	ARCHITECT	1	ABBOTT	23	6.935	0.210	3.03	6.200	7.600

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-005	1	BIURET	203	ROCHE	93	ROCHE	38	6.876	0.216	3.14	6.200	7.600
2023-005	1	BIURET	215	B.C DXC	134	BECKM.COUL	10	7.050	0.229	3.25	6.300	7.800
2023-005	1	BIURET	219	ATELLICA	143	SIEMENS	11	7.082	0.262	3.70	6.400	7.800
2023-005	1	BIURET	220	Medica E.	130	MEDICA	10	6.660	0.224	3.37	6.000	7.300
2023-005	3	BIURET COL	203	ROCHE	93	ROCHE	10	6.920	0.108	1.56	6.200	7.600
025	TRIGLYCERIDES		CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 25 %							
2023-001	2	ENZ. COLO.	165	VITROS	63	KODAK	149	146.259	4.204	2.87	110.000	183.000
2023-001	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	130.667	2.687	2.06	98.000	163.000
2023-001	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	130.880	3.592	2.74	98.000	164.000
2023-001	2	ENZ. COLO.	220	Medica E.	130	MEDICA	10	127.100	3.477	2.74	95.000	159.000
2023-001	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	89	122.551	4.092	3.34	92.000	153.000
2023-001	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	11	121.636	4.637	3.81	91.000	152.000
2023-001	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	28	130.750	4.298	3.29	98.000	163.000
2023-001	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	34	130.471	5.947	4.56	98.000	163.000
2023-001	9	GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	137.400	7.486	5.45	103.000	172.000
2023-001	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	18	127.889	3.710	2.90	96.000	160.000
2023-001	10	ENZYM. GPO	203	ROCHE	93	ROCHE	22	130.273	2.597	1.99	98.000	163.000
2023-001	10	ENZYM. GPO	219	ATELLICA	143	SIEMENS	11	131.364	3.772	2.87	99.000	164.000
2023-001	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	121.091	2.999	2.48	91.000	151.000
2023-002	2	ENZ. COLO.	165	VITROS	63	KODAK	149	126.946	4.105	3.23	95.000	159.000
2023-002	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	12	115.083	2.100	1.82	86.000	144.000
2023-002	2	ENZ. COLO.	203	ROCHE	93	ROCHE	25	114.625	2.870	2.50	86.000	143.000
2023-002	2	ENZ. COLO.	220	Medica E.	130	MEDICA	10	112.700	3.976	3.53	85.000	141.000
2023-002	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	89	106.135	4.120	3.88	80.000	133.000
2023-002	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	11	106.818	2.208	2.07	80.000	134.000
2023-002	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	28	114.286	3.432	3.00	86.000	143.000
2023-002	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	34	114.382	5.589	4.89	86.000	143.000
2023-002	9	GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	122.300	6.497	5.31	92.000	153.000
2023-002	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	18	113.500	3.948	3.48	85.000	142.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2023-002	10 ENZYM. GPO	203	ROCHE	93	ROCHE	22	115.455	2.919	2.53	87.000	144.000		
2023-002	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	11	114.273	3.250	2.84	86.000	143.000		
2023-002	11 GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	104.727	2.597	2.48	79.000	131.000		
025 TRIGLYCERIDES		CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 25 %									
2023-003	2 ENZ. COLO.	165	VITROS	63	KODAK	149	286.048	8.250	2.88	215.000	358.000		
2023-003	2 ENZ. COLO.	184	INTEGRA	93	ROCHE	12	232.167	5.047	2.17	174.000	290.000		
2023-003	2 ENZ. COLO.	203	ROCHE	93	ROCHE	25	233.680	7.460	3.19	175.000	292.000		
2023-003	2 ENZ. COLO.	220	Medica E.	130	MEDICA	10	226.200	6.226	2.75	170.000	283.000		
2023-003	4 ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	89	238.500	6.419	2.69	179.000	298.000		
2023-003	5 HANTZCH-C)	197	ARCHITECT	1	ABBOTT	11	235.455	9.595	4.08	177.000	294.000		
2023-003	9 GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	28	247.964	8.144	3.28	186.000	310.000		
2023-003	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	34	237.853	11.604	4.88	178.000	297.000		
2023-003	9 GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	258.400	15.207	5.88	194.000	323.000		
2023-003	10 ENZYM. GPO	184	INTEGRA	93	ROCHE	18	228.889	7.272	3.18	172.000	286.000		
2023-003	10 ENZYM. GPO	203	ROCHE	93	ROCHE	22	234.381	7.955	3.39	176.000	293.000		
2023-003	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	11	246.545	6.458	2.62	185.000	308.000		
2023-003	11 GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	229.364	4.354	1.90	172.000	287.000		
2023-004	2 ENZ. COLO.	165	VITROS	63	KODAK	149	194.730	6.376	3.27	146.000	243.000		
2023-004	2 ENZ. COLO.	184	INTEGRA	93	ROCHE	12	167.917	4.172	2.48	126.000	210.000		
2023-004	2 ENZ. COLO.	203	ROCHE	93	ROCHE	25	168.000	5.091	3.03	126.000	210.000		
2023-004	2 ENZ. COLO.	220	Medica E.	130	MEDICA	10	161.200	2.600	1.61	121.000	202.000		
2023-004	4 ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	89	162.978	5.742	3.52	122.000	204.000		
2023-004	5 HANTZCH-C)	197	ARCHITECT	1	ABBOTT	11	162.818	4.802	2.95	122.000	204.000		
2023-004	9 GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	28	172.286	4.847	2.81	129.000	215.000		
2023-004	9 GPO TRIND.	191	RX-SERIES	126	RANDOX	34	169.353	8.901	5.26	127.000	212.000		
2023-004	9 GPO TRIND.	215	B.C DXC	134	BECKM.COUL	10	181.300	9.716	5.36	136.000	227.000		
2023-004	10 ENZYM. GPO	184	INTEGRA	93	ROCHE	18	166.278	6.190	3.72	125.000	208.000		
2023-004	10 ENZYM. GPO	203	ROCHE	93	ROCHE	22	168.476	5.105	3.03	126.000	211.000		
2023-004	10 ENZYM. GPO	219	ATELLICA	143	SIEMENS	11	173.273	4.901	2.83	130.000	217.000		

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
2023-004	11 GLY PO4 OX	197 ARCHITECT	1 ABBOTT	11	159.909	4.601	2.88	120.000	200.000			
025	TRIGLYCERIDES	CLIA TEST ID #: 495	EVALUATION CRITERIA: TARGET VALUE 25 %									
2023-005	2 ENZ. COLO.	165 VITROS	63 KODAK	149	233.142	6.911	2.96	175.000	291.000			
2023-005	2 ENZ. COLO.	184 INTEGRA	93 ROCHE	12	193.750	7.496	3.87	145.000	242.000			
2023-005	2 ENZ. COLO.	203 ROCHE	93 ROCHE	25	195.880	5.778	2.95	147.000	245.000			
2023-005	2 ENZ. COLO.	220 Medica E.	130 MEDICA	10	188.200	6.194	3.29	141.000	235.000			
2023-005	4 ENZ. (GPD)	38 SIEMENS DI	143 SIEMENS	89	193.977	6.887	3.55	145.000	242.000			
2023-005	5 HANTZCH-C)	197 ARCHITECT	1 ABBOTT	11	191.091	3.801	1.99	143.000	239.000			
2023-005	9 GPO TRIND.	186 BECK. COUL	76 AU-BECKMAN	28	203.250	6.566	3.23	152.000	254.000			
2023-005	9 GPO TRIND.	191 RX-SERIES	126 RANDOX	34	198.412	10.446	5.26	149.000	248.000			
2023-005	9 GPO TRIND.	215 B.C DXC	134 BECKM.COUL	10	215.100	12.373	5.75	161.000	269.000			
2023-005	10 ENZYM. GPO	184 INTEGRA	93 ROCHE	18	191.556	6.362	3.32	144.000	239.000			
2023-005	10 ENZYM. GPO	203 ROCHE	93 ROCHE	22	195.318	4.496	2.30	146.000	244.000			
2023-005	10 ENZYM. GPO	219 ATELLICA	143 SIEMENS	11	203.182	4.802	2.36	152.000	254.000			
2023-005	11 GLY PO4 OX	197 ARCHITECT	1 ABBOTT	11	186.818	5.060	2.71	140.000	234.000			
026	UREA NITROGEN (BUN)	CLIA TEST ID #: 505	EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}									
2023-001	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	94	19.660	0.963	4.90	18.000	22.000			
2023-001	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	94	19.750	0.433	2.19	18.000	22.000			
2023-001	2 UREAS.GLDH	184 INTEGRA	93 ROCHE	36	19.250	0.862	4.48	17.000	21.000			
2023-001	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN	30	19.900	0.700	3.52	18.000	22.000			
2023-001	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX	40	19.333	0.915	4.73	17.000	21.000			
2023-001	2 UREAS.GLDH	203 ROCHE	93 ROCHE	49	19.449	0.859	4.41	17.000	21.000			
2023-001	2 UREAS.GLDH	203 ROCHE	93 ROCHE	49	19.000	1.000	5.26	17.000	21.000			
2023-001	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS	11	20.455	0.656	3.20	18.000	22.000			
2023-001	5 CHROMATOG.	197 ARCHITECT	1 ABBOTT	11	19.000	1.044	5.50	17.000	21.000			
2023-001	8 UREASE QUI	165 VITROS	63 KODAK	161	17.453	0.568	3.25	15.000	19.000			
2023-001	10 UREASE 37	220 Medica E.	130 MEDICA	11	19.182	0.716	3.73	17.000	21.000			
2023-002	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	94	16.500	0.500	3.03	15.000	19.000			
2023-002	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS	94	16.215	0.828	5.10	14.000	18.000			

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-002	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	36	15.889	0.737	4.64	14.000	18.000
2023-002	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	16.533	0.562	3.40	15.000	19.000
2023-002	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	40	16.275	0.774	4.76	14.000	18.000
2023-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	16.750	0.661	3.95	15.000	19.000
2023-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	16.000	0.700	4.37	14.000	18.000
2023-002	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	11	16.545	0.782	4.73	15.000	19.000
2023-002	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	11	16.273	1.052	6.47	14.000	18.000
2023-002	8	UREASE QUI	165	VITROS	63	KODAK	161	14.466	0.523	3.62	12.000	16.000
2023-002	10	UREASE 37	220	Medica E.	130	MEDICA	11	16.091	0.900	5.59	14.000	18.000
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505				EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2023-003	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	43.096	1.701	3.95	39.000	47.000
2023-003	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	44.250	0.433	0.98	40.000	48.000
2023-003	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	36	42.639	1.512	3.55	39.000	46.000
2023-003	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	43.500	1.522	3.50	40.000	47.000
2023-003	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	40	39.525	2.191	5.54	36.000	43.000
2023-003	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	42.521	1.756	4.13	39.000	46.000
2023-003	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	40.500	2.598	6.42	37.000	44.000
2023-003	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	11	41.545	1.157	2.79	38.000	45.000
2023-003	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	11	44.000	2.374	5.40	40.000	48.000
2023-003	8	UREASE QUI	165	VITROS	63	KODAK	161	39.356	1.045	2.66	36.000	43.000
2023-003	10	UREASE 37	220	Medica E.	130	MEDICA	11	40.364	1.226	3.04	37.000	44.000
2023-004	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	28.250	0.829	2.94	26.000	31.000
2023-004	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	27.581	1.347	4.88	25.000	30.000
2023-004	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	36	27.333	1.027	3.76	25.000	30.000
2023-004	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	27.933	0.892	3.19	25.000	30.000
2023-004	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	40	26.425	1.159	4.39	24.000	29.000
2023-004	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	27.250	1.199	4.40	25.000	30.000
2023-004	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	27.333	1.007	3.68	25.000	30.000
2023-004	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	11	28.000	0.853	3.05	25.000	31.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2023-004	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	11	27.364	0.979	3.58	25.000	30.000
2023-004	8	UREASE QUI	165	VITROS	63	KODAK	161	24.550	0.678	2.76	22.000	27.000
2023-004	10	UREASE 37	220	Medica E.	130	MEDICA	11	26.636	1.068	4.01	24.000	29.000
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505			EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2023-005	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	33.915	1.463	4.32	31.000	37.000
2023-005	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	94	35.250	0.829	2.35	32.000	38.000
2023-005	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	36	33.139	1.566	4.73	30.000	36.000
2023-005	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	30	34.100	1.300	3.81	31.000	37.000
2023-005	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	40	31.850	1.476	4.63	29.000	35.000
2023-005	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	33.313	1.261	3.79	30.000	36.000
2023-005	2	UREAS.GLDH	203	ROCHE	93	ROCHE	49	35.125	6.193	17.63	32.000	38.000
2023-005	2	UREAS.GLDH	219	ATELLICA	143	SIEMENS	11	33.727	0.862	2.56	31.000	37.000
2023-005	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	11	33.727	2.049	6.08	31.000	37.000
2023-005	8	UREASE QUI	165	VITROS	63	KODAK	161	30.566	0.843	2.76	28.000	33.000
2023-005	10	UREASE 37	220	Medica E.	130	MEDICA	11	32.909	0.793	2.41	30.000	36.000
027 URIC ACID			CLIA TEST ID #: 515			EVALUATION CRITERIA: TARGET VALUE 17 %						
2023-001	2	URICASE	38	SIEMENS DI	143	SIEMENS	50	4.155	0.101	2.43	3.400	4.900
2023-001	2	URICASE	165	VITROS	63	KODAK	96	4.212	0.098	2.33	3.500	4.900
2023-001	2	URICASE	184	INTEGRA	93	ROCHE	13	4.285	0.117	2.72	3.600	5.000
2023-001	2	URICASE	203	ROCHE	93	ROCHE	28	4.157	0.112	2.68	3.500	4.900
2023-001	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	18	4.267	0.111	2.59	3.500	5.000
2023-001	5	URICASE 37	215	B.C DXC	134	BECKM.COUL	10	4.150	0.112	2.69	3.400	4.900
2023-001	6	ENZY. COL	203	ROCHE	93	ROCHE	12	4.142	0.150	3.62	3.400	4.800
2023-002	2	URICASE	38	SIEMENS DI	143	SIEMENS	50	3.178	0.115	3.63	2.600	3.700
2023-002	2	URICASE	165	VITROS	63	KODAK	96	3.246	0.074	2.27	2.700	3.800
2023-002	2	URICASE	184	INTEGRA	93	ROCHE	13	3.269	0.107	3.26	2.700	3.800
2023-002	2	URICASE	203	ROCHE	93	ROCHE	28	3.152	0.096	3.04	2.600	3.700
2023-002	5	URICASE 37	186	BECK. COUL	76	AU-BECKMAN	18	3.306	0.062	1.88	2.700	3.900
2023-002	5	URICASE 37	215	B.C DXC	134	BECKM.COUL	10	3.150	0.067	2.13	2.600	3.700

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-002	6 ENZY. COL	203	ROCHE	93	ROCHE	12	3.142	0.138	4.40	2.600	3.700	
027	URIC ACID	CLIA TEST ID #: 515		EVALUATION CRITERIA: TARGET VALUE 17 %								
2023-003	2 URICASE	38	SIEMENS DI	143	SIEMENS	50	10.982	0.405	3.69	9.100	12.800	
2023-003	2 URICASE	165	VITROS	63	KODAK	96	11.111	0.246	2.21	9.200	13.000	
2023-003	2 URICASE	184	INTEGRA	93	ROCHE	13	11.254	0.323	2.87	9.300	13.200	
2023-003	2 URICASE	203	ROCHE	93	ROCHE	28	10.775	0.390	3.62	8.900	12.600	
2023-003	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	18	10.983	0.315	2.87	9.100	12.900	
2023-003	5 URICASE 37	215	B.C DXC	134	BECKM.COUL	10	10.370	0.269	2.59	8.600	12.100	
2023-003	6 ENZY. COL	203	ROCHE	93	ROCHE	12	11.133	0.788	7.08	9.200	13.000	
2023-004	2 URICASE	38	SIEMENS DI	143	SIEMENS	50	6.488	0.232	3.58	5.400	7.600	
2023-004	2 URICASE	165	VITROS	63	KODAK	96	6.546	0.153	2.34	5.400	7.700	
2023-004	2 URICASE	184	INTEGRA	93	ROCHE	13	6.631	0.223	3.37	5.500	7.800	
2023-004	2 URICASE	203	ROCHE	93	ROCHE	28	6.500	0.198	3.05	5.400	7.600	
2023-004	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	18	6.594	0.175	2.65	5.500	7.700	
2023-004	5 URICASE 37	215	B.C DXC	134	BECKM.COUL	10	6.380	0.172	2.70	5.300	7.500	
2023-004	6 ENZY. COL	203	ROCHE	93	ROCHE	12	6.442	0.225	3.50	5.300	7.500	
2023-005	2 URICASE	38	SIEMENS DI	143	SIEMENS	50	8.382	0.226	2.69	7.000	9.800	
2023-005	2 URICASE	165	VITROS	63	KODAK	96	8.452	0.192	2.27	7.000	9.900	
2023-005	2 URICASE	184	INTEGRA	93	ROCHE	13	8.500	0.277	3.26	7.100	9.900	
2023-005	2 URICASE	203	ROCHE	93	ROCHE	28	8.250	0.226	2.74	6.800	9.700	
2023-005	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	18	8.383	0.234	2.79	7.000	9.800	
2023-005	5 URICASE 37	215	B.C DXC	134	BECKM.COUL	10	8.060	0.237	2.95	6.700	9.400	
2023-005	6 ENZY. COL	203	ROCHE	93	ROCHE	12	8.258	0.325	3.94	6.900	9.700	
135	GGT (GAMMA GLU. TRA)	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2023-001	3 ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	11	109.545	2.872	2.62	88.000	131.000	
2023-001	5 KINETIC 37	165	VITROS	63	KODAK	23	213.348	5.961	2.79	171.000	256.000	
2023-002	3 ALPHA GGP	186	BECK. COUL	76	AU-BECKMAN	11	69.364	1.494	2.15	55.000	83.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE									
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE		
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
2023-002	5 KINETIC 37	165 VITROS	63 KODAK	23	139.304	4.143	2.97	111.000	167.000				
135 GGT (GAMMA GLU. TRA)						EVALUATION CRITERIA: TARGET VALUE 20 %							
2023-003	3 ALPHA GGP	186 BECK. COUL	76 AU-BECKMAN	11	377.455	12.536	3.32	302.000	453.000				
2023-003	5 KINETIC 37	165 VITROS	63 KODAK	23	596.864	18.910	3.17	477.000	716.000				
2023-004	3 ALPHA GGP	186 BECK. COUL	76 AU-BECKMAN	11	200.545	6.720	3.35	160.000	241.000				
2023-004	5 KINETIC 37	165 VITROS	63 KODAK	23	360.409	9.306	2.58	288.000	432.000				
2023-005	3 ALPHA GGP	186 BECK. COUL	76 AU-BECKMAN	11	272.545	10.578	3.88	218.000	327.000				
2023-005	5 KINETIC 37	165 VITROS	63 KODAK	23	462.955	11.633	2.51	370.000	556.000				
136 LACTIC ACID													
2023-001	1 LACTATE-P.	165 VITROS	63 KODAK	21	2.457	0.079	3.22	2.000	2.900				
2023-002	1 LACTATE-P.	165 VITROS	63 KODAK	21	1.662	0.049	2.92	1.300	2.000				
2023-003	1 LACTATE-P.	165 VITROS	63 KODAK	21	7.215	0.135	1.87	5.800	8.700				
2023-004	1 LACTATE-P.	165 VITROS	63 KODAK	21	4.195	0.100	2.38	3.400	5.000				
2023-005	1 LACTATE-P.	165 VITROS	63 KODAK	21	5.529	0.120	2.17	4.400	6.600				
137 LIPASE													
2023-001	1 COLORIMET.	203 ROCHE	93 ROCHE	15	37.067	2.670	7.20	30.000	44.000				
2023-001	2 ENZIMATIC	165 VITROS	63 KODAK	83	281.305	9.684	3.44	225.000	338.000				
2023-001	2 ENZIMATIC	215 B.C DXC	134 BECKM. COUL	10	42.600	3.555	8.35	34.000	51.000				
2023-001	4 ENZ/COLOR	184 INTEGRA	93 ROCHE	10	37.500	2.377	6.34	30.000	45.000				
2023-001	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	16	37.313	2.338	6.27	30.000	45.000				
2023-001	4 ENZ/COLOR	203 ROCHE	93 ROCHE	13	37.846	0.948	2.51	30.000	45.000				
2023-001	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	17	37.385	1.003	2.68	30.000	45.000				
2023-001	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	17	118.000	10.000	8.47	94.000	142.000				

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
137	LIPASE	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2023-002	1	COLORIMET.	203	ROCHE	93	ROCHE	15	29.133	2.553	8.76	23.000	35.000
2023-002	2	ENZIMATIC	165	VITROS	63	KODAK	83	193.695	7.246	3.74	155.000	232.000
2023-002	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	36.500	3.008	8.24	29.000	44.000
2023-002	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	29.000	1.949	6.72	23.000	35.000
2023-002	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	16	27.938	2.331	8.34	22.000	34.000
2023-002	4	ENZ/COLOR	203	ROCHE	93	ROCHE	13	29.231	1.049	3.59	23.000	35.000
2023-002	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	93.000	9.000	9.68	74.000	112.000
2023-002	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	29.462	0.843	2.86	24.000	35.000
2023-003	1	COLORIMET.	203	ROCHE	93	ROCHE	15	89.533	5.162	5.77	72.000	107.000
2023-003	2	ENZIMATIC	165	VITROS	63	KODAK	83	860.463	55.766	6.48	688.000	1033.000
2023-003	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	84.600	6.359	7.52	68.000	102.000
2023-003	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	88.400	5.407	6.12	71.000	106.000
2023-003	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	16	97.875	4.285	4.38	78.000	117.000
2023-003	4	ENZ/COLOR	203	ROCHE	93	ROCHE	13	91.615	3.991	4.36	73.000	110.000
2023-003	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	90.615	3.498	3.86	72.000	109.000
2023-003	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	288.000	30.000	10.42	230.000	346.000
2023-004	1	COLORIMET.	203	ROCHE	93	ROCHE	15	54.933	2.489	4.53	44.000	66.000
2023-004	2	ENZIMATIC	165	VITROS	63	KODAK	83	470.671	14.897	3.17	377.000	565.000
2023-004	2	ENZIMATIC	215	B.C DXC	134	BECKM.COUL	10	58.800	3.655	6.22	47.000	71.000
2023-004	4	ENZ/COLOR	184	INTEGRA	93	ROCHE	10	55.300	3.378	6.11	44.000	66.000
2023-004	4	ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	16	58.375	2.826	4.84	47.000	70.000
2023-004	4	ENZ/COLOR	203	ROCHE	93	ROCHE	13	56.333	1.700	3.02	45.000	68.000
2023-004	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	176.000	15.000	8.52	141.000	211.000
2023-004	5	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	17	56.231	1.423	2.53	45.000	67.000
2023-005	1	COLORIMET.	203	ROCHE	93	ROCHE	15	69.500	2.719	3.91	56.000	83.000
2023-005	2	ENZIMATIC	165	VITROS	63	KODAK	83	608.817	19.118	3.14	487.000	731.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2023-005	2 ENZIMATIC	215 B.C DXC	134 BECKM.COUL	10	70.000	5.675	8.11	56.000	84.000		
2023-005	4 ENZ/COLOR	184 INTEGRA	93 ROCHE	10	69.200	3.945	5.70	55.000	83.000		
2023-005	4 ENZ/COLOR	186 BECK. COUL	76 AU-BECKMAN	16	74.875	3.551	4.74	60.000	90.000		
2023-005	4 ENZ/COLOR	203 ROCHE	93 ROCHE	13	71.154	2.413	3.39	57.000	85.000		
2023-005	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	17	71.000	2.112	2.97	57.000	85.000		
2023-005	5 SIEMENS 37	38 SIEMENS DI	143 SIEMENS	17	224.000	20.000	8.93	179.000	269.000		
138 PHOSPHORUS		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %								
2023-001	1 PHOSPHOMO.	38 SIEMENS DI	143 SIEMENS	50	3.214	0.101	3.14	2.600	3.900		
2023-001	1 PHOSPHOMO.	165 VITROS	63 KODAK	92	3.202	0.100	3.12	2.600	3.800		
2023-001	1 PHOSPHOMO.	184 INTEGRA	93 ROCHE	16	3.006	0.139	4.63	2.400	3.600		
2023-001	1 PHOSPHOMO.	186 BECK. COUL	76 AU-BECKMAN	19	2.979	0.144	4.82	2.400	3.600		
2023-001	1 PHOSPHOMO.	203 ROCHE	93 ROCHE	37	3.014	0.099	3.29	2.400	3.600		
2023-001	1 PHOSPHOMO.	215 B.C DXC	134 BECKM.COUL	10	3.120	0.125	4.00	2.500	3.700		
2023-002	1 PHOSPHOMO.	38 SIEMENS DI	143 SIEMENS	50	2.673	0.090	3.36	2.100	3.200		
2023-002	1 PHOSPHOMO.	165 VITROS	63 KODAK	92	2.756	0.106	3.85	2.200	3.300		
2023-002	1 PHOSPHOMO.	184 INTEGRA	93 ROCHE	16	2.513	0.127	5.05	2.000	3.000		
2023-002	1 PHOSPHOMO.	186 BECK. COUL	76 AU-BECKMAN	19	2.484	0.087	3.52	2.000	3.000		
2023-002	1 PHOSPHOMO.	203 ROCHE	93 ROCHE	37	2.517	0.083	3.31	2.000	3.000		
2023-002	1 PHOSPHOMO.	215 B.C DXC	134 BECKM.COUL	10	2.610	0.122	4.68	2.100	3.100		
2023-003	1 PHOSPHOMO.	38 SIEMENS DI	143 SIEMENS	50	6.800	0.223	3.28	5.400	8.200		
2023-003	1 PHOSPHOMO.	165 VITROS	63 KODAK	92	6.448	0.183	2.84	5.200	7.700		
2023-003	1 PHOSPHOMO.	184 INTEGRA	93 ROCHE	16	6.419	0.238	3.70	5.100	7.700		
2023-003	1 PHOSPHOMO.	186 BECK. COUL	76 AU-BECKMAN	19	6.463	0.232	3.59	5.200	7.800		
2023-003	1 PHOSPHOMO.	203 ROCHE	93 ROCHE	37	6.577	0.193	2.93	5.300	7.900		
2023-003	1 PHOSPHOMO.	215 B.C DXC	134 BECKM.COUL	10	7.030	0.341	4.85	5.600	8.400		
2023-004	1 PHOSPHOMO.	38 SIEMENS DI	143 SIEMENS	50	4.456	0.112	2.50	3.600	5.300		
2023-004	1 PHOSPHOMO.	165 VITROS	63 KODAK	92	4.270	0.122	2.85	3.400	5.100		

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-004	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	16	4.144	0.150	3.62	3.300	5.000
2023-004	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	19	4.200	0.205	4.89	3.400	5.000
2023-004	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	37	4.246	0.115	2.72	3.400	5.100
2023-004	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	4.560	0.262	5.74	3.600	5.500
138	PHOSPHORUS	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2023-005	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	50	5.446	0.126	2.31	4.400	6.500
2023-005	1	PHOSPHOMO.	165	VITROS	63	KODAK	92	5.179	0.133	2.57	4.100	6.200
2023-005	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	16	5.063	0.132	2.60	4.100	6.100
2023-005	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	19	5.058	0.196	3.87	4.000	6.100
2023-005	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	37	5.181	0.133	2.57	4.100	6.200
2023-005	1	PHOSPHOMO.	215	B.C DXC	134	BECKM.COUL	10	5.630	0.228	4.05	4.500	6.800
169	CO2					EVALUATION CRITERIA: TARGET VALUE 3 SD						
2023-001	1	Generic Me	165	VITROS	63	KODAK	13	12.923	1.900	14.70	7.000	19.000
2023-001	1	Generic Me	184	INTEGRA	93	ROCHE	13	14.077	2.165	15.38	8.000	21.000
2023-001	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	13.760	2.232	16.22	7.000	20.000
2023-001	1	Generic Me	203	ROCHE	93	ROCHE	19	13.474	1.634	12.13	9.000	18.000
2023-001	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	73	16.260	2.364	14.54	9.000	23.000
2023-001	2	ENZYMATIC	165	VITROS	63	KODAK	70	12.986	1.711	13.18	8.000	18.000
2023-001	2	ENZYMATIC	165	VITROS	156	Kit 32	68	13.265	1.686	12.71	8.000	18.000
2023-001	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	12.692	1.976	15.57	7.000	19.000
2023-001	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	10	13.800	1.600	11.59	9.000	19.000
2023-002	1	Generic Me	165	VITROS	63	KODAK	13	12.538	1.278	10.19	9.000	16.000
2023-002	1	Generic Me	184	INTEGRA	93	ROCHE	13	12.769	2.547	19.94	5.000	20.000
2023-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	12.560	1.627	12.95	8.000	17.000
2023-002	1	Generic Me	203	ROCHE	93	ROCHE	19	12.474	1.728	13.85	7.000	18.000
2023-002	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	73	15.014	2.248	14.97	8.000	22.000
2023-002	2	ENZYMATIC	165	VITROS	63	KODAK	70	11.857	1.734	14.63	7.000	17.000
2023-002	2	ENZYMATIC	165	VITROS	156	Kit 32	68	12.044	1.667	13.84	7.000	17.000
2023-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	12.462	1.865	14.97	7.000	18.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-002	2	ENZYMATIC	219	APELLICA	143	SIEMENS	10	13.000	1.949	15.00	7.000	19.000
169	CO2	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2023-003	1	Generic Me	165	VITROS	63	KODAK	13	22.154	2.032	9.17	16.000	28.000
2023-003	1	Generic Me	184	INTEGRA	93	ROCHE	13	23.385	2.403	10.28	16.000	31.000
2023-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	24.480	3.176	12.98	15.000	34.000
2023-003	1	Generic Me	203	ROCHE	93	ROCHE	19	23.263	2.291	9.85	16.000	30.000
2023-003	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	73	26.458	2.217	8.38	20.000	33.000
2023-003	2	ENZYMATIC	165	VITROS	63	KODAK	70	21.897	1.941	8.87	16.000	28.000
2023-003	2	ENZYMATIC	165	VITROS	156	Kit 32	68	22.206	2.019	9.09	16.000	28.000
2023-003	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	21.308	2.728	12.80	13.000	29.000
2023-003	2	ENZYMATIC	219	APELLICA	143	SIEMENS	10	24.800	1.661	6.70	20.000	30.000
2023-004	1	Generic Me	165	VITROS	63	KODAK	13	15.538	1.393	8.97	11.000	20.000
2023-004	1	Generic Me	184	INTEGRA	93	ROCHE	13	16.923	2.586	15.28	9.000	25.000
2023-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	17.360	1.937	11.16	12.000	23.000
2023-004	1	Generic Me	203	ROCHE	93	ROCHE	19	16.789	1.436	8.55	12.000	21.000
2023-004	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	73	19.750	2.320	11.75	13.000	27.000
2023-004	2	ENZYMATIC	165	VITROS	63	KODAK	70	15.406	1.731	11.23	10.000	21.000
2023-004	2	ENZYMATIC	165	VITROS	156	Kit 32	68	16.000	1.807	11.29	11.000	21.000
2023-004	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	16.154	1.747	10.82	11.000	21.000
2023-004	2	ENZYMATIC	219	APELLICA	143	SIEMENS	10	17.800	1.833	10.30	12.000	23.000
2023-005	1	Generic Me	165	VITROS	63	KODAK	13	18.615	1.389	7.46	14.000	23.000
2023-005	1	Generic Me	184	INTEGRA	93	ROCHE	13	19.538	2.240	11.46	13.000	26.000
2023-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	25	20.200	1.918	9.50	14.000	26.000
2023-005	1	Generic Me	203	ROCHE	93	ROCHE	19	18.842	2.300	12.21	12.000	26.000
2023-005	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	73	22.397	1.978	8.83	16.000	28.000
2023-005	2	ENZYMATIC	165	VITROS	63	KODAK	70	18.294	1.926	10.53	13.000	24.000
2023-005	2	ENZYMATIC	165	VITROS	156	Kit 32	68	18.706	1.871	10.00	13.000	24.000
2023-005	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	19.154	2.381	12.43	12.000	26.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE							
ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2023-005	2	ENZYMATIC		219	ATELLICA	143	SIEMENS	10	20.300	2.532	12.47	13.000	28.000
170	DIRECT BILIRUBIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}								
2023-001	4	JEND.-GROG		38	SIEMENS DI	143	SIEMENS	49	0.406	0.037	9.18	0.300	0.500
2023-001	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.094	0.203	216.27	0	0.700
2023-001	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.800	0.071	8.84	0.600	1.000
2023-001	13	AZOBIL.W/D		203	ROCHE	93	ROCHE	17	0.344	0.050	14.43	0.200	0.500
2023-001	16	DIAZO ENDP		215	B.C DXC	134	BECKM.COUL	10	0.440	0.049	11.13	0.300	0.600
2023-001	18	DIAZ. SULF		191	RX-SERIES	126	RANDOX	12	0.625	0.136	21.79	0.200	1.000
2023-002	4	JEND.-GROG		38	SIEMENS DI	143	SIEMENS	49	0.229	0.045	19.76	0.100	0.400
2023-002	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.500	0.071	14.14	0.300	0.700
2023-002	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.097	0.192	198.26	0	0.700
2023-002	13	AZOBIL.W/D		203	ROCHE	93	ROCHE	17	0.200	0.034	17.15	0.100	0.300
2023-002	16	DIAZO ENDP		215	B.C DXC	134	BECKM.COUL	10	0.250	0.050	20.00	0.100	0.400
2023-002	18	DIAZ. SULF		191	RX-SERIES	126	RANDOX	12	0.350	0.076	21.82	0.100	0.600
2023-003	4	JEND.-GROG		38	SIEMENS DI	143	SIEMENS	49	1.643	0.099	6.02	1.300	2.000
2023-003	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.854	0.349	40.83	0	1.900
2023-003	11	SPECT. WIT		165	VITROS	63	KODAK	66	2.500	0.187	7.48	1.900	3.100
2023-003	13	AZOBIL.W/D		203	ROCHE	93	ROCHE	17	1.375	0.097	7.04	1.100	1.700
2023-003	16	DIAZO ENDP		215	B.C DXC	134	BECKM.COUL	10	1.530	0.046	3.00	1.200	1.800
2023-003	18	DIAZ. SULF		191	RX-SERIES	126	RANDOX	12	2.300	0.532	23.14	0.700	3.900
2023-004	4	JEND.-GROG		38	SIEMENS DI	143	SIEMENS	49	0.844	0.089	10.52	0.600	1.100
2023-004	11	SPECT. WIT		165	VITROS	63	KODAK	66	1.475	0.259	17.53	0.700	2.300
2023-004	11	SPECT. WIT		165	VITROS	63	KODAK	66	0.277	0.216	78.04	0	0.900
2023-004	13	AZOBIL.W/D		203	ROCHE	93	ROCHE	17	0.729	0.107	14.69	0.400	1.100
2023-004	16	DIAZO ENDP		215	B.C DXC	134	BECKM.COUL	10	0.830	0.046	5.52	0.700	1.000
2023-004	18	DIAZ. SULF		191	RX-SERIES	126	RANDOX	12	1.217	0.279	22.96	0.400	2.100

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 10 ROUTINE

ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
170	DIRECT BILIRUBIN		CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}						
2023-005	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	1.163	0.093	7.97	0.900	1.400	
2023-005	11	SPECT. WIT	165	VITROS	63	KODAK	66	0.512	0.247	48.24	0	1.300	
2023-005	11	SPECT. WIT	165	VITROS	63	KODAK	66	1.800	0.141	7.86	1.400	2.200	
2023-005	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	17	1.024	0.173	16.93	0.500	1.500	
2023-005	16	DIAZO ENDP	215	B.C DXC	134	BECKM.COUL	10	1.140	0.066	5.82	0.900	1.400	
2023-005	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	12	1.633	0.352	21.55	0.600	2.700	

SPEC: 10 CHEMISTRY SUB: 10 ROUTINE GRP: 15 WHOLE BLOOD GLUCOSE

ANALYTE													
SAMPLE	METHOD		SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
157	WHOLE BLOOD GLUCOSE						EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2023-101	20	ABBOT FREE					19	199.158	7.147	3.59	179.000	219.000	
2023-101	23	ABBOTT PRE					28	177.815	8.269	4.65	160.000	196.000	
2023-101	27	STAT SRIP.					48	122.000	10.000	8.20	110.000	134.000	
2023-101	27	STAT SRIP.					48	144.667	12.257	8.47	130.000	159.000	
2023-101	33	AC.CHEK II					31	167.226	4.499	2.69	151.000	184.000	
2023-101	34	FREE STYL					45	190.000	15.589	8.20	171.000	209.000	
2023-101	34	FREE STYL					45	167.000	3.300	1.98	150.000	184.000	
2023-102	20	ABBOT FREE					19	499.889	0.458	0.09	450.000	550.000	
2023-102	23	ABBOTT PRE					28	447.179	23.577	5.27	402.000	492.000	
2023-102	27	STAT SRIP.					48	299.574	26.662	8.90	270.000	330.000	
2023-102	27	STAT SRIP.					48	262.000	30.000	11.45	236.000	288.000	
2023-102	33	AC.CHEK II					31	429.355	15.541	3.62	386.000	472.000	
2023-102	34	FREE STYL					45	430.000	6.164	1.43	386.000	472.000	
2023-102	34	FREE STYL					45	491.636	19.575	3.98	442.000	541.000	
2023-103	20	ABBOT FREE					19	107.579	4.913	4.57	97.000	118.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 10 ROUTINE			GRP: 15 WHOLE BLOOD GLUCOSE			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2023-103	23	ABBOTT PRE		28	96.000	4.922	5.13	86.000	106.000
2023-103	27	STAT SRIP.		48	75.000	7.000	9.33	68.000	82.000
2023-103	27	STAT SRIP.		48	85.417	5.003	5.86	77.000	94.000
2023-103	33	AC.CHEK II		31	95.645	2.671	2.79	86.000	105.000
2023-103	34	FREE STYL		45	96.000	2.867	2.99	86.000	105.000
2023-103	34	FREE STYL		45	103.533	8.027	7.75	93.000	114.000
157 WHOLE BLOOD GLUCOSE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2023-104	20	ABBOT FREE		19	500.000	0.000	0.00	450.000	550.000
2023-104	23	ABBOTT PRE		28	448.000	26.193	5.85	403.000	493.000
2023-104	27	STAT SRIP.		48	297.277	26.922	9.06	268.000	327.000
2023-104	27	STAT SRIP.		48	262.000	20.000	7.63	236.000	288.000
2023-104	33	AC.CHEK II		31	430.900	17.236	4.00	388.000	474.000
2023-104	34	FREE STYL		45	487.289	25.785	5.29	439.000	536.000
2023-104	34	FREE STYL		45	431.000	25.171	5.84	388.000	474.000
2023-105	20	ABBOT FREE		19	108.421	2.797	2.58	98.000	119.000
2023-105	23	ABBOTT PRE		28	97.179	8.916	9.18	87.000	107.000
2023-105	27	STAT SRIP.		48	84.646	5.422	6.41	76.000	93.000
2023-105	27	STAT SRIP.		48	75.000	7.000	9.33	68.000	82.000
2023-105	33	AC.CHEK II		31	96.129	2.636	2.74	87.000	106.000
2023-105	34	FREE STYL		45	96.000	1.700	1.77	87.000	106.000
2023-105	34	FREE STYL		45	102.511	7.751	7.56	92.000	113.000
SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES			

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
007	BLOOD GASES-pCO2		CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE	8	% OR 5.00	{GREATER}				
2023-051	265 ROCHE COBA				31	81.694	5.589	6.84	75.200	88.200	
2023-052	265 ROCHE COBA				31	47.955	1.018	2.12	43.000	53.000	
2023-053	265 ROCHE COBA				31	21.945	0.688	3.13	16.900	26.900	
2023-054	265 ROCHE COBA				31	96.284	2.922	3.03	88.600	104.000	
2023-055	265 ROCHE COBA				31	21.826	0.701	3.21	16.800	26.800	
008	BLOOD GASES-pH		CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE	0.04						
2023-051	265 ROCHE COBA				31	7.080	0.008	0.12	7.040	7.120	
2023-052	265 ROCHE COBA				31	7.348	0.005	0.07	7.308	7.388	
2023-053	265 ROCHE COBA				31	7.673	0.009	0.11	7.633	7.713	
2023-054	265 ROCHE COBA				31	7.067	0.008	0.11	7.027	7.107	
2023-055	265 ROCHE COBA				31	7.675	0.010	0.13	7.635	7.715	
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	3	SD					
2023-051	265 ROCHE COBA				31	89.610	16.473	18.38	40.200	139.000	
2023-052	265 ROCHE COBA				31	121.558	7.553	6.21	98.900	144.200	
2023-053	265 ROCHE COBA				31	154.516	9.820	6.36	125.100	184.000	
2023-054	265 ROCHE COBA				31	81.863	10.206	12.47	51.200	112.500	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
009 BLOOD GASES-pO2			CLIA TEST ID #: 325			EVALUATION CRITERIA: TARGET VALUE 3 SD				
2023-055	265	ROCHE COBA			31	157.600	8.530	5.41	132.000	183.200

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
029 FOLL. STIM. HOR.-FSH			CLIA TEST ID #: 0							
2023-031	116	ROCHE COBA			16	17.313	0.945	5.46	14.500	20.100
2023-031	149	ARC i2000s			10	16.080	0.668	4.15	14.100	18.100
2023-032	116	ROCHE COBA			16	14.381	0.805	5.60	12.000	16.800
2023-032	149	ARC i2000s			10	13.350	0.533	4.00	11.700	15.000
2023-033	116	ROCHE COBA			16	36.638	1.598	4.36	31.800	41.400
2023-033	149	ARC i2000s			10	37.100	1.807	4.87	31.700	42.500
2023-034	116	ROCHE COBA			16	24.063	1.095	4.55	20.800	27.300
2023-034	149	ARC i2000s			10	23.010	0.847	3.68	20.500	25.600
2023-035	116	ROCHE COBA			16	29.475	1.197	4.06	25.900	33.100
2023-035	149	ARC i2000s			10	28.810	1.371	4.76	24.700	32.900
030 FREE THYROXINE			CLIA TEST ID #: 545							
2023-031	115	VITROS ECI			42	4.352	0.171	3.92	3.800	4.900
2023-031	116	ROCHE COBA			49	1.922	0.084	4.37	1.700	2.200
2023-031	125	B.C.ACCESS			43	1.631	0.094	5.75	1.300	1.900
2023-031	149	ARC i2000s			23	1.443	0.065	4.49	1.200	1.600
2023-031	160	SIEMENS EX			49	1.760	0.088	5.02	1.500	2.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE			NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	LABS	VALUE	DEVIATION	CV	LOW	HIGH
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2023-032	115 VITROS ECI		42	3.283	0.160	4.88	2.800	3.800
2023-032	116 ROCHE COBA		49	1.545	0.067	4.35	1.300	1.700
2023-032	125 B.C.ACCESS		43	1.350	0.085	6.31	1.100	1.600
2023-032	149 ARC i2000s		23	1.165	0.070	5.99	1.000	1.400
2023-032	160 SIEMENS EX		49	1.414	0.067	4.74	1.200	1.600
2023-033	115 VITROS ECI		42	7.000	0.000	0.00	7.000	7.000
2023-033	116 ROCHE COBA		49	4.149	0.157	3.78	3.700	4.600
2023-033	125 B.C.ACCESS		43	2.772	0.191	6.89	2.200	3.300
2023-033	149 ARC i2000s		23	2.591	0.153	5.90	2.100	3.100
2023-033	160 SIEMENS EX		49	3.733	0.139	3.72	3.300	4.200
2023-034	115 VITROS ECI		42	6.119	0.185	3.03	5.600	6.700
2023-034	116 ROCHE COBA		49	2.733	0.120	4.40	2.400	3.100
2023-034	125 B.C.ACCESS		43	2.150	0.152	7.05	1.700	2.600
2023-034	149 ARC i2000s		23	1.995	0.064	3.20	1.800	2.200
2023-034	160 SIEMENS EX		49	2.488	0.099	3.99	2.200	2.800
2023-035	115 VITROS ECI		42	6.948	0.077	1.11	6.700	7.200
2023-035	116 ROCHE COBA		49	3.333	0.142	4.26	2.900	3.800
2023-035	125 B.C.ACCESS		43	2.448	0.122	4.98	2.100	2.800
2023-035	149 ARC i2000s		23	2.300	0.114	4.97	2.000	2.600
2023-035	160 SIEMENS EX		49	3.044	0.138	4.54	2.600	3.500
032	hCG-QUANTITATIVE	CLIA TEST ID #: 555						
2023-031	115 VITROS ECI		20	289.890	11.436	3.94	255.600	324.200
2023-031	115 VITROS ECI		20	305.667	43.057	14.09	176.500	434.800
2023-031	116 ROCHE COBA		19	305.667	43.057	14.09	176.500	434.800
2023-031	116 ROCHE COBA		19	221.361	11.176	5.05	187.800	254.900
2023-031	125 B.C.ACCESS		12	221.442	10.245	4.63	190.700	252.200

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
032	hCG-QUANTITATIVE	CLIA TEST ID #: 555	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2023-032	115 VITROS ECI			20	170.017	6.522	3.84	150.500	189.600	
2023-032	115 VITROS ECI			20	168.120	6.329	3.76	149.100	187.100	
2023-032	116 ROCHE COBA			19	129.105	12.425	9.62	91.800	166.400	
2023-032	116 ROCHE COBA			19	170.017	6.522	3.84	150.500	189.600	
2023-032	125 B.C.ACCESS			12	132.692	6.056	4.56	114.500	150.900	
2023-033	115 VITROS ECI			20	1075.515	37.642	3.50	962.600	1188.400	
2023-033	115 VITROS ECI			20	1001.583	35.598	3.55	894.800	1108.400	
2023-033	116 ROCHE COBA			19	1001.583	35.598	3.55	894.800	1108.400	
2023-033	116 ROCHE COBA			19	857.600	48.378	5.64	712.500	1002.700	
2023-033	125 B.C.ACCESS			12	760.633	39.190	5.15	643.100	878.200	
2023-034	115 VITROS ECI			20	537.133	11.606	2.16	502.300	572.000	
2023-034	115 VITROS ECI			20	561.789	14.705	2.62	517.700	605.900	
2023-034	116 ROCHE COBA			19	430.756	24.228	5.62	358.100	503.400	
2023-034	116 ROCHE COBA			19	537.133	11.606	2.16	502.300	572.000	
2023-034	125 B.C.ACCESS			12	415.017	18.520	4.46	359.500	470.600	
2023-035	115 VITROS ECI			20	784.668	21.558	2.75	720.000	849.300	
2023-035	115 VITROS ECI			20	736.683	25.089	3.41	661.400	811.900	
2023-035	116 ROCHE COBA			19	736.683	25.089	3.41	661.400	811.900	
2023-035	116 ROCHE COBA			19	613.022	30.753	5.02	520.800	705.300	
2023-035	125 B.C.ACCESS			12	568.592	29.546	5.20	480.000	657.200	
035	PROLACTIN	CLIA TEST ID #: 0								
2023-031	116 ROCHE COBA			18	12.044	0.704	5.85	9.900	14.200	
2023-032	116 ROCHE COBA			18	8.489	0.510	6.01	7.000	10.000	
2023-033	116 ROCHE COBA			18	37.200	2.265	6.09	30.400	44.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
035	PROLACTIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2023-034	116 ROCHE COBA			18	20.239	1.107	5.47	16.900	23.600	
2023-035	116 ROCHE COBA			18	27.300	1.652	6.05	22.300	32.300	
037	TESTOSTERONE									
2023-031	149 ARC i2000s			10	5.170	0.287	5.54	4.300	6.000	
2023-032	149 ARC i2000s			10	3.470	0.179	5.16	2.900	4.000	
2023-033	149 ARC i2000s			10	14.510	1.470	10.13	10.100	18.900	
2023-034	149 ARC i2000s			10	9.940	1.775	17.86	4.600	15.300	
2023-035	149 ARC i2000s			10	13.140	1.037	7.90	10.000	16.300	
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585								
2023-031	106 TOSOH AIA			12	3.142	0.312	9.94	2.200	4.100	
2023-031	115 VITROS ECI			48	3.250	0.100	3.08	3.000	3.600	
2023-031	116 ROCHE COBA			54	3.089	0.114	3.70	2.700	3.400	
2023-031	125 B.C.ACCESS			57	2.668	0.180	6.74	2.100	3.200	
2023-031	149 ARC i2000s			25	2.400	0.117	4.86	2.100	2.700	
2023-031	160 SIEMENS EX			81	2.389	0.175	7.31	1.900	2.900	
2023-032	106 TOSOH AIA			12	2.283	0.234	10.25	1.600	3.000	
2023-032	115 VITROS ECI			48	2.277	0.080	3.50	2.000	2.500	
2023-032	116 ROCHE COBA			54	2.287	0.102	4.46	2.000	2.600	
2023-032	125 B.C.ACCESS			57	1.925	0.126	6.55	1.500	2.300	
2023-032	149 ARC i2000s			25	1.720	0.075	4.35	1.500	1.900	
2023-032	160 SIEMENS EX			81	1.740	0.127	7.30	1.400	2.100	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2023-033	106 TOSOH AIA			12	8.517	0.835	9.81	6.000	11.000	
2023-033	115 VITROS ECI			48	8.842	0.278	3.14	8.000	9.700	
2023-033	116 ROCHE COBA			54	7.694	0.295	3.84	6.800	8.600	
2023-033	125 B.C.ACCESS			57	7.661	0.452	5.90	6.300	9.000	
2023-033	149 ARC i2000s			25	6.808	0.290	4.26	5.900	7.700	
2023-033	160 SIEMENS EX			81	6.540	0.471	7.21	5.100	8.000	
2023-034	106 TOSOH AIA			12	5.050	0.578	11.45	3.300	6.800	
2023-034	115 VITROS ECI			48	5.273	0.176	3.35	4.700	5.800	
2023-034	116 ROCHE COBA			54	4.802	0.172	3.58	4.300	5.300	
2023-034	125 B.C.ACCESS			57	4.363	0.280	6.42	3.500	5.200	
2023-034	149 ARC i2000s			25	3.924	0.184	4.69	3.400	4.500	
2023-034	160 SIEMENS EX			81	3.830	0.257	6.70	3.100	4.600	
2023-035	106 TOSOH AIA			12	6.567	0.679	10.33	4.500	8.600	
2023-035	115 VITROS ECI			48	6.881	0.212	3.08	6.200	7.500	
2023-035	116 ROCHE COBA			54	6.079	0.223	3.66	5.400	6.700	
2023-035	125 B.C.ACCESS			57	5.760	0.358	6.22	4.700	6.800	
2023-035	149 ARC i2000s			25	5.163	0.182	3.53	4.600	5.700	
2023-035	160 SIEMENS EX			81	5.005	0.332	6.63	4.000	6.000	
040	THYROXINE (T4)	CLIA TEST ID #: 595	EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}							
2023-031	32 SIEM DIME.			50	7.939	0.532	6.70	6.400	9.500	
2023-031	115 VITROS ECI			38	6.589	0.337	5.11	5.300	7.900	
2023-031	116 ROCHE COBA			50	7.068	0.453	6.41	5.700	8.500	
2023-031	125 B.C.ACCESS			46	7.272	0.672	9.24	5.800	8.700	
2023-031	149 ARC i2000s			23	6.513	0.261	4.01	5.200	7.800	
2023-032	32 SIEM DIME.			50	6.308	0.529	8.38	5.000	7.600	
2023-032	115 VITROS ECI			38	5.203	0.211	4.06	4.200	6.200	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-032	116	ROCHE COBA		50	5.720	0.376	6.57	4.600	6.900
2023-032	125	B.C.ACCESS		46	5.726	0.625	10.91	4.600	6.900
2023-032	149	ARC i2000s		23	5.100	0.240	4.70	4.100	6.100
040	THYROXINE (T4)		CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}				
2023-033	32	SIEM DIME.		50	18.768	0.900	4.79	15.000	22.500
2023-033	115	VITROS ECI		38	15.121	0.761	5.03	12.100	18.100
2023-033	116	ROCHE COBA		50	16.100	1.049	6.51	12.900	19.300
2023-033	125	B.C.ACCESS		46	15.463	1.192	7.71	12.400	18.600
2023-033	149	ARC i2000s		23	15.304	1.049	6.85	12.200	18.400
2023-034	32	SIEM DIME.		50	11.476	0.662	5.77	9.200	13.800
2023-034	115	VITROS ECI		38	9.762	0.512	5.25	7.800	11.700
2023-034	116	ROCHE COBA		50	10.250	0.662	6.46	8.200	12.300
2023-034	125	B.C.ACCESS		46	10.574	0.912	8.62	8.500	12.700
2023-034	149	ARC i2000s		23	9.778	0.440	4.50	7.800	11.700
2023-035	32	SIEM DIME.		50	14.645	0.651	4.45	11.700	17.600
2023-035	115	VITROS ECI		38	12.018	0.599	4.98	9.600	14.400
2023-035	116	ROCHE COBA		50	12.824	0.795	6.20	10.300	15.400
2023-035	125	B.C.ACCESS		46	12.572	0.881	7.00	10.100	15.100
2023-035	149	ARC i2000s		23	12.343	0.723	5.86	9.900	14.800
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %				
2023-031	115	VITROS ECI		14	2.893	0.303	10.49	2.200	3.600
2023-031	116	ROCHE COBA		20	2.660	0.332	12.49	2.000	3.300
2023-031	125	B.C.ACCESS		12	4.067	0.266	6.53	3.100	5.100
2023-031	149	ARC i2000s		13	4.308	0.821	19.07	3.200	5.400
2023-032	115	VITROS ECI		14	1.979	0.227	11.49	1.500	2.500
2023-032	116	ROCHE COBA		20	2.047	0.135	6.60	1.500	2.600
2023-032	125	B.C.ACCESS		12	2.883	0.191	6.62	2.200	3.600

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-032	149	ARC i2000s		13	2.915	0.497	17.06	2.200	3.600	
141 FOLATE			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %					
2023-033	115	VITROS ECI		14	10.936	1.111	10.16	8.200	13.700	
2023-033	116	ROCHE COBA		20	10.740	1.373	12.78	8.100	13.400	
2023-033	125	B.C.ACCESS		12	13.083	0.811	6.20	9.800	16.400	
2023-033	149	ARC i2000s		13	15.154	1.576	10.40	11.400	18.900	
2023-034	115	VITROS ECI		14	5.550	0.583	10.50	4.200	6.900	
2023-034	116	ROCHE COBA		20	5.325	0.507	9.52	4.000	6.700	
2023-034	125	B.C.ACCESS		12	7.183	0.460	6.40	5.400	9.000	
2023-034	149	ARC i2000s		13	7.985	1.093	13.69	6.000	10.000	
2023-035	115	VITROS ECI		14	7.879	0.711	9.03	5.900	9.800	
2023-035	116	ROCHE COBA		20	7.750	0.824	10.63	5.800	9.700	
2023-035	125	B.C.ACCESS		12	9.558	0.681	7.13	7.200	11.900	
2023-035	149	ARC i2000s		13	10.346	1.521	14.70	7.800	12.900	
142 hLH (HUMAN LUT. HOR)										
2023-031	116	ROCHE COBA		14	19.657	0.866	4.40	14.700	24.600	
2023-032	116	ROCHE COBA		14	14.379	0.512	3.56	10.800	18.000	
2023-033	116	ROCHE COBA		14	53.050	1.967	3.71	39.800	66.300	
2023-034	116	ROCHE COBA		14	31.364	1.122	3.58	23.500	39.200	
2023-035	116	ROCHE COBA		14	40.657	1.531	3.77	30.500	50.800	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
031 hCG-QUALITATIVE													
2023-031	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100	
2023-031	142	INSTANT VI		002	002	002	002	002 - POSITIVE	41	41	41	100	
2023-031	150	AIM STEP		002	002	002	002	002 - POSITIVE	92	92	92	100	
2023-031	164	HCG Alere		002	002	002	002	002 - POSITIVE	71	71	71	100	
2023-031	165	Osom HCG C		002	002	002	002	002 - POSITIVE	24	24	24	100	
2023-031	166	FaStep		002	002	002	002	002 - POSITIVE	20	20	20	100	
2023-031	167	Tanner Sci		002	002	002	002	002 - POSITIVE	12	12	12	100	
2023-031	168	STANBIO 20		002	002	002	002	002 - POSITIVE	12	12	12	100	
2023-032	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100	
2023-032	142	INSTANT VI		002	002	002	002	002 - POSITIVE	41	41	41	100	
2023-032	150	AIM STEP		002	002	002	002	002 - POSITIVE	92	92	92	100	
2023-032	164	HCG Alere		002	002	002	002	002 - POSITIVE	71	71	71	100	
2023-032	165	Osom HCG C		002	002	002	002	002 - POSITIVE	24	24	24	100	
2023-032	166	FaStep		002	002	002	002	002 - POSITIVE	20	20	20	100	
2023-032	167	Tanner Sci		002	002	002	002	002 - POSITIVE	12	12	12	100	
2023-032	168	STANBIO 20		002	002	002	002	002 - POSITIVE	12	12	12	100	
2023-033	113	BIO-SIGN		002	002	002	002	002 - POSITIVE	22	22	22	100	
2023-033	142	INSTANT VI		002	002	002	002	002 - POSITIVE	41	41	41	100	
2023-033	150	AIM STEP		002	002	002	002	002 - POSITIVE	92	92	92	100	
2023-033	164	HCG Alere		002	002	002	002	002 - POSITIVE	71	71	71	100	
2023-033	165	Osom HCG C		002	002	002	002	001 - NEGATIVE	24	1	23	0	
2023-033	165	Osom HCG C		002	002	002	002	002 - POSITIVE	24	23	23	100	
2023-033	166	FaStep		002	002	002	002	002 - POSITIVE	20	20	20	100	
2023-033	167	Tanner Sci		002	002	002	002	002 - POSITIVE	12	12	12	100	
2023-033	168	STANBIO 20		002	002	002	002	002 - POSITIVE	12	12	12	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 40 ENDOCRINOLOGY (GEN.)				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE											
2023-034	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100
2023-034	142	INSTANT VI		002 002	002 002		002 - POSITIVE	41	41	41	100
2023-034	150	AIM STEP		002 002	002 002		002 - POSITIVE	92	92	92	100
2023-034	164	HCG Alere		002 002	002 002		002 - POSITIVE	71	71	71	100
2023-034	165	Osom HCG C		002 002	002 002		002 - POSITIVE	24	23	23	100
2023-034	165	Osom HCG C		002 002	002 002		001 - NEGATIVE	24	1	23	0
2023-034	166	FaStep		002 002	002 002		002 - POSITIVE	20	20	20	100
2023-034	167	Tanner Sci		002 002	002 002		002 - POSITIVE	12	12	12	100
2023-034	168	STANBIO 20		002 002	002 002		002 - POSITIVE	12	12	12	100
2023-035	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	22	22	22	100
2023-035	142	INSTANT VI		002 002	002 002		002 - POSITIVE	41	41	41	100
2023-035	150	AIM STEP		002 002	002 002		002 - POSITIVE	92	92	92	100
2023-035	164	HCG Alere		002 002	002 002		002 - POSITIVE	71	71	71	100
2023-035	165	Osom HCG C		002 002	002 002		002 - POSITIVE	24	24	24	100
2023-035	166	FaStep		002 002	002 002		002 - POSITIVE	20	20	20	100
2023-035	167	Tanner Sci		002 002	002 002		002 - POSITIVE	12	12	12	100
2023-035	168	STANBIO 20		002 002	002 002		002 - POSITIVE	12	12	12	100
SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
151 hCG ONLY QUALITATIVE											
2023-021	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100
2023-021	114	INSTANT VI		002 002	002 002		002 - POSITIVE	108	108	108	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-021	118	AIM STEP		002 002	002 002		002 - POSITIVE	155	155	155	100	
2023-021	130	ALERE HCG		002 002	002 002		002 - POSITIVE	91	91	91	100	
2023-021	131	OSOM HCG		002 002	002 002		002 - POSITIVE	30	30	30	100	
2023-021	133	FaStep		002 002	002 002		002 - POSITIVE	28	28	28	100	
2023-021	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	59	59	59	100	
2023-021	136	CLARITY		002 002	002 002		002 - POSITIVE	18	18	18	100	
151 hCG ONLY QUALITATIVE												
2023-022	018	BIO SIGN		002 002	002 002		001 - NEGATIVE	25	1	24	0	
2023-022	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	24	24	100	
2023-022	114	INSTANT VI		002 002	002 002		002 - POSITIVE	108	108	108	100	
2023-022	118	AIM STEP		002 002	002 002		002 - POSITIVE	155	155	155	100	
2023-022	130	ALERE HCG		002 002	002 002		002 - POSITIVE	91	91	91	100	
2023-022	131	OSOM HCG		002 002	002 002		002 - POSITIVE	30	30	30	100	
2023-022	133	FaStep		002 002	002 002		002 - POSITIVE	28	28	28	100	
2023-022	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	59	59	59	100	
2023-022	136	CLARITY		002 002	002 002		002 - POSITIVE	18	18	18	100	
2023-023	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	25	25	100	
2023-023	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	108	108	108	100	
2023-023	118	AIM STEP		001 001	001 001		001 - NEGATIVE	155	155	155	100	
2023-023	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	91	91	91	100	
2023-023	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	30	30	30	100	
2023-023	133	FaStep		001 001	001 001		001 - NEGATIVE	28	28	28	100	
2023-023	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	59	59	59	100	
2023-023	136	CLARITY		001 001	001 001		001 - NEGATIVE	18	18	18	100	
2023-024	018	BIO SIGN		001 001	001 001		002 - POSITIVE	25	1	24	0	
2023-024	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	25	24	24	100	
2023-024	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	108	108	108	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-024	118	AIM STEP		001 001	001 001		001 - NEGATIVE	155	155	155	100	
2023-024	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	91	91	91	100	
2023-024	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	30	30	30	100	
2023-024	133	FaStep		001 001	001 001		001 - NEGATIVE	28	28	28	100	
2023-024	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	59	59	59	100	
2023-024	136	CLARITY		001 001	001 001		001 - NEGATIVE	18	18	18	100	
151 hCG ONLY QUALITATIVE												
2023-025	018	BIO SIGN		002 002	002 002		002 - POSITIVE	25	25	25	100	
2023-025	114	INSTANT VI		002 002	002 002		002 - POSITIVE	108	108	108	100	
2023-025	118	AIM STEP		002 002	002 002		002 - POSITIVE	155	155	155	100	
2023-025	130	ALERE HCG		002 002	002 002		002 - POSITIVE	91	91	91	100	
2023-025	131	OSOM HCG		002 002	002 002		002 - POSITIVE	30	30	30	100	
2023-025	133	FaStep		002 002	002 002		002 - POSITIVE	28	27	27	100	
2023-025	133	FaStep		002 002	002 002		001 - NEGATIVE	28	1	27	0	
2023-025	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	59	59	59	100	
2023-025	136	CLARITY		002 002	002 002		002 - POSITIVE	18	18	18	100	

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
173 T3 UPTAKE												
CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD								
2023-031	1	%U	84 VITROS ECI	1	25-35	30	54.507	1.445	2.65	50.170	58.840	
2023-031	1	%U	91 B.C.ACCESS	2	35-45	29	51.036	1.970	3.86	45.130	56.950	
2023-031	2	TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.795	0.067	8.47	0.590	1.000	
2023-031	4	%	32 DIMENSION	2	35-45	52	39.757	1.592	4.00	34.980	44.530	
2023-031	4	%	91 B.C.ACCESS	2	35-45	14	50.468	2.795	5.54	42.080	58.850	
2023-031	5	TBI	98 ROCHE COBA	4	0.8-1.3	47	0.803	0.053	6.56	0.650	0.960	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE							NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
173 T3 UPTAKE		CLIA TEST ID #: 565	EVALUATION CRITERIA: TARGET VALUE 3 SD									
2023-032	1 %U	84 VITROS ECI	1	25-35	30	55.920	1.322	2.36	51.950	59.890		
2023-032	1 %U	91 B.C.ACCESS	2	35-45	29	51.231	2.491	4.86	43.760	58.700		
2023-032	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.723	0.060	8.34	0.540	0.900		
2023-032	4 %	32 DIMENSION	2	35-45	52	39.416	2.394	6.07	32.230	46.600		
2023-032	4 %	91 B.C.ACCESS	2	35-45	14	51.257	3.213	6.27	41.620	60.900		
2023-032	5 TBI	98 ROCHE COBA	4	0.8-1.3	47	0.844	0.052	6.21	0.690	1.000		
2023-033	1 %U	84 VITROS ECI	1	25-35	30	46.523	1.537	3.30	41.910	51.130		
2023-033	1 %U	91 B.C.ACCESS	2	35-45	29	46.400	2.425	5.23	39.120	53.680		
2023-033	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	1.113	0.096	8.59	0.830	1.400		
2023-033	4 %	32 DIMENSION	2	35-45	52	41.317	1.448	3.50	36.970	45.660		
2023-033	4 %	91 B.C.ACCESS	2	35-45	14	46.414	2.148	4.63	39.970	52.860		
2023-033	5 TBI	98 ROCHE COBA	4	0.8-1.3	47	0.568	0.075	13.15	0.340	0.790		
2023-034	1 %U	84 VITROS ECI	1	25-35	30	51.397	1.355	2.64	47.330	55.460		
2023-034	1 %U	91 B.C.ACCESS	2	35-45	29	49.397	2.524	5.11	41.820	56.970		
2023-034	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	0.924	0.072	7.80	0.710	1.140		
2023-034	4 %	32 DIMENSION	2	35-45	52	40.407	1.867	4.62	34.800	46.010		
2023-034	4 %	91 B.C.ACCESS	2	35-45	14	49.707	3.009	6.05	40.680	58.730		
2023-034	5 TBI	98 ROCHE COBA	4	0.8-1.3	47	0.727	0.061	8.33	0.550	0.910		
2023-035	1 %U	84 VITROS ECI	1	25-35	30	49.023	1.295	2.64	45.140	52.910		
2023-035	1 %U	91 B.C.ACCESS	2	35-45	29	48.364	2.780	5.75	40.020	56.700		
2023-035	2 TUV	95 Arc i2000s	3	0.7 - 1.2	17	1.016	0.077	7.54	0.790	1.250		
2023-035	4 %	32 DIMENSION	2	35-45	52	40.978	2.120	5.17	34.620	47.340		
2023-035	4 %	91 B.C.ACCESS	2	35-45	14	48.050	3.324	6.92	38.080	58.020		
2023-035	5 TBI	98 ROCHE COBA	4	0.8-1.3	47	0.661	0.071	10.69	0.450	0.870		

Participant Summary

MONTH 2 OF YEAR 2023

ANALYTE		METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
043 DIGOXIN				CLIA TEST ID #: 645	EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}						
2023-031	50	VITROS				15	0.647	0.088	13.68	0.400	0.800
2023-032	50	VITROS				15	0.464	0.061	13.14	0.300	0.700
2023-033	50	VITROS				15	2.000	0.085	4.23	1.600	2.400
2023-034	50	VITROS				15	1.020	0.091	8.91	0.800	1.200
2023-035	50	VITROS				15	1.380	0.083	6.03	1.100	1.700
045 FERRITIN				CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %						
2023-031	50	VITROS				18	52.283	1.786	3.42	39.200	65.400
2023-031	90	ROCHE COBA				14	90.143	5.213	5.78	67.600	112.700
2023-032	50	VITROS				18	36.467	1.621	4.45	27.400	45.600
2023-032	90	ROCHE COBA				14	63.314	3.091	4.88	47.500	79.100
2023-033	50	VITROS				18	161.500	6.752	4.18	121.100	201.900
2023-033	90	ROCHE COBA				14	276.086	15.431	5.59	207.100	345.100
2023-034	50	VITROS				18	90.217	3.242	3.59	67.700	112.800
2023-034	90	ROCHE COBA				14	153.357	8.012	5.22	115.000	191.700

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 40 TOXICOLOGY

GRP: 60 TOXICOLOGY

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
045	FERRITIN	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %							
2023-035	50 VITROS			18	120.667	6.351	5.26	90.500	150.800		
2023-035	90 ROCHE COBA			14	207.036	11.289	5.45	155.300	258.800		
046	GENTAMICIN	CLIA TEST ID #: 665									
2023-031	50 VITROS			15	3.147	0.167	5.30	2.400	3.900		
2023-032	50 VITROS			15	1.947	0.081	4.14	1.500	2.400		
2023-033	50 VITROS			15	11.887	0.490	4.12	8.900	14.900		
2023-034	50 VITROS			15	6.040	0.282	4.68	4.500	7.600		
2023-035	50 VITROS			15	8.707	0.509	5.85	6.500	10.900		
050	PHENYTOIN	CLIA TEST ID #: 695									
2023-031	50 VITROS			15	8.413	0.590	7.01	6.300	10.500		
2023-031	92 ROCHE COBA			10	7.810	0.295	3.77	5.900	9.800		
2023-032	50 VITROS			15	4.967	0.394	7.94	3.700	6.200		
2023-032	92 ROCHE COBA			10	4.650	0.377	8.12	3.500	5.800		
2023-033	50 VITROS			15	34.267	3.605	10.52	25.700	42.800		
2023-033	92 ROCHE COBA			10	31.070	1.526	4.91	23.300	38.800		
2023-034	50 VITROS			15	17.333	0.960	5.54	13.000	21.700		
2023-034	92 ROCHE COBA			10	15.360	0.541	3.52	11.500	19.200		
2023-035	50 VITROS			15	24.307	1.405	5.78	18.200	30.400		
2023-035	92 ROCHE COBA			10	22.240	0.940	4.23	16.700	27.800		

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
054 THEOPHYLLINE		CLIA TEST ID #: 735	EVALUATION CRITERIA: TARGET VALUE 25 %							
2023-031	50 VITROS			12	17.642	1.136	6.44	13.200	22.100	
2023-032	50 VITROS			12	11.167	0.754	6.75	8.400	14.000	
2023-033	50 VITROS			12	56.183	2.562	4.56	42.100	70.200	
2023-034	50 VITROS			12	32.250	1.438	4.46	24.200	40.300	
2023-035	50 VITROS			12	40.192	1.839	4.57	30.100	50.200	
127 VANCOMYCIN		CLIA TEST ID #: 0								
2023-031	50 VITROS			19	13.242	0.404	3.05	9.900	16.600	
2023-031	92 ROCHE COBA			10	13.540	0.599	4.42	10.200	16.900	
2023-032	50 VITROS			19	8.050	0.222	2.75	6.000	10.100	
2023-032	92 ROCHE COBA			10	8.210	0.406	4.95	6.200	10.300	
2023-033	50 VITROS			19	51.368	2.533	4.93	38.500	64.200	
2023-033	92 ROCHE COBA			10	47.600	3.383	7.11	35.700	59.500	
2023-034	50 VITROS			19	25.642	0.817	3.19	19.200	32.100	
2023-034	92 ROCHE COBA			10	25.330	1.037	4.10	19.000	31.700	
2023-035	50 VITROS			19	36.839	1.204	3.27	27.600	46.000	
2023-035	92 ROCHE COBA			10	35.540	1.525	4.29	26.700	44.400	
SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
065	URINA-PROTEIN QUANT.	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}			
2023-061	58 VITROS			40	5.692	1.470	25.83	0.700	10.700
2023-061	62 SIEM DIM.			53	21.937	1.469	6.70	16.500	27.400
2023-061	79 BECK. COUL			19	5.279	0.934	17.69	0.300	10.300
2023-061	93 ARCHITECT			20	6.747	0.179	2.65	1.700	11.700
2023-061	113 ROCHE COBA			33	3.838	0.443	11.54	0	8.800
2023-062	58 VITROS			40	177.282	11.170	6.30	133.000	221.600
2023-062	62 SIEM DIM.			53	121.413	2.178	1.79	91.100	151.800
2023-062	79 BECK. COUL			19	104.989	3.566	3.40	78.700	131.200
2023-062	93 ARCHITECT			20	104.195	3.294	3.16	78.100	130.200
2023-062	113 ROCHE COBA			33	96.727	2.294	2.37	72.500	120.900
2023-063	58 VITROS			40	5.000	0.000	0.00	0.000	10.000
2023-063	62 SIEM DIM.			53	14.642	1.237	8.45	9.600	19.600
2023-063	79 BECK. COUL			19	4.679	0.647	13.83	0	9.700
2023-063	93 ARCHITECT			20	6.916	1.042	15.07	1.900	11.900
2023-063	113 ROCHE COBA			33	3.972	0.298	7.51	0	9.000
2023-064	58 VITROS			40	169.564	10.874	6.41	127.200	212.000
2023-064	62 SIEM DIM.			53	119.536	2.009	1.68	89.700	149.400
2023-064	79 BECK. COUL			19	108.800	4.360	4.01	81.600	136.000
2023-064	93 ARCHITECT			20	102.420	3.107	3.03	76.800	128.000
2023-064	113 ROCHE COBA			33	93.288	1.902	2.04	70.000	116.600
2023-065	58 VITROS			40	132.325	10.776	8.14	99.200	165.400
2023-065	62 SIEM DIM.			53	112.123	2.553	2.28	84.100	140.200
2023-065	79 BECK. COUL			19	105.953	3.000	2.83	79.500	132.400
2023-065	93 ARCHITECT			20	100.500	3.253	3.24	75.400	125.600
2023-065	113 ROCHE COBA			33	91.833	1.695	1.85	68.900	114.800

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
067	URI-SPECIFIC GRAVITY	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD					
2023-061	11	AMES NM10S		47	1.015	0.004	0.38	1.004	1.027	
2023-061	13	BAYER CLI		31	1.014	0.003	0.33	1.005	1.024	
2023-061	67	URISCAN		55	1.012	0.003	0.31	1.003	1.021	
2023-061	72	URS-9-TECO		83	1.019	0.004	0.35	1.008	1.030	
2023-061	80	ROCHE (CHE		38	1.010	0.002	0.23	1.003	1.017	
2023-061	89	AIMSTRIP		129	1.015	0.003	0.30	1.006	1.024	
2023-061	94	CLINITEK		105	1.015	0.003	0.34	1.005	1.025	
2023-061	102	ACON LAB		141	1.015	0.003	0.32	1.005	1.024	
2023-061	131	iCHEM VELO		31	1.026	0.001	0.09	1.023	1.028	
2023-061	140	MISSION A		50	1.015	0.004	0.36	1.004	1.026	
2023-061	145	CLINITEK		26	1.031	0.001	0.10	1.028	1.035	
2023-061	147	Mission120		37	1.018	0.002	0.24	1.010	1.025	
2023-061	148	Mission500		79	1.015	0.002	0.24	1.008	1.022	
2023-061	151	Clari. Uro		14	1.014	0.003	0.29	1.005	1.022	
2023-062	11	AMES NM10S		47	1.017	0.004	0.36	1.006	1.028	
2023-062	13	BAYER CLI		31	1.017	0.004	0.35	1.006	1.028	
2023-062	67	URISCAN		55	1.013	0.003	0.31	1.004	1.022	
2023-062	72	URS-9-TECO		83	1.021	0.004	0.36	1.010	1.032	
2023-062	80	ROCHE (CHE		38	1.012	0.002	0.24	1.005	1.019	
2023-062	89	AIMSTRIP		129	1.016	0.003	0.33	1.006	1.026	
2023-062	94	CLINITEK		105	1.016	0.003	0.25	1.009	1.024	
2023-062	102	ACON LAB		141	1.016	0.004	0.38	1.005	1.028	
2023-062	131	iCHEM VELO		31	1.028	0.001	0.11	1.025	1.032	
2023-062	140	MISSION A		50	1.016	0.004	0.40	1.004	1.028	
2023-062	145	CLINITEK		26	1.031	0.001	0.07	1.029	1.033	
2023-062	147	Mission120		37	1.019	0.002	0.18	1.014	1.025	
2023-062	148	Mission500		79	1.018	0.002	0.23	1.011	1.025	
2023-062	151	Clari. Uro		14	1.013	0.003	0.31	1.004	1.022	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
067	URI-SPECIFIC GRAVITY	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2023-063	11 AMES NM10S			47	1.023	0.003	0.32	1.013	1.033
2023-063	13 BAYER CLI			31	1.021	0.005	0.45	1.007	1.035
2023-063	67 URISCAN			55	1.021	0.004	0.35	1.011	1.032
2023-063	72 URS-9-TECO			83	1.023	0.003	0.32	1.013	1.032
2023-063	80 ROCHE (CHE			38	1.017	0.003	0.27	1.009	1.026
2023-063	89 AIMSTRIP			129	1.023	0.004	0.36	1.011	1.034
2023-063	94 CLINITEK			105	1.022	0.003	0.31	1.013	1.032
2023-063	102 ACON LAB			141	1.021	0.003	0.32	1.011	1.031
2023-063	131 iCHEM VELO			31	1.027	0.001	0.11	1.024	1.031
2023-063	140 MISSION A			50	1.022	0.003	0.27	1.013	1.030
2023-063	145 CLINITEK			26	1.034	0.001	0.11	1.030	1.037
2023-063	147 Mission120			37	1.021	0.002	0.19	1.015	1.027
2023-063	148 Mission500			79	1.021	0.002	0.22	1.015	1.028
2023-063	151 Clari. Uro			14	1.024	0.003	0.34	1.013	1.034
2023-064	11 AMES NM10S			47	1.021	0.004	0.38	1.009	1.032
2023-064	13 BAYER CLI			31	1.020	0.002	0.23	1.014	1.028
2023-064	67 URISCAN			55	1.017	0.003	0.27	1.009	1.025
2023-064	72 URS-9-TECO			83	1.023	0.003	0.27	1.015	1.031
2023-064	80 ROCHE (CHE			38	1.012	0.002	0.24	1.005	1.019
2023-064	89 AIMSTRIP			129	1.019	0.003	0.25	1.011	1.027
2023-064	94 CLINITEK			105	1.021	0.002	0.21	1.015	1.027
2023-064	102 ACON LAB			141	1.018	0.003	0.26	1.010	1.027
2023-064	131 iCHEM VELO			31	1.025	0.001	0.09	1.023	1.028
2023-064	140 MISSION A			50	1.018	0.003	0.26	1.010	1.026
2023-064	145 CLINITEK			26	1.027	0.001	0.09	1.024	1.030
2023-064	147 Mission120			37	1.021	0.002	0.19	1.015	1.026
2023-064	148 Mission500			79	1.019	0.002	0.21	1.012	1.025
2023-064	151 Clari. Uro			14	1.016	0.002	0.22	1.010	1.023

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
067	URI-SPECIFIC GRAVITY	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD					
2023-065	11 AMES NM10S			47	1.025	0.003	0.27	1.016	1.033	
2023-065	13 BAYER CLI			31	1.024	0.003	0.28	1.015	1.032	
2023-065	67 URISCAN			55	1.022	0.005	0.47	1.008	1.037	
2023-065	72 URS-9-TECO			83	1.025	0.002	0.23	1.018	1.032	
2023-065	80 ROCHE (CHE			38	1.016	0.002	0.17	1.011	1.021	
2023-065	89 AIMSTRIP			129	1.023	0.002	0.23	1.016	1.031	
2023-065	94 CLINITEK			105	1.024	0.002	0.20	1.018	1.030	
2023-065	102 ACON LAB			141	1.021	0.002	0.24	1.014	1.029	
2023-065	131 iCHEM VELO			31	1.025	0.001	0.09	1.022	1.028	
2023-065	140 MISSION A			50	1.022	0.003	0.28	1.014	1.031	
2023-065	145 CLINITEK			26	1.030	0.001	0.09	1.027	1.033	
2023-065	147 Mission120			37	1.024	0.002	0.24	1.017	1.032	
2023-065	148 Mission500			79	1.020	0.000	0.00	1.020	1.020	
2023-065	151 Clari. Uro			14	1.023	0.002	0.24	1.015	1.030	
166	MICROALBUMIN		EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}				
2023-061	58 VITROS			45	6.000	0.000	0.00	1.000	11.000	
2023-061	62 SIEM DIM.			82	2.050	1.095	53.40	0	7.100	
2023-061	79 BECK. COUL			20	1.950	2.658	136.32	0	7.000	
2023-061	85 Rx DAYTONA			19	1.532	2.506	163.65	0	6.500	
2023-061	93 ARCHITECT			23	4.991	0.029	0.58	0.000	10.000	
2023-061	95 INTEGRA			19	3.389	0.949	27.99	0	8.400	
2023-061	113 ROCHE COBA			38	11.472	2.179	19.00	6.500	16.500	
2023-061	113 ROCHE COBA			38	5.000	0.000	0.00	0.000	10.000	
2023-061	146 ATELLICA			10	3.000	0.000	0.00	0	8.000	
2023-062	58 VITROS			45	847.496	35.332	4.17	635.600	1059.400	
2023-062	62 SIEM DIM.			82	870.468	57.133	6.56	652.900	1088.100	
2023-062	79 BECK. COUL			20	807.175	64.205	7.95	605.400	1009.000	
2023-062	85 Rx DAYTONA			19	806.761	150.107	18.61	605.100	1008.500	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-062	93	ARCHITECT		23	876.791	31.120	3.55	657.600	1096.000
2023-062	95	INTEGRA		19	851.495	43.742	5.14	638.600	1064.400
2023-062	113	ROCHE COBA		38	928.000	29.337	3.16	696.000	1160.000
2023-062	113	ROCHE COBA		38	814.332	48.221	5.92	610.700	1017.900
2023-062	146	APELLICA		10	712.300	19.519	2.74	534.200	890.400
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2023-063	58	VITROS		45	6.000	0.000	0.00	1.000	11.000
2023-063	62	SIEM DIM.		82	2.652	1.523	57.43	0	7.700
2023-063	79	BECK. COUL		20	1.970	2.659	134.99	0	7.000
2023-063	85	Rx DAYTONA		19	1.732	2.362	136.43	0	6.700
2023-063	93	ARCHITECT		23	4.991	0.029	0.58	0.000	10.000
2023-063	95	INTEGRA		19	3.361	1.027	30.57	0	8.400
2023-063	113	ROCHE COBA		38	11.472	2.179	19.00	6.500	16.500
2023-063	113	ROCHE COBA		38	5.000	0.000	0.00	0.000	10.000
2023-063	146	APELLICA		10	3.000	0.000	0.00	0	8.000
2023-064	58	VITROS		45	876.831	41.615	4.75	657.600	1096.000
2023-064	62	SIEM DIM.		82	889.511	48.380	5.44	667.100	1111.900
2023-064	79	BECK. COUL		20	828.165	71.066	8.58	621.100	1035.200
2023-064	85	Rx DAYTONA		19	810.639	144.031	17.77	608.000	1013.300
2023-064	93	ARCHITECT		23	893.891	27.563	3.08	670.400	1117.400
2023-064	95	INTEGRA		19	865.642	45.351	5.24	649.200	1082.100
2023-064	113	ROCHE COBA		38	948.667	19.939	2.10	711.500	1185.800
2023-064	113	ROCHE COBA		38	829.746	50.086	6.04	622.300	1037.200
2023-064	146	APELLICA		10	728.400	27.284	3.75	546.300	910.500
2023-065	58	VITROS		45	866.916	38.502	4.44	650.200	1083.600
2023-065	62	SIEM DIM.		82	868.538	44.405	5.11	651.400	1085.700
2023-065	79	BECK. COUL		20	813.635	63.463	7.80	610.200	1017.000
2023-065	85	Rx DAYTONA		19	720.453	255.169	35.42	540.300	900.600

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-065	93	ARCHITECT		23	886.339	59.359	6.70	664.800	1107.900	
2023-065	95	INTEGRA		19	841.732	46.798	5.56	631.300	1052.200	
2023-065	113	ROCHE COBA		38	813.195	50.953	6.27	609.900	1016.500	
2023-065	113	ROCHE COBA		38	981.667	80.060	8.16	736.300	1227.100	
2023-065	146	APELLICA		10	710.440	33.327	4.69	532.800	888.100	
167 CREATININE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2023-061	58	VITROS		47	244.011	12.278	5.03	183.000	305.000	
2023-061	62	SIEM DIM.		75	237.386	6.860	2.89	178.000	296.700	
2023-061	79	BECK. COUL		21	214.210	13.098	6.11	160.700	267.800	
2023-061	85	Rx DAYTONA		11	210.973	30.355	14.39	158.200	263.700	
2023-061	93	ARCHITECT		22	233.500	7.142	3.06	175.100	291.900	
2023-061	95	INTEGRA		18	243.753	11.569	4.75	182.800	304.700	
2023-061	113	ROCHE COBA		39	242.721	10.034	4.13	182.000	303.400	
2023-061	146	APELLICA		10	224.110	2.924	1.30	168.100	280.100	
2023-062	58	VITROS		47	237.970	6.228	2.62	178.500	297.500	
2023-062	62	SIEM DIM.		75	232.419	6.705	2.89	174.300	290.500	
2023-062	79	BECK. COUL		21	197.655	10.017	5.07	148.200	247.100	
2023-062	85	Rx DAYTONA		11	212.882	26.472	12.43	159.700	266.100	
2023-062	93	ARCHITECT		22	229.819	6.714	2.92	172.400	287.300	
2023-062	95	INTEGRA		18	237.076	10.830	4.57	177.800	296.300	
2023-062	113	ROCHE COBA		39	238.058	7.588	3.19	178.500	297.600	
2023-062	146	APELLICA		10	217.360	3.181	1.46	163.000	271.700	
2023-063	58	VITROS		47	3.185	0.102	3.21	0	8.200	
2023-063	62	SIEM DIM.		75	9.223	5.500	59.64	4.200	14.200	
2023-063	79	BECK. COUL		21	0.368	0.450	122.04	0	5.400	
2023-063	85	Rx DAYTONA		11	0.691	1.377	199.26	0	5.700	
2023-063	93	ARCHITECT		22	4.990	0.029	0.59	0.000	10.000	
2023-063	95	INTEGRA		18	0.153	0.261	170.97	0	5.200	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2023-063	113	ROCHE COBA		39	3.569	1.112	31.15	0	8.600	
2023-063	146	APELLICA		10	3.000	0.000	0.00	0	8.000	
167	CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}						
2023-064	58	VITROS		47	238.050	8.340	3.50	178.500	297.600	
2023-064	62	SIEM DIM.		75	242.207	6.677	2.76	181.700	302.800	
2023-064	79	BECK. COUL		21	216.405	12.173	5.63	162.300	270.500	
2023-064	85	Rx DAYTONA		11	216.527	26.805	12.38	162.400	270.700	
2023-064	93	ARCHITECT		22	235.757	6.920	2.94	176.800	294.700	
2023-064	95	INTEGRA		18	245.318	10.419	4.25	184.000	306.600	
2023-064	113	ROCHE COBA		39	246.976	7.897	3.20	185.200	308.700	
2023-064	146	APELLICA		10	225.960	3.238	1.43	169.500	282.500	
2023-065	58	VITROS		47	3.185	0.102	3.21	0	8.200	
2023-065	62	SIEM DIM.		75	9.224	5.499	59.62	4.200	14.200	
2023-065	79	BECK. COUL		21	0.442	0.386	87.24	0	5.400	
2023-065	85	Rx DAYTONA		11	0.955	1.525	159.72	0	6.000	
2023-065	93	ARCHITECT		22	4.895	0.425	8.68	0	9.900	
2023-065	95	INTEGRA		18	0.388	0.291	74.90	0	5.400	
2023-065	113	ROCHE COBA		39	3.503	1.247	35.59	0	8.500	
2023-065	146	APELLICA		10	3.000	0.000	0.00	0	8.000	

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
057 URINALYSIS-BILIRUBIN												
2023-061	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	47	47	47	100
2023-061	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	31	31	31	100
2023-061	067	URISCAN		057	057	057	057	057 - NEGATIVE	54	54	54	100
2023-061	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	85	85	85	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-061	080	ROCHE (CHE		057	057	057	057 - NEGATIVE	37	37	37	100
2023-061	089	AIMSTRIP		057	057	057	057 - NEGATIVE	130	130	130	100
2023-061	094	CLINITEK		057	057	057	057 - NEGATIVE	105	105	105	100
2023-061	102	ACON LAB		057	057	057	057 - NEGATIVE	136	136	136	100
2023-061	131	iCHEM VELO		057	057	057	057 - NEGATIVE	30	30	30	100
2023-061	140	MISSION A		057	057	057	057 - NEGATIVE	48	48	48	100
2023-061	145	CLINITEK		057	057	057	057 - NEGATIVE	26	26	26	100
2023-061	147	Mission120		057	057	057	057 - NEGATIVE	39	39	39	100
2023-061	148	Mission500		057	057	057	057 - NEGATIVE	80	80	80	100
2023-061	151	Clari. Uro		057	057	057	057 - NEGATIVE	14	14	14	100
057 URINALYSIS-BILIRUBIN											
2023-062	011	AMES NM10S		058	060	057	060 - 3+	47	5	47	100
2023-062	011	AMES NM10S		058	060	057	059 - 2+	47	36	47	100
2023-062	011	AMES NM10S		058	060	057	058 - TRACES, 1+	47	6	47	100
2023-062	013	BAYER CLI		058	060	057	059 - 2+	31	22	31	100
2023-062	013	BAYER CLI		058	060	057	058 - TRACES, 1+	31	9	31	100
2023-062	067	URISCAN		057	059	057	057 - NEGATIVE	54	6	54	100
2023-062	067	URISCAN		057	059	057	059 - 2+	54	9	54	100
2023-062	067	URISCAN		057	059	057	058 - TRACES, 1+	54	39	54	100
2023-062	072	URS-9-TECO		058	060	057	057 - NEGATIVE	85	1	85	100
2023-062	072	URS-9-TECO		058	060	057	058 - TRACES, 1+	85	17	85	100
2023-062	072	URS-9-TECO		058	060	057	059 - 2+	85	47	85	100
2023-062	072	URS-9-TECO		058	060	057	060 - 3+	85	20	85	100
2023-062	080	ROCHE (CHE		057	059	057	059 - 2+	37	2	37	100
2023-062	080	ROCHE (CHE		057	059	057	058 - TRACES, 1+	37	34	37	100
2023-062	080	ROCHE (CHE		057	059	057	057 - NEGATIVE	37	1	37	100
2023-062	089	AIMSTRIP		057	059	057	060 - 3+	130	4	126	0
2023-062	089	AIMSTRIP		057	059	057	059 - 2+	130	52	126	100
2023-062	089	AIMSTRIP		057	059	057	058 - TRACES, 1+	130	73	126	100
2023-062	089	AIMSTRIP		057	059	057	057 - NEGATIVE	130	1	126	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	094	CLINITEK		058 060	057 059		059 - 2+	105	89	105	100	
2023-062	094	CLINITEK		058 060	057 059		060 - 3+	105	4	105	100	
2023-062	094	CLINITEK		058 060	057 059		058 - TRACES, 1+	105	12	105	100	
2023-062	102	ACON LAB		057 059	057 059		060 - 3+	136	4	132	0	
2023-062	102	ACON LAB		057 059	057 059		057 - NEGATIVE	136	1	132	100	
2023-062	102	ACON LAB		057 059	057 059		058 - TRACES, 1+	136	98	132	100	
2023-062	102	ACON LAB		057 059	057 059		059 - 2+	136	33	132	100	
2023-062	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	30	30	30	100	
2023-062	140	MISSION A		057 059	057 059		058 - TRACES, 1+	48	35	46	100	
2023-062	140	MISSION A		057 059	057 059		059 - 2+	48	11	46	100	
2023-062	140	MISSION A		057 059	057 059		060 - 3+	48	2	46	0	
2023-062	145	CLINITEK		057 057	057 059		058 - TRACES, 1+	26	1	26	100	
2023-062	145	CLINITEK		057 057	057 059		057 - NEGATIVE	26	25	26	100	
2023-062	147	Mission120		057 059	057 059		059 - 2+	39	8	39	100	
2023-062	147	Mission120		057 059	057 059		058 - TRACES, 1+	39	31	39	100	
2023-062	148	Mission500		057 059	057 059		059 - 2+	80	16	80	100	
2023-062	148	Mission500		057 059	057 059		058 - TRACES, 1+	80	64	80	100	
2023-062	151	Clari. Uro		057 059	057 059		059 - 2+	14	6	14	100	
2023-062	151	Clari. Uro		057 059	057 059		058 - TRACES, 1+	14	8	14	100	
057 URINALYSIS-BILIRUBIN												
2023-063	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	47	47	47	100	
2023-063	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	31	31	31	100	
2023-063	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2023-063	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	85	85	85	100	
2023-063	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2023-063	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	130	130	130	100	
2023-063	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2023-063	102	ACON LAB		057 057	057 057		057 - NEGATIVE	136	136	136	100	
2023-063	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2023-063	140	MISSION A		057 057	057 057		057 - NEGATIVE	48	48	48	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-063	145	CLINITEK		057 057	057 057		057 - NEGATIVE	26	26	26	100	
2023-063	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2023-063	148	Mission500		057 057	057 057		057 - NEGATIVE	80	80	80	100	
2023-063	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	14	14	14	100	
057 URINALYSIS-BILIRUBIN												
2023-064	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	47	47	47	100	
2023-064	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	31	31	31	100	
2023-064	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2023-064	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	85	85	85	100	
2023-064	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2023-064	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	130	130	130	100	
2023-064	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2023-064	102	ACON LAB		057 057	057 057		057 - NEGATIVE	136	136	136	100	
2023-064	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2023-064	140	MISSION A		057 057	057 057		057 - NEGATIVE	48	48	48	100	
2023-064	145	CLINITEK		057 057	057 057		057 - NEGATIVE	26	26	26	100	
2023-064	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2023-064	148	Mission500		057 057	057 057		057 - NEGATIVE	80	80	80	100	
2023-064	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	14	14	14	100	
2023-065	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	47	47	47	100	
2023-065	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	31	31	31	100	
2023-065	067	URISCAN		057 057	057 057		057 - NEGATIVE	54	54	54	100	
2023-065	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	85	85	85	100	
2023-065	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	37	37	37	100	
2023-065	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	130	130	130	100	
2023-065	094	CLINITEK		057 057	057 057		057 - NEGATIVE	105	105	105	100	
2023-065	102	ACON LAB		057 057	057 057		057 - NEGATIVE	136	136	136	100	
2023-065	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	30	30	30	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-065	140	MISSION A		057 057	057 057		057 - NEGATIVE	48	48	48	100	
2023-065	145	CLINITEK		057 057	057 057		057 - NEGATIVE	26	26	26	100	
2023-065	147	Mission120		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2023-065	148	Mission500		057 057	057 057		057 - NEGATIVE	80	80	80	100	
2023-065	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	14	14	14	100	
058 URINALYSIS-GLUCOSE												
2023-061	011	AMES NM10S		076 078	075 077		076 - 500mg/dl2+	47	11	46	100	
2023-061	011	AMES NM10S		076 078	075 077		074 - TRACES	47	1	46	0	
2023-061	011	AMES NM10S		076 078	075 077		077 - 1000mg/dl	47	32	46	100	
2023-061	011	AMES NM10S		076 078	075 077		078 - 2000mg/dl	47	3	46	100	
2023-061	013	BAYER CLI		076 078	075 077		077 - 1000mg/dl	31	16	31	100	
2023-061	013	BAYER CLI		076 078	075 077		076 - 500mg/dl2+	31	15	31	100	
2023-061	067	URISCAN		077 078	075 077		078 - 2000mg/dl	54	37	53	100	
2023-061	067	URISCAN		077 078	075 077		076 - 500mg/dl2+	54	3	53	100	
2023-061	067	URISCAN		077 078	075 077		077 - 1000mg/dl	54	13	53	100	
2023-061	067	URISCAN		077 078	075 077		073 - NEGATIVE	54	1	53	0	
2023-061	072	URS-9-TECO		076 078	075 077		077 - 1000mg/dl	85	57	84	100	
2023-061	072	URS-9-TECO		076 078	075 077		078 - 2000mg/dl	85	8	84	100	
2023-061	072	URS-9-TECO		076 078	075 077		076 - 500mg/dl2+	85	19	84	100	
2023-061	072	URS-9-TECO		076 078	075 077		073 - NEGATIVE	85	1	84	0	
2023-061	080	ROCHE (CHE		076 078	075 077		075 - 250mg/dl-+	38	3	38	100	
2023-061	080	ROCHE (CHE		076 078	075 077		078 - 2000mg/dl	38	2	38	100	
2023-061	080	ROCHE (CHE		076 078	075 077		077 - 1000mg/dl	38	33	38	100	
2023-061	089	AIMSTRIP		076 078	075 077		078 - 2000mg/dl	130	1	130	100	
2023-061	089	AIMSTRIP		076 078	075 077		075 - 250mg/dl-+	130	4	130	100	
2023-061	089	AIMSTRIP		076 078	075 077		077 - 1000mg/dl	130	72	130	100	
2023-061	089	AIMSTRIP		076 078	075 077		076 - 500mg/dl2+	130	53	130	100	
2023-061	094	CLINITEK		076 078	075 077		078 - 2000mg/dl	105	2	104	100	
2023-061	094	CLINITEK		076 078	075 077		077 - 1000mg/dl	105	73	104	100	
2023-061	094	CLINITEK		076 078	075 077		076 - 500mg/dl2+	105	29	104	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-061	094	CLINITEK		076 078	075 077		073 - NEGATIVE	105	1	104	0
2023-061	102	ACON LAB		076 078	075 077		078 - 2000mg/dl	139	8	138	100
2023-061	102	ACON LAB		076 078	075 077		075 - 250mg/dl-+	139	4	138	100
2023-061	102	ACON LAB		076 078	075 077		076 - 500mg/dl2+	139	55	138	100
2023-061	102	ACON LAB		076 078	075 077		077 - 1000mg/dl	139	71	138	100
2023-061	102	ACON LAB		076 078	075 077		074 - TRACES	139	1	138	0
2023-061	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	31	29	31	100
2023-061	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	31	2	31	100
2023-061	140	MISSION A		076 078	075 077		078 - 2000mg/dl	50	9	50	100
2023-061	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	50	5	50	100
2023-061	140	MISSION A		076 078	075 077		077 - 1000mg/dl	50	36	50	100
2023-061	145	CLINITEK		076 078	075 077		078 - 2000mg/dl	26	4	26	100
2023-061	145	CLINITEK		076 078	075 077		076 - 500mg/dl2+	26	8	26	100
2023-061	145	CLINITEK		076 078	075 077		077 - 1000mg/dl	26	14	26	100
2023-061	147	Mission120		076 078	075 077		076 - 500mg/dl2+	37	4	37	100
2023-061	147	Mission120		076 078	075 077		077 - 1000mg/dl	37	20	37	100
2023-061	147	Mission120		076 078	075 077		078 - 2000mg/dl	37	13	37	100
2023-061	148	Mission500		076 078	075 077		077 - 1000mg/dl	79	51	79	100
2023-061	148	Mission500		076 078	075 077		076 - 500mg/dl2+	79	15	79	100
2023-061	148	Mission500		076 078	075 077		078 - 2000mg/dl	79	11	79	100
2023-061	148	Mission500		076 078	075 077		075 - 250mg/dl-+	79	2	79	100
2023-061	151	Clari. Uro		076 078	075 077		077 - 1000mg/dl	14	14	14	100
058 URINALYSIS-GLUCOSE											
2023-062	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	47	47	47	100
2023-062	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	31	31	31	100
2023-062	067	URISCAN		073 073	073 073		073 - NEGATIVE	54	54	54	100
2023-062	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	85	84	84	100
2023-062	072	URS-9-TECO		073 073	073 073		075 - 250mg/dl-+	85	1	84	0
2023-062	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	38	38	38	100
2023-062	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	130	129	129	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	089	AIMSTRIP		073 073	073 073		074 - TRACES	130	1	129	0	
2023-062	094	CLINITEK		073 073	073 073		073 - NEGATIVE	105	105	105	100	
2023-062	102	ACON LAB		073 073	073 073		073 - NEGATIVE	139	139	139	100	
2023-062	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	31	31	31	100	
2023-062	140	MISSION A		073 073	073 073		073 - NEGATIVE	50	50	50	100	
2023-062	145	CLINITEK		073 073	073 073		073 - NEGATIVE	26	26	26	100	
2023-062	147	Mission120		073 073	073 073		073 - NEGATIVE	37	37	37	100	
2023-062	148	Mission500		073 073	073 073		073 - NEGATIVE	79	79	79	100	
2023-062	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	14	14	14	100	
058 URINALYSIS-GLUCOSE												
2023-063	011	AMES NM10S		074 076	074 076		076 - 500mg/dl2+	47	1	47	100	
2023-063	011	AMES NM10S		074 076	074 076		074 - TRACES	47	17	47	100	
2023-063	011	AMES NM10S		074 076	074 076		075 - 250mg/dl-+	47	29	47	100	
2023-063	013	BAYER CLI		074 076	074 076		074 - TRACES	31	13	31	100	
2023-063	013	BAYER CLI		074 076	074 076		075 - 250mg/dl-+	31	18	31	100	
2023-063	067	URISCAN		075 077	074 076		076 - 500mg/dl2+	54	23	53	100	
2023-063	067	URISCAN		075 077	074 076		073 - NEGATIVE	54	1	53	0	
2023-063	067	URISCAN		075 077	074 076		077 - 1000mg/dl	54	10	53	100	
2023-063	067	URISCAN		075 077	074 076		074 - TRACES	54	1	53	100	
2023-063	067	URISCAN		075 077	074 076		075 - 250mg/dl-+	54	19	53	100	
2023-063	072	URS-9-TECO		074 076	074 076		074 - TRACES	85	29	81	100	
2023-063	072	URS-9-TECO		074 076	074 076		073 - NEGATIVE	85	4	81	0	
2023-063	072	URS-9-TECO		074 076	074 076		075 - 250mg/dl-+	85	47	81	100	
2023-063	072	URS-9-TECO		074 076	074 076		076 - 500mg/dl2+	85	5	81	100	
2023-063	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	38	34	38	100	
2023-063	080	ROCHE (CHE		076 078	074 076		075 - 250mg/dl-+	38	2	38	100	
2023-063	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	38	2	38	100	
2023-063	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	130	101	129	100	
2023-063	089	AIMSTRIP		074 076	074 076		076 - 500mg/dl2+	130	1	129	100	
2023-063	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	130	1	129	0	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-063	089	AIMSTRIP		074 076	074 076		074 - TRACES	130	27	129	100
2023-063	094	CLINITEK		074 076	074 076		074 - TRACES	105	48	105	100
2023-063	094	CLINITEK		074 076	074 076		075 - 250mg/dl-+	105	57	105	100
2023-063	102	ACON LAB		074 076	074 076		075 - 250mg/dl-+	139	118	135	100
2023-063	102	ACON LAB		074 076	074 076		074 - TRACES	139	17	135	100
2023-063	102	ACON LAB		074 076	074 076		073 - NEGATIVE	139	4	135	0
2023-063	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	31	29	31	100
2023-063	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	31	2	31	100
2023-063	140	MISSION A		074 076	074 076		074 - TRACES	50	5	50	100
2023-063	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	50	45	50	100
2023-063	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	26	15	26	100
2023-063	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	26	3	26	100
2023-063	145	CLINITEK		076 078	074 076		075 - 250mg/dl-+	26	1	26	100
2023-063	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	26	7	26	100
2023-063	147	Mission120		074 076	074 076		075 - 250mg/dl-+	37	32	36	100
2023-063	147	Mission120		074 076	074 076		073 - NEGATIVE	37	1	36	0
2023-063	147	Mission120		074 076	074 076		074 - TRACES	37	4	36	100
2023-063	148	Mission500		074 076	074 076		075 - 250mg/dl-+	79	77	78	100
2023-063	148	Mission500		074 076	074 076		074 - TRACES	79	1	78	100
2023-063	148	Mission500		074 076	074 076		073 - NEGATIVE	79	1	78	0
2023-063	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	14	14	14	100
058 URINALYSIS-GLUCOSE											
2023-064	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	47	47	47	100
2023-064	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	31	31	31	100
2023-064	067	URISCAN		073 073	073 073		073 - NEGATIVE	54	54	54	100
2023-064	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	85	85	85	100
2023-064	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	38	38	38	100
2023-064	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	130	129	129	100
2023-064	089	AIMSTRIP		073 073	073 073		074 - TRACES	130	1	129	0
2023-064	094	CLINITEK		073 073	073 073		074 - TRACES	105	1	104	0

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-064	094	CLINITEK		073 073	073 073		073 - NEGATIVE	105	104	104	100
2023-064	102	ACON LAB		073 073	073 073		073 - NEGATIVE	139	139	139	100
2023-064	131	iCHEM VELO		073 073	073 073		073 - NEGATIVE	31	31	31	100
2023-064	140	MISSION A		073 073	073 073		073 - NEGATIVE	50	50	50	100
2023-064	145	CLINITEK		073 073	073 073		073 - NEGATIVE	26	26	26	100
2023-064	147	Mission120		073 073	073 073		073 - NEGATIVE	37	37	37	100
2023-064	148	Mission500		073 073	073 073		073 - NEGATIVE	79	79	79	100
2023-064	151	Clari. Uro		073 073	073 073		073 - NEGATIVE	14	14	14	100
058 URINALYSIS-GLUCOSE											
2023-065	011	AMES NM10S		076 078	076 078		076 - 500mg/dl2+	47	9	45	100
2023-065	011	AMES NM10S		076 078	076 078		077 - 1000mg/dl	47	35	45	100
2023-065	011	AMES NM10S		076 078	076 078		075 - 250mg/dl-+	47	2	45	0
2023-065	011	AMES NM10S		076 078	076 078		078 - 2000mg/dl	47	1	45	100
2023-065	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	31	13	31	100
2023-065	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	31	18	31	100
2023-065	067	URISCAN		077 078	076 078		077 - 1000mg/dl	54	14	52	100
2023-065	067	URISCAN		077 078	076 078		075 - 250mg/dl-+	54	2	52	0
2023-065	067	URISCAN		077 078	076 078		078 - 2000mg/dl	54	36	52	100
2023-065	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	54	2	52	100
2023-065	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	85	67	85	100
2023-065	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	85	12	85	100
2023-065	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	85	6	85	100
2023-065	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	38	36	38	100
2023-065	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	38	2	38	100
2023-065	089	AIMSTRIP		075 077	076 078		076 - 500mg/dl2+	130	68	128	100
2023-065	089	AIMSTRIP		075 077	076 078		073 - NEGATIVE	130	2	128	0
2023-065	089	AIMSTRIP		075 077	076 078		077 - 1000mg/dl	130	59	128	100
2023-065	089	AIMSTRIP		075 077	076 078		078 - 2000mg/dl	130	1	128	100
2023-065	094	CLINITEK		076 078	076 078		078 - 2000mg/dl	105	2	103	100
2023-065	094	CLINITEK		076 078	076 078		076 - 500mg/dl2+	105	32	103	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-065	094	CLINITEK		076 078	076 078		077 - 1000mg/dl	105	69	103	100
2023-065	094	CLINITEK		076 078	076 078		075 - 250mg/dl-+	105	2	103	0
2023-065	102	ACON LAB		075 077	076 078		077 - 1000mg/dl	139	61	139	100
2023-065	102	ACON LAB		075 077	076 078		075 - 250mg/dl-+	139	1	139	100
2023-065	102	ACON LAB		075 077	076 078		078 - 2000mg/dl	139	6	139	100
2023-065	102	ACON LAB		075 077	076 078		076 - 500mg/dl2+	139	71	139	100
2023-065	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	31	29	30	100
2023-065	131	iCHEM VELO		075 077	076 078		073 - NEGATIVE	31	1	30	0
2023-065	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	31	1	30	100
2023-065	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	50	12	50	100
2023-065	140	MISSION A		076 078	076 078		077 - 1000mg/dl	50	33	50	100
2023-065	140	MISSION A		076 078	076 078		078 - 2000mg/dl	50	5	50	100
2023-065	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	26	20	26	100
2023-065	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	26	2	26	100
2023-065	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	26	4	26	100
2023-065	147	Mission120		076 078	076 078		077 - 1000mg/dl	37	27	37	100
2023-065	147	Mission120		076 078	076 078		078 - 2000mg/dl	37	8	37	100
2023-065	147	Mission120		076 078	076 078		076 - 500mg/dl2+	37	2	37	100
2023-065	148	Mission500		076 078	076 078		078 - 2000mg/dl	79	3	78	100
2023-065	148	Mission500		076 078	076 078		076 - 500mg/dl2+	79	30	78	100
2023-065	148	Mission500		076 078	076 078		073 - NEGATIVE	79	1	78	0
2023-065	148	Mission500		076 078	076 078		077 - 1000mg/dl	79	45	78	100
2023-065	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	14	3	13	100
2023-065	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	14	10	13	100
2023-065	151	Clari. Uro		076 078	076 078		073 - NEGATIVE	14	1	13	0
059 URINALYS.HG.OR BLOOD											
2023-061	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	46	46	46	100
2023-061	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	31	31	31	100
2023-061	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	54	54	100
2023-061	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	84	84	84	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2023-061	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	130	130	130	100	
2023-061	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100	
2023-061	102	ACON LAB		066 066	066 066		066 - NEGATIVE	141	141	141	100	
2023-061	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	31	31	31	100	
2023-061	140	MISSION A		066 066	066 066		066 - NEGATIVE	48	48	48	100	
2023-061	145	CLINITEK		066 066	066 066		066 - NEGATIVE	26	26	26	100	
2023-061	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2023-061	148	Mission500		066 066	066 066		066 - NEGATIVE	79	79	79	100	
2023-061	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	14	14	14	100	
059 URINALYS.HG.OR BLOOD												
2023-062	011	AMES NM10S		068 069	067 069		069 - POS.(3+)	46	38	46	100	
2023-062	011	AMES NM10S		068 069	067 069		068 - POS.(1-2+)	46	8	46	100	
2023-062	013	BAYER CLI		068 069	067 069		068 - POS.(1-2+)	31	5	31	100	
2023-062	013	BAYER CLI		068 069	067 069		069 - POS.(3+)	31	26	31	100	
2023-062	067	URISCAN		068 069	067 069		068 - POS.(1-2+)	54	10	54	100	
2023-062	067	URISCAN		068 069	067 069		069 - POS.(3+)	54	44	54	100	
2023-062	072	URS-9-TECO		068 069	067 069		068 - POS.(1-2+)	84	15	84	100	
2023-062	072	URS-9-TECO		068 069	067 069		069 - POS.(3+)	84	69	84	100	
2023-062	080	ROCHE (CHE		068 069	067 069		068 - POS.(1-2+)	38	3	38	100	
2023-062	080	ROCHE (CHE		068 069	067 069		069 - POS.(3+)	38	35	38	100	
2023-062	089	AIMSTRIP		068 069	067 069		069 - POS.(3+)	130	122	130	100	
2023-062	089	AIMSTRIP		068 069	067 069		068 - POS.(1-2+)	130	8	130	100	
2023-062	094	CLINITEK		068 069	067 069		069 - POS.(3+)	106	88	106	100	
2023-062	094	CLINITEK		068 069	067 069		068 - POS.(1-2+)	106	18	106	100	
2023-062	102	ACON LAB		068 069	067 069		068 - POS.(1-2+)	141	1	141	100	
2023-062	102	ACON LAB		068 069	067 069		069 - POS.(3+)	141	140	141	100	
2023-062	131	iCHEM VELO		067 069	067 069		069 - POS.(3+)	31	1	31	100	
2023-062	131	iCHEM VELO		067 069	067 069		068 - POS.(1-2+)	31	28	31	100	
2023-062	131	iCHEM VELO		067 069	067 069		067 - TRACES	31	2	31	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	140	MISSION A		068 069	067 069		069 - POS.(3+)	48	45	48	100	
2023-062	140	MISSION A		068 069	067 069		068 - POS.(1-2+)	48	3	48	100	
2023-062	145	CLINITEK		067 069	067 069		068 - POS.(1-2+)	26	16	26	100	
2023-062	145	CLINITEK		067 069	067 069		069 - POS.(3+)	26	10	26	100	
2023-062	147	Mission120		068 069	067 069		069 - POS.(3+)	38	38	38	100	
2023-062	148	Mission500		068 069	067 069		069 - POS.(3+)	79	79	79	100	
2023-062	151	Clari. Uro		068 069	067 069		069 - POS.(3+)	14	14	14	100	
059 URINALYS.HG.OR BLOOD												
2023-063	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	46	45	45	100	
2023-063	011	AMES NM10S		066 066	066 066		067 - TRACES	46	1	45	0	
2023-063	013	BAYER CLI		066 066	066 066		066 - NEGATIVE	31	31	31	100	
2023-063	067	URISCAN		066 066	066 066		066 - NEGATIVE	54	52	52	100	
2023-063	067	URISCAN		066 066	066 066		067 - TRACES	54	1	52	0	
2023-063	067	URISCAN		066 066	066 066		068 - POS.(1-2+)	54	1	52	0	
2023-063	072	URS-9-TECO		066 066	066 066		066 - NEGATIVE	84	84	84	100	
2023-063	080	ROCHE (CHE		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2023-063	089	AIMSTRIP		066 066	066 066		066 - NEGATIVE	130	130	130	100	
2023-063	094	CLINITEK		066 066	066 066		066 - NEGATIVE	106	106	106	100	
2023-063	102	ACON LAB		066 066	066 066		066 - NEGATIVE	141	141	141	100	
2023-063	131	iCHEM VELO		066 066	066 066		066 - NEGATIVE	31	31	31	100	
2023-063	140	MISSION A		066 066	066 066		066 - NEGATIVE	48	48	48	100	
2023-063	145	CLINITEK		066 066	066 066		066 - NEGATIVE	26	26	26	100	
2023-063	147	Mission120		066 066	066 066		066 - NEGATIVE	38	38	38	100	
2023-063	148	Mission500		066 066	066 066		066 - NEGATIVE	79	79	79	100	
2023-063	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	14	14	14	100	
2023-064	011	AMES NM10S		068 069	068 069		069 - POS.(3+)	46	44	46	100	
2023-064	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	46	2	46	100	
2023-064	013	BAYER CLI		068 069	068 069		069 - POS.(3+)	31	31	31	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2023-064	067	URISCAN		068	069	068	069	068	- POS.(1-2+)	54	5	54	100
2023-064	067	URISCAN		068	069	068	069	069	- POS.(3+)	54	49	54	100
2023-064	072	URS-9-TECO		068	069	068	069	068	- POS.(1-2+)	84	3	84	100
2023-064	072	URS-9-TECO		068	069	068	069	069	- POS.(3+)	84	81	84	100
2023-064	080	ROCHE (CHE		068	069	068	069	068	- POS.(1-2+)	38	3	38	100
2023-064	080	ROCHE (CHE		068	069	068	069	069	- POS.(3+)	38	35	38	100
2023-064	089	AIMSTRIP		068	069	068	069	068	- POS.(1-2+)	130	5	129	100
2023-064	089	AIMSTRIP		068	069	068	069	069	- POS.(3+)	130	124	129	100
2023-064	089	AIMSTRIP		068	069	068	069	066	- NEGATIVE	130	1	129	0
2023-064	094	CLINITEK		068	069	068	069	069	- POS.(3+)	106	103	106	100
2023-064	094	CLINITEK		068	069	068	069	068	- POS.(1-2+)	106	3	106	100
2023-064	102	ACON LAB		068	069	068	069	068	- POS.(1-2+)	141	2	140	100
2023-064	102	ACON LAB		068	069	068	069	069	- POS.(3+)	141	138	140	100
2023-064	102	ACON LAB		068	069	068	069	066	- NEGATIVE	141	1	140	0
2023-064	131	iCHEM VELO		068	069	068	069	069	- POS.(3+)	31	29	31	100
2023-064	131	iCHEM VELO		068	069	068	069	068	- POS.(1-2+)	31	2	31	100
2023-064	140	MISSION A		068	069	068	069	069	- POS.(3+)	48	46	48	100
2023-064	140	MISSION A		068	069	068	069	068	- POS.(1-2+)	48	2	48	100
2023-064	145	CLINITEK		068	069	068	069	069	- POS.(3+)	26	26	26	100
2023-064	147	Mission120		068	069	068	069	069	- POS.(3+)	38	38	38	100
2023-064	148	Mission500		068	069	068	069	066	- NEGATIVE	79	1	78	0
2023-064	148	Mission500		068	069	068	069	069	- POS.(3+)	79	78	78	100
2023-064	151	Clari. Uro		068	069	068	069	069	- POS.(3+)	14	14	14	100
059 URINALYS.HG.OR BLOOD													
2023-065	011	AMES NM10S		068	069	068	069	069	- POS.(3+)	46	43	46	100
2023-065	011	AMES NM10S		068	069	068	069	068	- POS.(1-2+)	46	3	46	100
2023-065	013	BAYER CLI		068	069	068	069	069	- POS.(3+)	31	30	31	100
2023-065	013	BAYER CLI		068	069	068	069	068	- POS.(1-2+)	31	1	31	100
2023-065	067	URISCAN		068	069	068	069	069	- POS.(3+)	54	46	54	100
2023-065	067	URISCAN		068	069	068	069	068	- POS.(1-2+)	54	8	54	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2023-065	072	URS-9-TECO		068	069	068	069	068	- POS.(1-2+)	84	5	84	100
2023-065	072	URS-9-TECO		068	069	068	069	069	- POS.(3+)	84	79	84	100
2023-065	080	ROCHE (CHE		068	069	068	069	069	- POS.(3+)	38	34	38	100
2023-065	080	ROCHE (CHE		068	069	068	069	068	- POS.(1-2+)	38	4	38	100
2023-065	089	AIMSTRIP		068	069	068	069	068	- POS.(1-2+)	130	9	130	100
2023-065	089	AIMSTRIP		068	069	068	069	069	- POS.(3+)	130	121	130	100
2023-065	094	CLINITEK		068	069	068	069	069	- POS.(3+)	106	102	106	100
2023-065	094	CLINITEK		068	069	068	069	068	- POS.(1-2+)	106	4	106	100
2023-065	102	ACON LAB		068	069	068	069	068	- POS.(1-2+)	141	3	141	100
2023-065	102	ACON LAB		068	069	068	069	069	- POS.(3+)	141	138	141	100
2023-065	131	iCHEM VELO		068	069	068	069	068	- POS.(1-2+)	31	4	31	100
2023-065	131	iCHEM VELO		068	069	068	069	069	- POS.(3+)	31	27	31	100
2023-065	140	MISSION A		068	069	068	069	069	- POS.(3+)	48	45	48	100
2023-065	140	MISSION A		068	069	068	069	068	- POS.(1-2+)	48	3	48	100
2023-065	145	CLINITEK		068	069	068	069	069	- POS.(3+)	26	26	26	100
2023-065	147	Mission120		068	069	068	069	069	- POS.(3+)	38	37	38	100
2023-065	147	Mission120		068	069	068	069	068	- POS.(1-2+)	38	1	38	100
2023-065	148	Mission500		068	069	068	069	069	- POS.(3+)	79	78	78	100
2023-065	148	Mission500		068	069	068	069	066	- NEGATIVE	79	1	78	0
2023-065	151	Clari. Uro		068	069	068	069	069	- POS.(3+)	14	14	14	100
060 URINALYSIS-KETONES													
2023-061	011	AMES NM10S		090	090	090	090	090	- NEGATIVE	46	46	46	100
2023-061	013	BAYER CLI		090	090	090	090	090	- NEGATIVE	31	31	31	100
2023-061	067	URISCAN		090	090	090	090	090	- NEGATIVE	54	54	54	100
2023-061	072	URS-9-TECO		090	090	090	090	090	- NEGATIVE	84	84	84	100
2023-061	080	ROCHE (CHE		090	090	090	090	090	- NEGATIVE	38	38	38	100
2023-061	089	AIMSTRIP		090	090	090	090	090	- NEGATIVE	130	130	130	100
2023-061	094	CLINITEK		090	090	090	090	090	- NEGATIVE	106	106	106	100
2023-061	102	ACON LAB		090	090	090	090	090	- NEGATIVE	140	140	140	100
2023-061	131	iCHEM VELO		090	090	090	090	090	- NEGATIVE	31	31	31	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	140	MISSION A		090 090	090 090		090 - NEGATIVE	50	50	50	100	
2023-061	145	CLINITEK		090 090	090 090		090 - NEGATIVE	26	26	26	100	
2023-061	147	Mission120		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2023-061	148	Mission500		090 090	090 090		090 - NEGATIVE	79	79	79	100	
2023-061	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	14	14	14	100	
060 URINALYSIS-KETONES												
2023-062	011	AMES NM10S		093 094	093 094		094 - LARGE-3-4+	46	43	46	100	
2023-062	011	AMES NM10S		093 094	093 094		093 - MOD. (2+)	46	3	46	100	
2023-062	013	BAYER CLI		093 094	093 094		093 - MOD. (2+)	31	3	31	100	
2023-062	013	BAYER CLI		093 094	093 094		094 - LARGE-3-4+	31	28	31	100	
2023-062	067	URISCAN		093 094	093 094		093 - MOD. (2+)	54	17	54	100	
2023-062	067	URISCAN		093 094	093 094		094 - LARGE-3-4+	54	37	54	100	
2023-062	072	URS-9-TECO		093 094	093 094		094 - LARGE-3-4+	84	81	84	100	
2023-062	072	URS-9-TECO		093 094	093 094		093 - MOD. (2+)	84	3	84	100	
2023-062	080	ROCHE (CHE		093 094	093 094		094 - LARGE-3-4+	38	33	38	100	
2023-062	080	ROCHE (CHE		093 094	093 094		093 - MOD. (2+)	38	5	38	100	
2023-062	089	AIMSTRIP		093 094	093 094		093 - MOD. (2+)	130	3	130	100	
2023-062	089	AIMSTRIP		093 094	093 094		094 - LARGE-3-4+	130	127	130	100	
2023-062	094	CLINITEK		093 094	093 094		093 - MOD. (2+)	106	2	106	100	
2023-062	094	CLINITEK		093 094	093 094		094 - LARGE-3-4+	106	104	106	100	
2023-062	102	ACON LAB		093 094	093 094		093 - MOD. (2+)	140	2	139	100	
2023-062	102	ACON LAB		093 094	093 094		092 - SMALL (1+)	140	1	139	0	
2023-062	102	ACON LAB		093 094	093 094		094 - LARGE-3-4+	140	137	139	100	
2023-062	131	iCHEM VELO		092 094	093 094		093 - MOD. (2+)	31	17	31	100	
2023-062	131	iCHEM VELO		092 094	093 094		094 - LARGE-3-4+	31	14	31	100	
2023-062	140	MISSION A		093 094	093 094		093 - MOD. (2+)	50	1	50	100	
2023-062	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	50	49	50	100	
2023-062	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	26	25	26	100	
2023-062	145	CLINITEK		093 094	093 094		093 - MOD. (2+)	26	1	26	100	
2023-062	147	Mission120		093 094	093 094		094 - LARGE-3-4+	37	37	37	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	148	Mission500		093 094	093 094		094 - LARGE-3-4+	79	79	79	100	
2023-062	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	14	14	14	100	
060 URINALYSIS-KETONES												
2023-063	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	46	32	46	100	
2023-063	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	46	11	46	100	
2023-063	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	46	3	46	100	
2023-063	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	31	15	31	100	
2023-063	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	31	16	31	100	
2023-063	067	URISCAN		092 094	092 094		093 - MOD. (2+)	54	37	54	100	
2023-063	067	URISCAN		092 094	092 094		092 - SMALL (1+)	54	12	54	100	
2023-063	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	54	5	54	100	
2023-063	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	84	8	84	100	
2023-063	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	84	65	84	100	
2023-063	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	84	11	84	100	
2023-063	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	38	29	38	100	
2023-063	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	38	8	38	100	
2023-063	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	38	1	38	100	
2023-063	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	130	25	129	100	
2023-063	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	130	87	129	100	
2023-063	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	130	17	129	100	
2023-063	089	AIMSTRIP		092 094	092 094		091 - TRACE	130	1	129	0	
2023-063	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	106	62	106	100	
2023-063	094	CLINITEK		092 094	092 094		094 - LARGE-3-4+	106	2	106	100	
2023-063	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	106	42	106	100	
2023-063	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	140	108	139	100	
2023-063	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	140	13	139	100	
2023-063	102	ACON LAB		092 094	092 094		090 - NEGATIVE	140	1	139	0	
2023-063	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	140	18	139	100	
2023-063	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	31	23	31	100	
2023-063	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	31	7	31	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-063	131	iCHEM VELO		091 093	092 094		094 - LARGE-3-4+	31	1	31	100	
2023-063	140	MISSION A		093 094	092 094		093 - MOD. (2+)	50	22	50	100	
2023-063	140	MISSION A		093 094	092 094		092 - SMALL (1+)	50	5	50	100	
2023-063	140	MISSION A		093 094	092 094		094 - LARGE-3-4+	50	23	50	100	
2023-063	145	CLINITEK		092 094	092 094		091 - TRACE	26	1	25	0	
2023-063	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	26	25	25	100	
2023-063	147	Mission120		093 094	092 094		093 - MOD. (2+)	37	12	37	100	
2023-063	147	Mission120		093 094	092 094		094 - LARGE-3-4+	37	25	37	100	
2023-063	148	Mission500		092 094	092 094		094 - LARGE-3-4+	79	3	78	100	
2023-063	148	Mission500		092 094	092 094		091 - TRACE	79	1	78	0	
2023-063	148	Mission500		092 094	092 094		093 - MOD. (2+)	79	75	78	100	
2023-063	151	Clari. Uro		093 094	092 094		093 - MOD. (2+)	14	4	14	100	
2023-063	151	Clari. Uro		093 094	092 094		094 - LARGE-3-4+	14	10	14	100	
060 URINALYSIS-KETONES												
2023-064	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	46	46	46	100	
2023-064	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	31	31	31	100	
2023-064	067	URISCAN		090 090	090 090		090 - NEGATIVE	54	54	54	100	
2023-064	072	URS-9-TECO		090 090	090 090		091 - TRACE	84	1	83	0	
2023-064	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	84	83	83	100	
2023-064	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	38	38	38	100	
2023-064	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	130	130	130	100	
2023-064	094	CLINITEK		090 090	090 090		090 - NEGATIVE	106	106	106	100	
2023-064	102	ACON LAB		090 090	090 090		090 - NEGATIVE	140	139	139	100	
2023-064	102	ACON LAB		090 090	090 090		094 - LARGE-3-4+	140	1	139	0	
2023-064	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	31	31	31	100	
2023-064	140	MISSION A		090 090	090 090		090 - NEGATIVE	50	50	50	100	
2023-064	145	CLINITEK		090 090	090 090		090 - NEGATIVE	26	26	26	100	
2023-064	147	Mission120		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2023-064	148	Mission500		090 090	090 090		090 - NEGATIVE	79	79	79	100	
2023-064	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	14	14	14	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
060 URINALYSIS-KETONES													
2023-065	011	AMES NM10S		090	090	090	090	090 - NEGATIVE	46	46	46	100	
2023-065	013	BAYER CLI		090	090	090	090	090 - NEGATIVE	31	31	31	100	
2023-065	067	URISCAN		090	090	090	090	090 - NEGATIVE	54	54	54	100	
2023-065	072	URS-9-TECO		090	090	090	090	090 - NEGATIVE	84	84	84	100	
2023-065	080	ROCHE (CHE		090	090	090	090	090 - NEGATIVE	38	37	37	100	
2023-065	080	ROCHE (CHE		090	090	090	090	091 - TRACE	38	1	37	0	
2023-065	089	AIMSTRIP		090	090	090	090	090 - NEGATIVE	130	130	130	100	
2023-065	094	CLINITEK		090	090	090	090	090 - NEGATIVE	106	106	106	100	
2023-065	102	ACON LAB		090	090	090	090	094 - LARGE-3-4+	140	1	139	0	
2023-065	102	ACON LAB		090	090	090	090	090 - NEGATIVE	140	139	139	100	
2023-065	131	iCHEM VELO		090	090	090	090	090 - NEGATIVE	31	31	31	100	
2023-065	140	MISSION A		090	090	090	090	090 - NEGATIVE	50	50	50	100	
2023-065	145	CLINITEK		090	090	090	090	090 - NEGATIVE	26	26	26	100	
2023-065	147	Mission120		090	090	090	090	090 - NEGATIVE	37	37	37	100	
2023-065	148	Mission500		090	090	090	090	090 - NEGATIVE	79	79	79	100	
2023-065	151	Clari. Uro		090	090	090	090	090 - NEGATIVE	14	14	14	100	
061 URINALYSIS-NITRATE													
2023-061	011	AMES NM10S		070	070	070	070	070 - NEGATIVE	46	45	45	100	
2023-061	011	AMES NM10S		070	070	070	070	072 - POSITIVE	46	1	45	0	
2023-061	013	BAYER CLI		070	070	070	070	070 - NEGATIVE	31	31	31	100	
2023-061	067	URISCAN		070	070	070	070	070 - NEGATIVE	54	54	54	100	
2023-061	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	84	84	84	100	
2023-061	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2023-061	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	130	130	130	100	
2023-061	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	105	105	100	
2023-061	094	CLINITEK		070	070	070	070	072 - POSITIVE	106	1	105	0	
2023-061	102	ACON LAB		070	070	070	070	070 - NEGATIVE	140	140	140	100	
2023-061	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	31	31	31	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	140	MISSION A		070 070	070 070		070 - NEGATIVE	49	49	49	100	
2023-061	145	CLINITEK		070 070	070 070		070 - NEGATIVE	26	26	26	100	
2023-061	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2023-061	148	Mission500		070 070	070 070		070 - NEGATIVE	79	79	79	100	
2023-061	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	14	14	14	100	
061 URINALYSIS-NITRATE												
2023-062	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	46	46	46	100	
2023-062	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	31	31	31	100	
2023-062	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	
2023-062	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	84	84	84	100	
2023-062	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2023-062	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	130	130	130	100	
2023-062	094	CLINITEK		070 070	070 070		070 - NEGATIVE	106	106	106	100	
2023-062	102	ACON LAB		070 070	070 070		072 - POSITIVE	140	1	139	0	
2023-062	102	ACON LAB		070 070	070 070		070 - NEGATIVE	140	139	139	100	
2023-062	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	31	31	31	100	
2023-062	140	MISSION A		070 070	070 070		070 - NEGATIVE	49	49	49	100	
2023-062	145	CLINITEK		070 070	070 070		070 - NEGATIVE	26	26	26	100	
2023-062	147	Mission120		070 070	070 070		070 - NEGATIVE	38	38	38	100	
2023-062	148	Mission500		070 070	070 070		070 - NEGATIVE	79	79	79	100	
2023-062	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	14	14	14	100	
2023-063	011	AMES NM10S		071 072	071 072		072 - POSITIVE	46	45	46	100	
2023-063	011	AMES NM10S		071 072	071 072		071 - WEAK POS.	46	1	46	100	
2023-063	013	BAYER CLI		071 072	071 072		072 - POSITIVE	31	30	30	100	
2023-063	013	BAYER CLI		071 072	071 072		070 - NEGATIVE	31	1	30	0	
2023-063	067	URISCAN		071 072	071 072		071 - WEAK POS.	54	1	51	100	
2023-063	067	URISCAN		071 072	071 072		070 - NEGATIVE	54	3	51	0	
2023-063	067	URISCAN		071 072	071 072		072 - POSITIVE	54	50	51	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-063	072	URS-9-TECO		071 072	071 072		071 - WEAK POS.	84	1	83	100	
2023-063	072	URS-9-TECO		071 072	071 072		070 - NEGATIVE	84	1	83	0	
2023-063	072	URS-9-TECO		071 072	071 072		072 - POSITIVE	84	82	83	100	
2023-063	080	ROCHE (CHE		071 072	071 072		072 - POSITIVE	38	37	38	100	
2023-063	080	ROCHE (CHE		071 072	071 072		071 - WEAK POS.	38	1	38	100	
2023-063	089	AIMSTRIP		071 072	071 072		071 - WEAK POS.	130	5	125	100	
2023-063	089	AIMSTRIP		071 072	071 072		072 - POSITIVE	130	120	125	100	
2023-063	089	AIMSTRIP		071 072	071 072		070 - NEGATIVE	130	5	125	0	
2023-063	094	CLINITEK		071 072	071 072		072 - POSITIVE	106	105	106	100	
2023-063	094	CLINITEK		071 072	071 072		071 - WEAK POS.	106	1	106	100	
2023-063	102	ACON LAB		071 072	071 072		070 - NEGATIVE	140	10	130	0	
2023-063	102	ACON LAB		071 072	071 072		072 - POSITIVE	140	128	130	100	
2023-063	102	ACON LAB		071 072	071 072		071 - WEAK POS.	140	2	130	100	
2023-063	131	iCHEM VELO		071 072	071 072		070 - NEGATIVE	31	1	30	0	
2023-063	131	iCHEM VELO		071 072	071 072		072 - POSITIVE	31	30	30	100	
2023-063	140	MISSION A		071 072	071 072		071 - WEAK POS.	49	2	44	100	
2023-063	140	MISSION A		071 072	071 072		070 - NEGATIVE	49	5	44	0	
2023-063	140	MISSION A		071 072	071 072		072 - POSITIVE	49	42	44	100	
2023-063	145	CLINITEK		071 072	071 072		070 - NEGATIVE	26	1	25	0	
2023-063	145	CLINITEK		071 072	071 072		072 - POSITIVE	26	25	25	100	
2023-063	147	Mission120		071 072	071 072		070 - NEGATIVE	38	1	37	0	
2023-063	147	Mission120		071 072	071 072		072 - POSITIVE	38	37	37	100	
2023-063	148	Mission500		071 072	071 072		072 - POSITIVE	79	68	68	100	
2023-063	148	Mission500		071 072	071 072		070 - NEGATIVE	79	11	68	0	
2023-063	151	Clari. Uro			071 072		072 - POSITIVE	14	11	11	100	
2023-063	151	Clari. Uro			071 072		070 - NEGATIVE	14	3	11	0	
061 URINALYSIS-NITRATE												
2023-064	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	46	46	46	100	
2023-064	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	31	31	31	100	
2023-064	067	URISCAN		070 070	070 070		070 - NEGATIVE	54	54	54	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2023-064	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	84	84	84	100	
2023-064	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2023-064	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	130	130	130	100	
2023-064	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	106	106	100	
2023-064	102	ACON LAB		070	070	070	070	070 - NEGATIVE	140	140	140	100	
2023-064	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	31	31	31	100	
2023-064	140	MISSION A		070	070	070	070	070 - NEGATIVE	49	49	49	100	
2023-064	145	CLINITEK		070	070	070	070	070 - NEGATIVE	26	26	26	100	
2023-064	147	Mission120		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2023-064	148	Mission500		070	070	070	070	070 - NEGATIVE	79	79	79	100	
2023-064	151	Clari. Uro		070	070	070	070	070 - NEGATIVE	14	14	14	100	
061 URINALYSIS-NITRATE													
2023-065	011	AMES NM10S		070	070	070	070	072 - POSITIVE	46	1	45	0	
2023-065	011	AMES NM10S		070	070	070	070	070 - NEGATIVE	46	45	45	100	
2023-065	013	BAYER CLI		070	070	070	070	070 - NEGATIVE	31	31	31	100	
2023-065	067	URISCAN		070	070	070	070	070 - NEGATIVE	54	54	54	100	
2023-065	072	URS-9-TECO		070	070	070	070	070 - NEGATIVE	84	84	84	100	
2023-065	080	ROCHE (CHE		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2023-065	089	AIMSTRIP		070	070	070	070	070 - NEGATIVE	130	130	130	100	
2023-065	094	CLINITEK		070	070	070	070	070 - NEGATIVE	106	106	106	100	
2023-065	102	ACON LAB		070	070	070	070	070 - NEGATIVE	140	140	140	100	
2023-065	131	iCHEM VELO		070	070	070	070	070 - NEGATIVE	31	31	31	100	
2023-065	140	MISSION A		070	070	070	070	070 - NEGATIVE	49	49	49	100	
2023-065	145	CLINITEK		070	070	070	070	070 - NEGATIVE	26	26	26	100	
2023-065	147	Mission120		070	070	070	070	070 - NEGATIVE	38	38	38	100	
2023-065	148	Mission500		070	070	070	070	070 - NEGATIVE	79	79	79	100	
2023-065	151	Clari. Uro		070	070	070	070	070 - NEGATIVE	14	14	14	100	
062 URINALYSIS-pH													
2023-061	011	AMES NM10S		085	088	085	088	087 - 7.5	46	34	46	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	011	AMES NM10S		085 088	085 088		086 - 7.0	46	4	46	100	
2023-061	011	AMES NM10S		085 088	085 088		088 - 8.0OR MORE	46	8	46	100	
2023-061	013	BAYER CLI		085 088	085 088		087 - 7.5	31	28	31	100	
2023-061	013	BAYER CLI		085 088	085 088		088 - 8.0OR MORE	31	2	31	100	
2023-061	013	BAYER CLI		085 088	085 088		086 - 7.0	31	1	31	100	
2023-061	067	URISCAN		085 088	085 088		087 - 7.5	54	37	54	100	
2023-061	067	URISCAN		085 088	085 088		086 - 7.0	54	16	54	100	
2023-061	067	URISCAN		085 088	085 088		088 - 8.0OR MORE	54	1	54	100	
2023-061	072	URS-9-TECO		084 088	085 088		088 - 8.0OR MORE	84	1	84	100	
2023-061	072	URS-9-TECO		084 088	085 088		086 - 7.0	84	49	84	100	
2023-061	072	URS-9-TECO		084 088	085 088		087 - 7.5	84	30	84	100	
2023-061	072	URS-9-TECO		084 088	085 088		085 - 6.5	84	4	84	100	
2023-061	080	ROCHE (CHE		084 088	085 088		086 - 7.0	38	34	38	100	
2023-061	080	ROCHE (CHE		084 088	085 088		088 - 8.0OR MORE	38	4	38	100	
2023-061	089	AIMSTRIP		085 088	085 088		087 - 7.5	130	119	130	100	
2023-061	089	AIMSTRIP		085 088	085 088		086 - 7.0	130	11	130	100	
2023-061	094	CLINITEK		085 088	085 088		087 - 7.5	106	87	106	100	
2023-061	094	CLINITEK		085 088	085 088		086 - 7.0	106	10	106	100	
2023-061	094	CLINITEK		085 088	085 088		088 - 8.0OR MORE	106	9	106	100	
2023-061	102	ACON LAB		085 088	085 088		087 - 7.5	140	116	140	100	
2023-061	102	ACON LAB		085 088	085 088		086 - 7.0	140	22	140	100	
2023-061	102	ACON LAB		085 088	085 088		088 - 8.0OR MORE	140	2	140	100	
2023-061	131	iCHEM VELO		084 088	085 088		082 - 5.0	31	1	30	0	
2023-061	131	iCHEM VELO		084 088	085 088		086 - 7.0	31	30	30	100	
2023-061	140	MISSION A		085 088	085 088		085 - 6.5	50	1	50	100	
2023-061	140	MISSION A		085 088	085 088		087 - 7.5	50	46	50	100	
2023-061	140	MISSION A		085 088	085 088		086 - 7.0	50	2	50	100	
2023-061	140	MISSION A		085 088	085 088		088 - 8.0OR MORE	50	1	50	100	
2023-061	145	CLINITEK		085 088	085 088		087 - 7.5	26	26	26	100	
2023-061	147	Mission120		085 088	085 088		087 - 7.5	37	23	37	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	147	Mission120		085 088	085 088		086 - 7.0	37	14	37	100	
2023-061	148	Mission500		085 088	085 088		086 - 7.0	79	14	79	100	
2023-061	148	Mission500		085 088	085 088		087 - 7.5	79	65	79	100	
2023-061	151	Clari. Uro		085 088	085 088		086 - 7.0	14	1	14	100	
2023-061	151	Clari. Uro		085 088	085 088		087 - 7.5	14	13	14	100	
062 URINALYSIS-pH												
2023-062	011	AMES NM10S		086 088	086 088		087 - 7.5	46	13	46	100	
2023-062	011	AMES NM10S		086 088	086 088		088 - 8.0OR MORE	46	33	46	100	
2023-062	013	BAYER CLI		086 088	086 088		087 - 7.5	31	12	31	100	
2023-062	013	BAYER CLI		086 088	086 088		088 - 8.0OR MORE	31	19	31	100	
2023-062	067	URISCAN		085 088	086 088		087 - 7.5	54	42	54	100	
2023-062	067	URISCAN		085 088	086 088		088 - 8.0OR MORE	54	11	54	100	
2023-062	067	URISCAN		085 088	086 088		086 - 7.0	54	1	54	100	
2023-062	072	URS-9-TECO		085 088	086 088		086 - 7.0	84	18	84	100	
2023-062	072	URS-9-TECO		085 088	086 088		088 - 8.0OR MORE	84	3	84	100	
2023-062	072	URS-9-TECO		085 088	086 088		087 - 7.5	84	63	84	100	
2023-062	080	ROCHE (CHE		086 088	086 088		086 - 7.0	38	17	38	100	
2023-062	080	ROCHE (CHE		086 088	086 088		088 - 8.0OR MORE	38	21	38	100	
2023-062	089	AIMSTRIP		086 088	086 088		088 - 8.0OR MORE	130	78	130	100	
2023-062	089	AIMSTRIP		086 088	086 088		087 - 7.5	130	52	130	100	
2023-062	094	CLINITEK		086 088	086 088		087 - 7.5	106	26	106	100	
2023-062	094	CLINITEK		086 088	086 088		088 - 8.0OR MORE	106	80	106	100	
2023-062	102	ACON LAB		086 088	086 088		087 - 7.5	140	55	139	100	
2023-062	102	ACON LAB		086 088	086 088		086 - 7.0	140	1	139	100	
2023-062	102	ACON LAB		086 088	086 088		088 - 8.0OR MORE	140	83	139	100	
2023-062	102	ACON LAB		086 088	086 088		085 - 6.5	140	1	139	0	
2023-062	131	iCHEM VELO		084 088	086 088		086 - 7.0	31	23	31	100	
2023-062	131	iCHEM VELO		084 088	086 088		088 - 8.0OR MORE	31	8	31	100	
2023-062	140	MISSION A		086 088	086 088		087 - 7.5	50	19	50	100	
2023-062	140	MISSION A		086 088	086 088		086 - 7.0	50	1	50	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	140	MISSION A		086 088	086 088		088 - 8.00R MORE	50	30	50	100	
2023-062	145	CLINITEK		085 088	086 088		087 - 7.5	26	20	26	100	
2023-062	145	CLINITEK		085 088	086 088		088 - 8.00R MORE	26	6	26	100	
2023-062	147	Mission120		085 088	086 088		087 - 7.5	37	25	37	100	
2023-062	147	Mission120		085 088	086 088		086 - 7.0	37	1	37	100	
2023-062	147	Mission120		085 088	086 088		088 - 8.00R MORE	37	11	37	100	
2023-062	148	Mission500		086 088	086 088		088 - 8.00R MORE	79	52	79	100	
2023-062	148	Mission500		086 088	086 088		087 - 7.5	79	27	79	100	
2023-062	151	Clari. Uro		086 088	086 088		088 - 8.00R MORE	14	11	14	100	
2023-062	151	Clari. Uro		086 088	086 088		087 - 7.5	14	3	14	100	
062 URINALYSIS-pH												
2023-063	011	AMES NM10S		080 084	080 084		084 - 6.0	46	15	45	100	
2023-063	011	AMES NM10S		080 084	080 084		085 - 6.5	46	1	45	0	
2023-063	011	AMES NM10S		080 084	080 084		082 - 5.0	46	16	45	100	
2023-063	011	AMES NM10S		080 084	080 084		083 - 5.5	46	14	45	100	
2023-063	013	BAYER CLI		080 084	080 084		083 - 5.5	31	11	31	100	
2023-063	013	BAYER CLI		080 084	080 084		084 - 6.0	31	5	31	100	
2023-063	013	BAYER CLI		080 084	080 084		082 - 5.0	31	15	31	100	
2023-063	067	URISCAN		080 084	080 084		083 - 5.5	54	12	54	100	
2023-063	067	URISCAN		080 084	080 084		082 - 5.0	54	42	54	100	
2023-063	072	URS-9-TECO		082 086	080 084		083 - 5.5	84	11	84	100	
2023-063	072	URS-9-TECO		082 086	080 084		084 - 6.0	84	57	84	100	
2023-063	072	URS-9-TECO		082 086	080 084		086 - 7.0	84	1	84	100	
2023-063	072	URS-9-TECO		082 086	080 084		085 - 6.5	84	3	84	100	
2023-063	072	URS-9-TECO		082 086	080 084		082 - 5.0	84	12	84	100	
2023-063	080	ROCHE (CHE		080 084	080 084		082 - 5.0	38	37	38	100	
2023-063	080	ROCHE (CHE		080 084	080 084		083 - 5.5	38	1	38	100	
2023-063	089	AIMSTRIP		080 084	080 084		083 - 5.5	130	30	130	100	
2023-063	089	AIMSTRIP		080 084	080 084		084 - 6.0	130	44	130	100	
2023-063	089	AIMSTRIP		080 084	080 084		082 - 5.0	130	56	130	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-063	094	CLINITEK		081 085	080 084		084 - 6.0	106	23	106	100	
2023-063	094	CLINITEK		081 085	080 084		083 - 5.5	106	62	106	100	
2023-063	094	CLINITEK		081 085	080 084		085 - 6.5	106	1	106	100	
2023-063	094	CLINITEK		081 085	080 084		082 - 5.0	106	20	106	100	
2023-063	102	ACON LAB		082 086	080 084		082 - 5.0	140	42	140	100	
2023-063	102	ACON LAB		082 086	080 084		084 - 6.0	140	73	140	100	
2023-063	102	ACON LAB		082 086	080 084		083 - 5.5	140	25	140	100	
2023-063	131	iCHEM VELO		080 084	080 084		082 - 5.0	31	31	31	100	
2023-063	140	MISSION A		081 085	080 084		083 - 5.5	50	23	50	100	
2023-063	140	MISSION A		081 085	080 084		084 - 6.0	50	12	50	100	
2023-063	140	MISSION A		081 085	080 084		082 - 5.0	50	15	50	100	
2023-063	145	CLINITEK		081 085	080 084		082 - 5.0	26	11	26	100	
2023-063	145	CLINITEK		081 085	080 084		084 - 6.0	26	1	26	100	
2023-063	145	CLINITEK		081 085	080 084		083 - 5.5	26	14	26	100	
2023-063	147	Mission120		081 085	080 084		082 - 5.0	37	12	37	100	
2023-063	147	Mission120		081 085	080 084		084 - 6.0	37	1	37	100	
2023-063	147	Mission120		081 085	080 084		083 - 5.5	37	24	37	100	
2023-063	148	Mission500		082 086	080 084		082 - 5.0	79	1	79	100	
2023-063	148	Mission500		082 086	080 084		084 - 6.0	79	71	79	100	
2023-063	148	Mission500		082 086	080 084		083 - 5.5	79	7	79	100	
2023-063	151	Clari. Uro		081 085	080 084		082 - 5.0	14	5	14	100	
2023-063	151	Clari. Uro		081 085	080 084		083 - 5.5	14	6	14	100	
2023-063	151	Clari. Uro		081 085	080 084		084 - 6.0	14	3	14	100	
062 URINALYSIS-pH												
2023-064	011	AMES NM10S		084 088	084 088		087 - 7.5	46	19	46	100	
2023-064	011	AMES NM10S		084 088	084 088		086 - 7.0	46	27	46	100	
2023-064	013	BAYER CLI		084 088	084 088		087 - 7.5	31	12	31	100	
2023-064	013	BAYER CLI		084 088	084 088		086 - 7.0	31	19	31	100	
2023-064	067	URISCAN		084 088	084 088		087 - 7.5	54	1	54	100	
2023-064	067	URISCAN		084 088	084 088		088 - 8.0OR MORE	54	1	54	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-064	067	URISCAN		084 088	084 088		086 - 7.0	54	40	54	100
2023-064	067	URISCAN		084 088	084 088		085 - 6.5	54	12	54	100
2023-064	072	URS-9-TECO		084 088	084 088		086 - 7.0	84	82	84	100
2023-064	072	URS-9-TECO		084 088	084 088		087 - 7.5	84	2	84	100
2023-064	080	ROCHE (CHE		084 088	084 088		086 - 7.0	38	38	38	100
2023-064	089	AIMSTRIP		084 088	084 088		086 - 7.0	130	104	130	100
2023-064	089	AIMSTRIP		084 088	084 088		087 - 7.5	130	26	130	100
2023-064	094	CLINITEK		084 088	084 088		087 - 7.5	106	50	106	100
2023-064	094	CLINITEK		084 088	084 088		086 - 7.0	106	56	106	100
2023-064	102	ACON LAB		084 088	084 088		087 - 7.5	140	18	140	100
2023-064	102	ACON LAB		084 088	084 088		086 - 7.0	140	121	140	100
2023-064	102	ACON LAB		084 088	084 088		085 - 6.5	140	1	140	100
2023-064	131	iCHEM VELO		084 088	084 088		086 - 7.0	31	31	31	100
2023-064	140	MISSION A		084 088	084 088		087 - 7.5	50	3	50	100
2023-064	140	MISSION A		084 088	084 088		086 - 7.0	50	44	50	100
2023-064	140	MISSION A		084 088	084 088		085 - 6.5	50	3	50	100
2023-064	145	CLINITEK		084 088	084 088		086 - 7.0	26	26	26	100
2023-064	147	Mission120		084 088	084 088		086 - 7.0	37	36	37	100
2023-064	147	Mission120		084 088	084 088		085 - 6.5	37	1	37	100
2023-064	148	Mission500		084 088	084 088		086 - 7.0	79	79	79	100
2023-064	151	Clari. Uro		084 088	084 088		086 - 7.0	14	14	14	100
062 URINALYSIS-pH											
2023-065	011	AMES NM10S		083 087	083 087		086 - 7.0	46	4	46	100
2023-065	011	AMES NM10S		083 087	083 087		085 - 6.5	46	41	46	100
2023-065	011	AMES NM10S		083 087	083 087		084 - 6.0	46	1	46	100
2023-065	013	BAYER CLI		083 087	083 087		086 - 7.0	31	8	31	100
2023-065	013	BAYER CLI		083 087	083 087		085 - 6.5	31	23	31	100
2023-065	067	URISCAN		083 087	083 087		083 - 5.5	54	2	54	100
2023-065	067	URISCAN		083 087	083 087		084 - 6.0	54	22	54	100
2023-065	067	URISCAN		083 087	083 087		085 - 6.5	54	30	54	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-065	072	URS-9-TECO		083 087	083 087		086 - 7.0	84	6	83	100
2023-065	072	URS-9-TECO		083 087	083 087		082 - 5.0	84	1	83	0
2023-065	072	URS-9-TECO		083 087	083 087		085 - 6.5	84	70	83	100
2023-065	072	URS-9-TECO		083 087	083 087		084 - 6.0	84	7	83	100
2023-065	080	ROCHE (CHE		083 087	083 087		085 - 6.5	38	36	38	100
2023-065	080	ROCHE (CHE		083 087	083 087		084 - 6.0	38	2	38	100
2023-065	089	AIMSTRIP		083 087	083 087		082 - 5.0	130	1	129	0
2023-065	089	AIMSTRIP		083 087	083 087		085 - 6.5	130	81	129	100
2023-065	089	AIMSTRIP		083 087	083 087		084 - 6.0	130	41	129	100
2023-065	089	AIMSTRIP		083 087	083 087		086 - 7.0	130	7	129	100
2023-065	094	CLINITEK		083 087	083 087		085 - 6.5	106	93	106	100
2023-065	094	CLINITEK		083 087	083 087		086 - 7.0	106	12	106	100
2023-065	094	CLINITEK		083 087	083 087		084 - 6.0	106	1	106	100
2023-065	102	ACON LAB		083 087	083 087		084 - 6.0	140	23	140	100
2023-065	102	ACON LAB		083 087	083 087		085 - 6.5	140	106	140	100
2023-065	102	ACON LAB		083 087	083 087		086 - 7.0	140	11	140	100
2023-065	131	iCHEM VELO		082 086	083 087		084 - 6.0	31	30	31	100
2023-065	131	iCHEM VELO		082 086	083 087		082 - 5.0	31	1	31	100
2023-065	140	MISSION A		083 087	083 087		084 - 6.0	50	14	50	100
2023-065	140	MISSION A		083 087	083 087		086 - 7.0	50	2	50	100
2023-065	140	MISSION A		083 087	083 087		085 - 6.5	50	34	50	100
2023-065	145	CLINITEK		083 087	083 087		085 - 6.5	26	26	26	100
2023-065	147	Mission120		083 087	083 087		085 - 6.5	37	32	37	100
2023-065	147	Mission120		083 087	083 087		084 - 6.0	37	5	37	100
2023-065	148	Mission500		083 087	083 087		085 - 6.5	79	78	79	100
2023-065	148	Mission500		083 087	083 087		083 - 5.5	79	1	79	100
2023-065	151	Clari. Uro		082 086	083 087		085 - 6.5	14	5	14	100
2023-065	151	Clari. Uro		082 086	083 087		084 - 6.0	14	9	14	100
064 URIN-PROTEIN QUALI.											
2023-061	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	47	47	47	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	31	31	31	100	
2023-061	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	54	54	100	
2023-061	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	85	81	81	100	
2023-061	072	URS-9-TECO		051 051	051 051		052 - TRACES	85	4	81	0	
2023-061	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	38	38	38	100	
2023-061	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	129	125	125	100	
2023-061	089	AIMSTRIP		051 051	051 051		053 - 1+	129	1	125	0	
2023-061	089	AIMSTRIP		051 051	051 051		052 - TRACES	129	3	125	0	
2023-061	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	106	106	100	
2023-061	102	ACON LAB		051 051	051 051		051 - NEGATIVE	141	140	140	100	
2023-061	102	ACON LAB		051 051	051 051		052 - TRACES	141	1	140	0	
2023-061	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	31	31	31	100	
2023-061	140	MISSION A		051 051	051 051		052 - TRACES	49	1	48	0	
2023-061	140	MISSION A		051 051	051 051		051 - NEGATIVE	49	48	48	100	
2023-061	145	CLINITEK		051 051	051 051		051 - NEGATIVE	26	26	26	100	
2023-061	147	Mission120		051 051	051 051		051 - NEGATIVE	38	38	38	100	
2023-061	148	Mission500		051 051	051 051		052 - TRACES	79	3	76	0	
2023-061	148	Mission500		051 051	051 051		051 - NEGATIVE	79	76	76	100	
2023-061	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	13	13	13	100	
064 URIN-PROTEIN QUALI.												
2023-062	011	AMES NM10S		053 055	054 056		053 - 1+	47	2	47	100	
2023-062	011	AMES NM10S		053 055	054 056		054 - 2+	47	30	47	100	
2023-062	011	AMES NM10S		053 055	054 056		055 - 3+	47	15	47	100	
2023-062	013	BAYER CLI		053 055	054 056		055 - 3+	31	14	31	100	
2023-062	013	BAYER CLI		053 055	054 056		054 - 2+	31	17	31	100	
2023-062	067	URISCAN		053 055	054 056		054 - 2+	54	47	54	100	
2023-062	067	URISCAN		053 055	054 056		053 - 1+	54	1	54	100	
2023-062	067	URISCAN		053 055	054 056		055 - 3+	54	6	54	100	
2023-062	072	URS-9-TECO		054 056	054 056		056 - 4+	85	2	81	100	
2023-062	072	URS-9-TECO		054 056	054 056		054 - 2+	85	26	81	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	072	URS-9-TECO		054 056	054 056		055 - 3+	85	53	81	100	
2023-062	072	URS-9-TECO		054 056	054 056		053 - 1+	85	4	81	0	
2023-062	080	ROCHE (CHE		053 055	054 056		055 - 3+	38	9	38	100	
2023-062	080	ROCHE (CHE		053 055	054 056		054 - 2+	38	29	38	100	
2023-062	089	AIMSTRIP		054 056	054 056		055 - 3+	129	106	128	100	
2023-062	089	AIMSTRIP		054 056	054 056		056 - 4+	129	3	128	100	
2023-062	089	AIMSTRIP		054 056	054 056		054 - 2+	129	19	128	100	
2023-062	089	AIMSTRIP		054 056	054 056		053 - 1+	129	1	128	0	
2023-062	094	CLINITEK		053 055	054 056		054 - 2+	106	88	106	100	
2023-062	094	CLINITEK		053 055	054 056		056 - 4+	106	2	106	100	
2023-062	094	CLINITEK		053 055	054 056		055 - 3+	106	15	106	100	
2023-062	094	CLINITEK		053 055	054 056		053 - 1+	106	1	106	100	
2023-062	102	ACON LAB		054 056	054 056		056 - 4+	141	1	139	100	
2023-062	102	ACON LAB		054 056	054 056		055 - 3+	141	78	139	100	
2023-062	102	ACON LAB		054 056	054 056		053 - 1+	141	2	139	0	
2023-062	102	ACON LAB		054 056	054 056		054 - 2+	141	60	139	100	
2023-062	131	iCHEM VELO		053 055	054 056		055 - 3+	31	11	31	100	
2023-062	131	iCHEM VELO		053 055	054 056		054 - 2+	31	18	31	100	
2023-062	131	iCHEM VELO		053 055	054 056		056 - 4+	31	2	31	100	
2023-062	140	MISSION A		053 055	054 056		055 - 3+	49	21	49	100	
2023-062	140	MISSION A		053 055	054 056		054 - 2+	49	28	49	100	
2023-062	145	CLINITEK		054 056	054 056		055 - 3+	26	15	25	100	
2023-062	145	CLINITEK		054 056	054 056		053 - 1+	26	1	25	0	
2023-062	145	CLINITEK		054 056	054 056		054 - 2+	26	10	25	100	
2023-062	147	Mission120		053 055	054 056		055 - 3+	38	7	38	100	
2023-062	147	Mission120		053 055	054 056		054 - 2+	38	30	38	100	
2023-062	147	Mission120		053 055	054 056		053 - 1+	38	1	38	100	
2023-062	148	Mission500		054 056	054 056		055 - 3+	79	51	77	100	
2023-062	148	Mission500		054 056	054 056		054 - 2+	79	26	77	100	
2023-062	148	Mission500		054 056	054 056		053 - 1+	79	2	77	0	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	151	Clari. Uro		054 056	054 056		055 - 3+	13	11	13	100	
2023-062	151	Clari. Uro		054 056	054 056		054 - 2+	13	2	13	100	
064 URIN-PROTEIN QUALI.												
2023-063	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	47	47	47	100	
2023-063	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	31	31	31	100	
2023-063	067	URISCAN		051 051	051 051		051 - NEGATIVE	54	54	54	100	
2023-063	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	85	85	85	100	
2023-063	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	38	38	38	100	
2023-063	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	129	129	129	100	
2023-063	094	CLINITEK		051 051	051 051		051 - NEGATIVE	106	106	106	100	
2023-063	102	ACON LAB		051 051	051 051		051 - NEGATIVE	141	141	141	100	
2023-063	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	31	31	31	100	
2023-063	140	MISSION A		051 051	051 051		051 - NEGATIVE	49	49	49	100	
2023-063	145	CLINITEK		051 051	051 051		051 - NEGATIVE	26	26	26	100	
2023-063	147	Mission120		051 051	051 051		051 - NEGATIVE	38	37	37	100	
2023-063	147	Mission120		051 051	051 051		054 - 2+	38	1	37	0	
2023-063	148	Mission500		051 051	051 051		051 - NEGATIVE	79	79	79	100	
2023-063	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	13	13	13	100	
2023-064	011	AMES NM10S		053 055	053 055		053 - 1+	47	1	47	100	
2023-064	011	AMES NM10S		053 055	053 055		054 - 2+	47	28	47	100	
2023-064	011	AMES NM10S		053 055	053 055		055 - 3+	47	18	47	100	
2023-064	013	BAYER CLI		053 055	053 055		055 - 3+	31	11	30	100	
2023-064	013	BAYER CLI		053 055	053 055		051 - NEGATIVE	31	1	30	0	
2023-064	013	BAYER CLI		053 055	053 055		054 - 2+	31	18	30	100	
2023-064	013	BAYER CLI		053 055	053 055		053 - 1+	31	1	30	100	
2023-064	067	URISCAN		053 055	053 055		055 - 3+	54	3	54	100	
2023-064	067	URISCAN		053 055	053 055		054 - 2+	54	47	54	100	
2023-064	067	URISCAN		053 055	053 055		053 - 1+	54	4	54	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-064	072	URS-9-TECO		054 056	053 055		054 - 2+	85	37	83	100
2023-064	072	URS-9-TECO		054 056	053 055		056 - 4+	85	2	83	100
2023-064	072	URS-9-TECO		054 056	053 055		055 - 3+	85	43	83	100
2023-064	072	URS-9-TECO		054 056	053 055		051 - NEGATIVE	85	2	83	0
2023-064	072	URS-9-TECO		054 056	053 055		053 - 1+	85	1	83	100
2023-064	080	ROCHE (CHE		053 055	053 055		054 - 2+	38	29	38	100
2023-064	080	ROCHE (CHE		053 055	053 055		055 - 3+	38	9	38	100
2023-064	089	AIMSTRIP		054 056	053 055		054 - 2+	129	27	129	100
2023-064	089	AIMSTRIP		054 056	053 055		053 - 1+	129	2	129	100
2023-064	089	AIMSTRIP		054 056	053 055		056 - 4+	129	3	129	100
2023-064	089	AIMSTRIP		054 056	053 055		055 - 3+	129	97	129	100
2023-064	094	CLINITEK		053 055	053 055		055 - 3+	106	15	104	100
2023-064	094	CLINITEK		053 055	053 055		053 - 1+	106	1	104	100
2023-064	094	CLINITEK		053 055	053 055		054 - 2+	106	88	104	100
2023-064	094	CLINITEK		053 055	053 055		056 - 4+	106	2	104	0
2023-064	102	ACON LAB		053 055	053 055		054 - 2+	141	78	140	100
2023-064	102	ACON LAB		053 055	053 055		056 - 4+	141	1	140	0
2023-064	102	ACON LAB		053 055	053 055		055 - 3+	141	62	140	100
2023-064	131	iCHEM VELO		053 055	053 055		055 - 3+	31	4	31	100
2023-064	131	iCHEM VELO		053 055	053 055		054 - 2+	31	27	31	100
2023-064	140	MISSION A		053 055	053 055		054 - 2+	49	33	49	100
2023-064	140	MISSION A		053 055	053 055		055 - 3+	49	16	49	100
2023-064	145	CLINITEK		054 056	053 055		055 - 3+	26	19	26	100
2023-064	145	CLINITEK		054 056	053 055		053 - 1+	26	1	26	100
2023-064	145	CLINITEK		054 056	053 055		054 - 2+	26	6	26	100
2023-064	147	Mission120		053 055	053 055		053 - 1+	38	1	38	100
2023-064	147	Mission120		053 055	053 055		054 - 2+	38	35	38	100
2023-064	147	Mission120		053 055	053 055		055 - 3+	38	2	38	100
2023-064	148	Mission500		054 056	053 055		054 - 2+	79	37	79	100
2023-064	148	Mission500		054 056	053 055		053 - 1+	79	2	79	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-064	148	Mission500		054 056	053 055		055 - 3+	79	40	79	100	
2023-064	151	Clari. Uro		054 056	053 055		054 - 2+	13	4	13	100	
2023-064	151	Clari. Uro		054 056	053 055		055 - 3+	13	9	13	100	
064 URIN-PROTEIN QUALI.												
2023-065	011	AMES NM10S		053 055	053 055		055 - 3+	47	11	47	100	
2023-065	011	AMES NM10S		053 055	053 055		053 - 1+	47	3	47	100	
2023-065	011	AMES NM10S		053 055	053 055		054 - 2+	47	33	47	100	
2023-065	013	BAYER CLI		053 055	053 055		054 - 2+	31	22	31	100	
2023-065	013	BAYER CLI		053 055	053 055		053 - 1+	31	1	31	100	
2023-065	013	BAYER CLI		053 055	053 055		055 - 3+	31	8	31	100	
2023-065	067	URISCAN		053 055	053 055		053 - 1+	54	14	54	100	
2023-065	067	URISCAN		053 055	053 055		054 - 2+	54	38	54	100	
2023-065	067	URISCAN		053 055	053 055		055 - 3+	54	2	54	100	
2023-065	072	URS-9-TECO		053 055	053 055		054 - 2+	85	45	84	100	
2023-065	072	URS-9-TECO		053 055	053 055		053 - 1+	85	3	84	100	
2023-065	072	URS-9-TECO		053 055	053 055		056 - 4+	85	1	84	0	
2023-065	072	URS-9-TECO		053 055	053 055		055 - 3+	85	36	84	100	
2023-065	080	ROCHE (CHE		053 055	053 055		054 - 2+	38	30	38	100	
2023-065	080	ROCHE (CHE		053 055	053 055		055 - 3+	38	8	38	100	
2023-065	089	AIMSTRIP		054 056	053 055		056 - 4+	129	3	129	100	
2023-065	089	AIMSTRIP		054 056	053 055		055 - 3+	129	64	129	100	
2023-065	089	AIMSTRIP		054 056	053 055		053 - 1+	129	2	129	100	
2023-065	089	AIMSTRIP		054 056	053 055		054 - 2+	129	60	129	100	
2023-065	094	CLINITEK		053 055	053 055		053 - 1+	106	1	106	100	
2023-065	094	CLINITEK		053 055	053 055		054 - 2+	106	96	106	100	
2023-065	094	CLINITEK		053 055	053 055		055 - 3+	106	9	106	100	
2023-065	102	ACON LAB		053 055	053 055		053 - 1+	141	3	140	100	
2023-065	102	ACON LAB		053 055	053 055		054 - 2+	141	99	140	100	
2023-065	102	ACON LAB		053 055	053 055		055 - 3+	141	38	140	100	
2023-065	102	ACON LAB		053 055	053 055		056 - 4+	141	1	140	0	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-065	131	iCHEM VELO		053 055	053 055		055 - 3+	31	1	31	100	
2023-065	131	iCHEM VELO		053 055	053 055		054 - 2+	31	30	31	100	
2023-065	140	MISSION A		053 055	053 055		055 - 3+	49	12	49	100	
2023-065	140	MISSION A		053 055	053 055		054 - 2+	49	35	49	100	
2023-065	140	MISSION A		053 055	053 055		053 - 1+	49	2	49	100	
2023-065	145	CLINITEK		053 055	053 055		054 - 2+	26	22	26	100	
2023-065	145	CLINITEK		053 055	053 055		053 - 1+	26	1	26	100	
2023-065	145	CLINITEK		053 055	053 055		055 - 3+	26	3	26	100	
2023-065	147	Mission120		053 055	053 055		053 - 1+	38	3	38	100	
2023-065	147	Mission120		053 055	053 055		054 - 2+	38	35	38	100	
2023-065	148	Mission500		053 055	053 055		054 - 2+	79	63	79	100	
2023-065	148	Mission500		053 055	053 055		055 - 3+	79	11	79	100	
2023-065	148	Mission500		053 055	053 055		053 - 1+	79	5	79	100	
2023-065	151	Clari. Uro		053 055	053 055		055 - 3+	13	4	13	100	
2023-065	151	Clari. Uro		053 055	053 055		054 - 2+	13	9	13	100	
066 URINAL.-UROBILINOGEN												
2023-061	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	48	48	48	100	
2023-061	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-061	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2023-061	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	85	85	85	100	
2023-061	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2023-061	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	130	130	130	100	
2023-061	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	105	105	100	
2023-061	094	CLINITEK		061 061	061 061		063 - 4	106	1	105	0	
2023-061	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	138	138	138	100	
2023-061	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-061	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	
2023-061	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	26	26	26	100	
2023-061	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	37	37	100	
2023-061	147	Mission120		061 061	061 061		062 - 2	38	1	37	0	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-061	148	Mission500		061 061	061 061		061 - NORMAL,NEG	79	79	79	100	
2023-061	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
066 URINAL.-UROBILINOGEN												
2023-062	011	AMES NM10S		062 064	061 063		061 - NORMAL,NEG	48	4	48	100	
2023-062	011	AMES NM10S		062 064	061 063		064 - 8	48	1	48	100	
2023-062	011	AMES NM10S		062 064	061 063		063 - 4	48	24	48	100	
2023-062	011	AMES NM10S		062 064	061 063		062 - 2	48	19	48	100	
2023-062	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	31	8	31	100	
2023-062	013	BAYER CLI		061 063	061 063		062 - 2	31	19	31	100	
2023-062	013	BAYER CLI		061 063	061 063		063 - 4	31	4	31	100	
2023-062	067	URISCAN			061 063		061 - NORMAL,NEG	54	14	51	100	
2023-062	067	URISCAN			061 063		064 - 8	54	3	51	0	
2023-062	067	URISCAN			061 063		062 - 2	54	7	51	100	
2023-062	067	URISCAN			061 063		063 - 4	54	30	51	100	
2023-062	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	85	11	84	100	
2023-062	072	URS-9-TECO		061 063	061 063		064 - 8	85	1	84	0	
2023-062	072	URS-9-TECO		061 063	061 063		062 - 2	85	48	84	100	
2023-062	072	URS-9-TECO		061 063	061 063		063 - 4	85	25	84	100	
2023-062	080	ROCHE (CHE		061 061	061 063		062 - 2	38	1	38	100	
2023-062	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	38	37	38	100	
2023-062	089	AIMSTRIP			061 063		063 - 4	130	5	129	100	
2023-062	089	AIMSTRIP			061 063		062 - 2	130	33	129	100	
2023-062	089	AIMSTRIP			061 063		061 - NORMAL,NEG	130	91	129	100	
2023-062	089	AIMSTRIP			061 063		064 - 8	130	1	129	0	
2023-062	094	CLINITEK		062 064	061 063		064 - 8	106	2	106	100	
2023-062	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	106	13	106	100	
2023-062	094	CLINITEK		062 064	061 063		062 - 2	106	36	106	100	
2023-062	094	CLINITEK		062 064	061 063		063 - 4	106	55	106	100	
2023-062	102	ACON LAB			061 063		061 - NORMAL,NEG	138	105	138	100	
2023-062	102	ACON LAB			061 063		062 - 2	138	29	138	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-062	102	ACON LAB			061	063	063 - 4	138	4	138	100
2023-062	131	iCHEM VELO		062	064	061	063	063 - 4	31	31	100
2023-062	140	MISSION A		061	061	061	063	061 - NORMAL,NEG	49	42	100
2023-062	140	MISSION A		061	061	061	063	062 - 2	49	4	100
2023-062	140	MISSION A		061	061	061	063	063 - 4	49	3	100
2023-062	145	CLINITEK		061	063	061	063	061 - NORMAL,NEG	26	1	100
2023-062	145	CLINITEK		061	063	061	063	062 - 2	26	25	100
2023-062	147	Mission120		061	061	061	063	062 - 2	38	1	100
2023-062	147	Mission120		061	061	061	063	061 - NORMAL,NEG	38	37	100
2023-062	148	Mission500		061	061	061	063	061 - NORMAL,NEG	79	75	100
2023-062	148	Mission500		061	061	061	063	063 - 4	79	1	100
2023-062	148	Mission500		061	061	061	063	062 - 2	79	3	100
2023-062	151	Clari. Uro			061	063	062 - 2	12	4	12	100
2023-062	151	Clari. Uro			061	063	063 - 4	12	1	12	100
2023-062	151	Clari. Uro			061	063	061 - NORMAL,NEG	12	7	12	100
066 URINAL.-UROBILINOGEN											
2023-063	011	AMES NM10S		061	061	061	061	061 - NORMAL,NEG	48	48	100
2023-063	013	BAYER CLI		061	061	061	061	061 - NORMAL,NEG	31	31	100
2023-063	067	URISCAN		061	061	061	061	061 - NORMAL,NEG	54	54	100
2023-063	072	URS-9-TECO		061	061	061	061	061 - NORMAL,NEG	85	85	100
2023-063	080	ROCHE (CHE		061	061	061	061	062 - 2	38	1	0
2023-063	080	ROCHE (CHE		061	061	061	061	061 - NORMAL,NEG	38	37	100
2023-063	089	AIMSTRIP		061	061	061	061	063 - 4	130	1	0
2023-063	089	AIMSTRIP		061	061	061	061	061 - NORMAL,NEG	130	129	100
2023-063	094	CLINITEK		061	061	061	061	061 - NORMAL,NEG	106	106	100
2023-063	102	ACON LAB		061	061	061	061	061 - NORMAL,NEG	138	138	100
2023-063	131	iCHEM VELO		061	061	061	061	061 - NORMAL,NEG	31	31	100
2023-063	140	MISSION A		061	061	061	061	061 - NORMAL,NEG	49	49	100
2023-063	145	CLINITEK		061	061	061	061	061 - NORMAL,NEG	26	26	100
2023-063	147	Mission120		061	061	061	061	061 - NORMAL,NEG	38	37	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-063	147	Mission120		061 061	061 061		062 - 2	38	1	37	0	
2023-063	148	Mission500		061 061	061 061		061 - NORMAL,NEG	79	79	79	100	
2023-063	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
066 URINAL.-UROBILINOGEN												
2023-064	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	48	48	48	100	
2023-064	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-064	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2023-064	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	85	85	85	100	
2023-064	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2023-064	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	130	130	130	100	
2023-064	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2023-064	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	138	138	138	100	
2023-064	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-064	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	
2023-064	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	26	26	26	100	
2023-064	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	37	37	100	
2023-064	147	Mission120		061 061	061 061		062 - 2	38	1	37	0	
2023-064	148	Mission500		061 061	061 061		062 - 2	79	1	78	0	
2023-064	148	Mission500		061 061	061 061		061 - NORMAL,NEG	79	78	78	100	
2023-064	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
2023-065	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	48	48	48	100	
2023-065	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-065	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	54	54	54	100	
2023-065	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	85	85	85	100	
2023-065	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	38	38	38	100	
2023-065	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	130	130	130	100	
2023-065	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	106	106	106	100	
2023-065	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	138	138	138	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-065	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	31	31	31	100	
2023-065	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	49	49	49	100	
2023-065	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	26	26	26	100	
2023-065	147	Mission120		061 061	061 061		062 - 2	38	1	37	0	
2023-065	147	Mission120		061 061	061 061		061 - NORMAL,NEG	38	37	37	100	
2023-065	148	Mission500		061 061	061 061		061 - NORMAL,NEG	79	79	79	100	
2023-065	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	12	12	12	100	
184 URINALYSIS LEUKOCYTE												
2023-061	011	AMES NM10S		001 001	001 001		001 - Negative	48	48	48	100	
2023-061	013	BAYER CLI		001 001	001 001		001 - Negative	31	31	31	100	
2023-061	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2023-061	072	URS-9-TECO		001 001	001 001		001 - Negative	79	79	79	100	
2023-061	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100	
2023-061	089	AIMSTRIP		001 001	001 001		001 - Negative	127	127	127	100	
2023-061	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2023-061	102	ACON LAB		001 001	001 001		001 - Negative	127	127	127	100	
2023-061	131	iCHEM VELO		001 001	001 001		001 - Negative	31	31	31	100	
2023-061	140	MISSION A		001 001	001 001		001 - Negative	54	54	54	100	
2023-061	145	CLINITEK		001 001	001 001		001 - Negative	26	26	26	100	
2023-061	147	Mission120		001 001	001 001		001 - Negative	36	36	36	100	
2023-061	148	Mission500		001 001	001 001		001 - Negative	80	80	80	100	
2023-061	151	Clari. Uro		001 001	001 001		001 - Negative	15	15	15	100	
2023-062	011	AMES NM10S		001 001	001 001		001 - Negative	48	48	48	100	
2023-062	013	BAYER CLI		001 001	001 001		001 - Negative	31	31	31	100	
2023-062	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2023-062	072	URS-9-TECO		001 001	001 001		001 - Negative	79	79	79	100	
2023-062	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100	
2023-062	089	AIMSTRIP		001 001	001 001		001 - Negative	127	127	127	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-062	094 CLINITEK			001 001	001 001		001 - Negative	105	105	105	100	
2023-062	102 ACON LAB			001 001	001 001		004 - Moderate	127	1	126	0	
2023-062	102 ACON LAB			001 001	001 001		001 - Negative	127	126	126	100	
2023-062	131 iCHEM VELO			001 001	001 001		001 - Negative	31	31	31	100	
2023-062	140 MISSION A			001 001	001 001		001 - Negative	54	54	54	100	
2023-062	145 CLINITEK			001 001	001 001		001 - Negative	26	26	26	100	
2023-062	147 Mission120			001 001	001 001		001 - Negative	36	36	36	100	
2023-062	148 Mission500			001 001	001 001		001 - Negative	80	80	80	100	
2023-062	151 Clari. Uro			001 001	001 001		001 - Negative	15	15	15	100	
184 URINALYSIS LEUKOCYTE												
2023-063	011 AMES NM10S			002 004	003 005		003 - Small	48	38	47	100	
2023-063	011 AMES NM10S			002 004	003 005		002 - Traces	48	6	47	100	
2023-063	011 AMES NM10S			002 004	003 005		004 - Moderate	48	3	47	100	
2023-063	011 AMES NM10S			002 004	003 005		001 - Negative	48	1	47	0	
2023-063	013 BAYER CLI			002 004	003 005		003 - Small	31	23	31	100	
2023-063	013 BAYER CLI			002 004	003 005		002 - Traces	31	6	31	100	
2023-063	013 BAYER CLI			002 004	003 005		004 - Moderate	31	2	31	100	
2023-063	067 URISCAN			004 005	003 005		005 - Large	54	25	54	100	
2023-063	067 URISCAN			004 005	003 005		004 - Moderate	54	23	54	100	
2023-063	067 URISCAN			004 005	003 005		003 - Small	54	6	54	100	
2023-063	072 URS-9-TECO			002 004	003 005		004 - Moderate	79	33	77	100	
2023-063	072 URS-9-TECO			002 004	003 005		001 - Negative	79	2	77	0	
2023-063	072 URS-9-TECO			002 004	003 005		002 - Traces	79	1	77	100	
2023-063	072 URS-9-TECO			002 004	003 005		005 - Large	79	1	77	100	
2023-063	072 URS-9-TECO			002 004	003 005		003 - Small	79	42	77	100	
2023-063	080 ROCHE (CHE			004 005	003 005		003 - Small	35	1	35	100	
2023-063	080 ROCHE (CHE			004 005	003 005		005 - Large	35	32	35	100	
2023-063	080 ROCHE (CHE			004 005	003 005		004 - Moderate	35	2	35	100	
2023-063	089 AIMSTRIP			002 004	003 005		005 - Large	127	1	127	100	
2023-063	089 AIMSTRIP			002 004	003 005		002 - Traces	127	18	127	100	

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY

SUB: 50 URINALYSIS

GRP: 70 URINALYSIS

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2023-063	089	AIMSTRIP		002 004	003 005		004 - Moderate	127	15	127	100
2023-063	089	AIMSTRIP		002 004	003 005		003 - Small	127	93	127	100
2023-063	094	CLINITEK		002 004	003 005		003 - Small	105	89	105	100
2023-063	094	CLINITEK		002 004	003 005		002 - Traces	105	13	105	100
2023-063	094	CLINITEK		002 004	003 005		004 - Moderate	105	3	105	100
2023-063	102	ACON LAB		002 004	003 005		002 - Traces	127	22	124	100
2023-063	102	ACON LAB		002 004	003 005		004 - Moderate	127	18	124	100
2023-063	102	ACON LAB		002 004	003 005		001 - Negative	127	3	124	0
2023-063	102	ACON LAB		002 004	003 005		003 - Small	127	84	124	100
2023-063	131	iCHEM VELO		004 005	003 005		004 - Moderate	31	1	31	100
2023-063	131	iCHEM VELO		004 005	003 005		005 - Large	31	30	31	100
2023-063	140	MISSION A		002 004	003 005		003 - Small	54	35	53	100
2023-063	140	MISSION A		002 004	003 005		002 - Traces	54	10	53	100
2023-063	140	MISSION A		002 004	003 005		001 - Negative	54	1	53	0
2023-063	140	MISSION A		002 004	003 005		004 - Moderate	54	8	53	100
2023-063	145	CLINITEK		003 005	003 005		003 - Small	26	2	26	100
2023-063	145	CLINITEK		003 005	003 005		004 - Moderate	26	24	26	100
2023-063	147	Mission120		001 003	003 005		004 - Moderate	36	4	36	100
2023-063	147	Mission120		001 003	003 005		003 - Small	36	14	36	100
2023-063	147	Mission120		001 003	003 005		002 - Traces	36	18	36	100
2023-063	148	Mission500		002 004	003 005		002 - Traces	80	23	80	100
2023-063	148	Mission500		002 004	003 005		004 - Moderate	80	8	80	100
2023-063	148	Mission500		002 004	003 005		003 - Small	80	49	80	100
2023-063	151	Clari. Uro		002 004	003 005		003 - Small	15	13	15	100
2023-063	151	Clari. Uro		002 004	003 005		002 - Traces	15	1	15	100
2023-063	151	Clari. Uro		002 004	003 005		004 - Moderate	15	1	15	100
184 URINALYSIS LEUKOCYTE											
2023-064	011	AMES NM10S		001 001	001 001		001 - Negative	48	48	48	100
2023-064	013	BAYER CLI		001 001	001 001		001 - Negative	31	31	31	100
2023-064	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2023-064	072	URS-9-TECO		001 001	001 001		003 - Small	79	1	78	0	
2023-064	072	URS-9-TECO		001 001	001 001		001 - Negative	79	78	78	100	
2023-064	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100	
2023-064	089	AIMSTRIP		001 001	001 001		001 - Negative	127	127	127	100	
2023-064	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2023-064	102	ACON LAB		001 001	001 001		001 - Negative	127	127	127	100	
2023-064	131	iCHEM VELO		001 001	001 001		001 - Negative	31	31	31	100	
2023-064	140	MISSION A		001 001	001 001		001 - Negative	54	54	54	100	
2023-064	145	CLINITEK		001 001	001 001		001 - Negative	26	26	26	100	
2023-064	147	Mission120		001 001	001 001		001 - Negative	36	36	36	100	
2023-064	148	Mission500		001 001	001 001		001 - Negative	80	80	80	100	
2023-064	151	Clari. Uro		001 001	001 001		001 - Negative	15	15	15	100	
184 URINALYSIS LEUKOCYTE												
2023-065	011	AMES NM10S		001 001	001 001		001 - Negative	48	48	48	100	
2023-065	013	BAYER CLI		001 001	001 001		001 - Negative	31	31	31	100	
2023-065	067	URISCAN		001 001	001 001		001 - Negative	54	54	54	100	
2023-065	072	URS-9-TECO		001 001	001 001		004 - Moderate	79	1	78	0	
2023-065	072	URS-9-TECO		001 001	001 001		001 - Negative	79	78	78	100	
2023-065	080	ROCHE (CHE		001 001	001 001		001 - Negative	35	35	35	100	
2023-065	089	AIMSTRIP		001 001	001 001		001 - Negative	127	127	127	100	
2023-065	094	CLINITEK		001 001	001 001		001 - Negative	105	105	105	100	
2023-065	102	ACON LAB		001 001	001 001		001 - Negative	127	127	127	100	
2023-065	131	iCHEM VELO		001 001	001 001		001 - Negative	31	31	31	100	
2023-065	140	MISSION A		001 001	001 001		001 - Negative	54	54	54	100	
2023-065	145	CLINITEK		001 001	001 001		001 - Negative	26	26	26	100	
2023-065	147	Mission120		001 001	001 001		001 - Negative	36	36	36	100	
2023-065	148	Mission500		001 001	001 001		001 - Negative	80	80	80	100	
2023-065	151	Clari. Uro		001 001	001 001		001 - Negative	15	15	15	100	

Participant Summary
MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST												
2023-061	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2023-061	101	HCG Alere		001	001	001	001	001 - NEGATIVE	27	26	26	100
2023-061	101	HCG Alere		001	001	001	001	002 - POSITIVE	27	1	26	0
2023-062	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100
2023-062	101	HCG Alere		002	002	002	002	002 - POSITIVE	27	27	27	100
2023-063	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2023-063	101	HCG Alere		001	001	001	001	001 - NEGATIVE	27	27	27	100
2023-064	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100
2023-064	101	HCG Alere		002	002	002	002	002 - POSITIVE	27	26	26	100
2023-064	101	HCG Alere		002	002	002	002	001 - NEGATIVE	27	1	26	0
2023-065	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2023-065	101	HCG Alere		001	001	001	001	001 - NEGATIVE	27	26	26	100
2023-065	101	HCG Alere		001	001	001	001	002 - POSITIVE	27	1	26	0

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2023-071					014 014		014 - CA. OXALAT	894	892	892	100
2023-071					014 014		015 - CA. SULFAT	894	2	892	0
2023-072					037 037		037 - SPERMAT. .	894	894	894	100
2023-073					009 009		007 - WHITE CELL	894	1	880	0
2023-073					009 009		042 - WBC in clu	894	1	880	0
2023-073					009 009		036 - STARCH CR.	894	1	880	0
2023-073					009 009		008 - ERYTHROCYT	894	10	880	0
2023-073					009 009		035 - POLLEN GR.	894	1	880	0
2023-073					009 009		009 - LEUKOCYTE	894	880	880	100
2023-074					007 007		006 - WAXY CAST	894	1	876	0
2023-074					007 007		002 - FATTY CAST	894	12	876	0
2023-074					007 007		042 - WBC in clu	894	2	876	0
2023-074					007 007		001 - E.C. CAST	894	3	876	0
2023-074					007 007		007 - WHITE CELL	894	876	876	100
2023-075					011 011		001 - E.C. CAST	894	3	890	0
2023-075					011 011		011 - SQUAMOUS E	894	890	890	100
2023-075					011 011		027 - CA. PHOSP.	894	1	890	0

Participant Summary

MONTH 2 OF YEAR 2023

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
154 FECAL OCCULT BLOOD												
2023-081	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	406	1	405	0
2023-081	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	406	405	405	100
2023-081	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	721	1	720	0
2023-081	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	721	720	720	100
2023-082	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	406	406	406	100
2023-082	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	721	721	721	100
2023-083	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	406	406	406	100
2023-083	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	721	1	720	0
2023-083	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	721	720	720	100
2023-084	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	406	406	406	100
2023-084	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	721	721	721	100
2023-085	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	406	1	405	0
2023-085	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	406	405	405	100
2023-085	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	721	720	720	100
2023-085	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	721	1	720	0

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. LABS	PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
068 CARCINOE. ANTIG. CEA				CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}			
2023-031	29	VITROS		12		10.450	0.433	4.14	9.200	11.700	
2023-031	38	ROCHE E		20		9.090	0.382	4.20	7.900	10.200	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-031	44	BECK.COUL.		19	8.253	0.532	6.45	6.700	9.900
2023-031	50	ARC		10	10.530	0.363	3.45	9.400	11.600
068	CARCINOE. ANTIG. CEA		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}				
2023-032	29	VITROS		12	6.250	0.269	4.31	5.400	7.100
2023-032	38	ROCHE E		20	5.730	0.247	4.31	5.000	6.500
2023-032	44	BECK.COUL.		19	5.063	0.370	7.31	4.000	6.200
2023-032	50	ARC		10	6.390	0.230	3.60	5.700	7.100
2023-033	29	VITROS		12	39.250	1.263	3.22	35.500	43.000
2023-033	38	ROCHE E		20	31.415	1.048	3.33	28.300	34.600
2023-033	44	BECK.COUL.		19	31.505	1.836	5.83	26.000	37.000
2023-033	50	ARC		10	38.920	1.210	3.11	35.300	42.500
2023-034	29	VITROS		12	20.158	0.860	4.26	17.600	22.700
2023-034	38	ROCHE E		20	16.755	0.728	4.34	14.600	18.900
2023-034	44	BECK.COUL.		19	15.537	0.993	6.39	12.600	18.500
2023-034	50	ARC		10	19.750	0.742	3.76	17.500	22.000
2023-035	29	VITROS		12	28.292	1.311	4.63	24.400	32.200
2023-035	38	ROCHE E		20	23.050	0.855	3.71	20.500	25.600
2023-035	44	BECK.COUL.		19	22.074	1.181	5.35	18.500	25.600
2023-035	50	ARC		10	27.820	0.974	3.50	24.900	30.700
069	PROS. SPEC-ANTIG-PSA								
2023-031	29	VITROS		42	8.400	1.000	11.90	6.300	10.500
2023-031	29	VITROS		42	4.121	0.171	4.15	3.600	4.600
2023-031	36	TOSOH AIA		11	5.091	0.303	5.95	4.200	6.000
2023-031	38	ROCHE E		51	8.360	0.442	5.29	7.000	9.700
2023-031	38	ROCHE E		51	8.400	1.000	11.90	6.300	10.500
2023-031	39	DIMENS.RXL		10	7.790	0.432	5.55	6.500	9.100
2023-031	44	BECK.COUL.		53	8.400	1.000	11.90	6.300	10.500

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST			
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-031	44	BECK.COUL.		53	8.112	0.396	4.88	6.900	9.300
2023-031	50	ARC		22	6.077	0.291	4.78	5.200	6.900
2023-031	57	S. EXL 200		61	7.725	0.409	5.30	6.500	9.000
2023-031	57	S. EXL 200		61	8.400	1.000	11.90	6.300	10.500
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}						
2023-032	29	VITROS		42	2.520	0.099	3.94	2.200	2.800
2023-032	29	VITROS		42	4.500	1.000	22.22	3.400	5.600
2023-032	36	TOSOH AIA		11	3.036	0.235	7.73	2.300	3.700
2023-032	38	ROCHE E		51	4.500	1.000	22.22	3.400	5.600
2023-032	38	ROCHE E		51	4.928	0.254	5.15	4.200	5.700
2023-032	39	DIMENS.RXL		10	4.530	0.261	5.76	3.700	5.300
2023-032	44	BECK.COUL.		53	4.779	0.249	5.21	4.000	5.500
2023-032	44	BECK.COUL.		53	4.500	1.000	22.22	6.300	10.500
2023-032	50	ARC		22	3.545	0.188	5.29	3.000	4.100
2023-032	57	S. EXL 200		61	4.500	1.000	22.22	3.400	5.600
2023-032	57	S. EXL 200		61	4.518	0.213	4.72	3.900	5.200
2023-033	29	VITROS		42	31.900	3.000	9.40	23.900	39.800
2023-033	29	VITROS		42	14.900	0.644	4.32	13.000	16.800
2023-033	36	TOSOH AIA		11	18.630	0.756	4.06	16.400	20.900
2023-033	38	ROCHE E		51	30.986	1.666	5.38	26.000	36.000
2023-033	38	ROCHE E		51	31.900	3.000	9.40	23.900	39.800
2023-033	39	DIMENS.RXL		10	30.460	1.580	5.19	25.700	35.200
2023-033	44	BECK.COUL.		53	31.900	3.000	9.40	23.900	39.800
2023-033	44	BECK.COUL.		53	30.863	1.520	4.92	26.300	35.400
2023-033	50	ARC		22	24.295	1.442	5.94	20.000	28.600
2023-033	57	S. EXL 200		61	30.070	1.463	4.87	25.700	34.500
2023-033	57	S. EXL 200		61	31.900	3.000	9.40	23.900	39.800
2023-034	29	VITROS		42	7.698	0.265	3.45	6.900	8.500

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2023-034	29	VITROS		42	16.200	2.000	12.35	12.100	20.200	
2023-034	36	TOSOH AIA		11	9.982	0.774	7.76	7.700	12.300	
2023-034	38	ROCHE E		51	16.200	2.000	12.35	12.100	20.200	
2023-034	38	ROCHE E		51	15.968	0.821	5.14	13.500	18.400	
2023-034	39	DIMENS.RXL		10	15.430	0.826	5.35	13.000	17.900	
2023-034	44	BECK.COUL.		53	15.800	0.831	5.26	13.300	18.300	
2023-034	44	BECK.COUL.		53	16.200	2.000	12.35	12.100	20.200	
2023-034	50	ARC		22	12.150	0.624	5.14	10.300	14.000	
2023-034	57	S. EXL 200		61	16.200	2.000	12.35	12.100	20.200	
2023-034	57	S. EXL 200		61	15.244	0.734	4.82	13.000	17.400	
069	PROS. SPEC-ANTIG-PSA		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2023-035	29	VITROS		42	23.000	2.000	8.70	17.200	28.700	
2023-035	29	VITROS		42	10.737	0.504	4.69	9.200	12.200	
2023-035	36	TOSOH AIA		11	13.891	0.999	7.19	10.900	16.900	
2023-035	38	ROCHE E		51	22.408	1.190	5.31	18.800	26.000	
2023-035	38	ROCHE E		51	23.000	2.000	8.70	17.200	28.700	
2023-035	39	DIMENS.RXL		10	21.900	1.073	4.90	18.700	25.100	
2023-035	44	BECK.COUL.		53	23.000	2.000	8.70	17.200	28.700	
2023-035	44	BECK.COUL.		53	22.061	1.043	4.73	18.900	25.200	
2023-035	50	ARC		22	17.414	0.702	4.03	15.300	19.500	
2023-035	57	S. EXL 200		61	21.572	1.174	5.44	18.000	25.100	
2023-035	57	S. EXL 200		61	23.000	2.000	8.70	17.200	28.700	
071	VITAMIN B 12									
2023-031	29	VITROS		25	456.000	13.856	3.04	414.000	498.000	
2023-031	38	ROCHE E		30	463.667	48.741	10.51	348.000	580.000	
2023-031	44	BECK.COUL.		29	359.276	30.722	8.55	269.000	449.000	
2023-031	50	ARC		21	443.952	39.808	8.97	333.000	555.000	
2023-031	57	S. EXL 200		19	486.111	22.198	4.57	420.000	553.000	
2023-032	29	VITROS		25	352.560	11.257	3.19	319.000	386.000	

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-032	38	ROCHE E		30	356.067	52.298	14.69	267.000	445.000
2023-032	44	BECK.COUL.		29	285.862	19.527	6.83	227.000	344.000
2023-032	50	ARC		21	335.550	21.268	6.34	272.000	399.000
2023-032	57	S. EXL 200		19	402.842	19.424	4.82	345.000	461.000
071 VITAMIN B 12			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2023-033	29	VITROS		25	784.000	61.544	7.85	599.000	969.000
2023-033	38	ROCHE E		30	1223.345	57.704	4.72	1050.000	1396.000
2023-033	44	BECK.COUL.		29	802.429	53.925	6.72	641.000	964.000
2023-033	50	ARC		21	1089.143	94.440	8.67	817.000	1361.000
2023-033	57	S. EXL 200		19	1110.000	43.843	3.95	978.000	1242.000
2023-034	29	VITROS		25	679.040	34.179	5.03	577.000	782.000
2023-034	38	ROCHE E		30	731.300	44.107	6.03	599.000	864.000
2023-034	44	BECK.COUL.		29	536.931	39.853	7.42	417.000	656.000
2023-034	50	ARC		21	673.333	50.204	7.46	523.000	824.000
2023-034	57	S. EXL 200		19	699.053	34.080	4.88	597.000	801.000
2023-035	29	VITROS		25	777.400	37.220	4.79	666.000	889.000
2023-035	38	ROCHE E		30	955.967	40.443	4.23	835.000	1077.000
2023-035	44	BECK.COUL.		29	667.241	40.782	6.11	545.000	790.000
2023-035	50	ARC		21	862.571	69.989	8.11	653.000	1073.000
2023-035	57	S. EXL 200		19	889.947	36.681	4.12	780.000	1000.000

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
146 GLYCOHEMOGLOBIN									
2023-041	12	COBAS/INT.		29	8.400	0.362	4.31	7.300	9.500
2023-041	14	IMMUNOTUR.		14	8.500	0.321	3.77	7.500	9.500

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-041	22	VITROS		48	8.396	0.171	2.03	7.900	8.900
2023-041	30	DAYTONA		11	9.473	0.529	5.59	7.900	11.100
2023-041	31	IMMUNOTURB		38	8.311	0.291	3.50	7.400	9.200
2023-041	31	IMMUNOTURB		38	8.200	1.000	12.20	6.200	10.200
2023-041	40	SIEMENS DI		80	8.616	0.258	2.99	7.800	9.400
2023-041	40	SIEMENS DI		80	8.200	1.000	12.20	6.200	10.200
2023-041	46	ARCHITECT		19	8.283	0.224	2.71	7.600	9.000
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2023-042	12	COBAS/INT.		29	5.545	0.319	5.75	4.600	6.500
2023-042	14	IMMUNOTUR.		14	5.600	0.405	7.24	4.400	6.800
2023-042	22	VITROS		48	5.364	0.086	1.61	5.100	5.600
2023-042	30	DAYTONA		11	6.145	0.350	5.69	5.100	7.200
2023-042	31	IMMUNOTURB		38	5.600	1.000	17.86	4.200	7.000
2023-042	31	IMMUNOTURB		38	5.228	0.228	4.36	4.500	5.900
2023-042	40	SIEMENS DI		80	5.600	1.000	17.86	4.200	7.000
2023-042	40	SIEMENS DI		80	5.555	0.218	3.92	4.900	6.200
2023-042	46	ARCHITECT		19	5.444	0.164	3.01	5.000	5.900
2023-043	12	COBAS/INT.		29	6.083	0.352	5.79	5.000	7.100
2023-043	14	IMMUNOTUR.		14	6.171	0.353	5.73	5.100	7.200
2023-043	22	VITROS		48	5.911	0.119	2.01	5.600	6.300
2023-043	30	DAYTONA		11	6.509	0.560	8.60	4.900	8.100
2023-043	31	IMMUNOTURB		38	5.786	0.289	4.99	4.900	6.700
2023-043	31	IMMUNOTURB		38	6.200	1.000	16.13	4.600	7.800
2023-043	40	SIEMENS DI		80	6.182	0.248	4.01	5.400	6.900
2023-043	40	SIEMENS DI		80	6.200	1.000	16.13	4.600	7.800
2023-043	46	ARCHITECT		19	5.958	0.221	3.71	5.300	6.600
2023-044	12	COBAS/INT.		29	8.459	0.340	4.02	7.400	9.500
2023-044	14	IMMUNOTUR.		14	8.514	0.372	4.37	7.400	9.600

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2023-044	22	VITROS		48	8.389	0.163	1.94	7.900	8.900
2023-044	30	DAYTONA		11	9.645	0.538	5.58	8.000	11.300
2023-044	31	IMMUNOTURB		38	8.200	1.000	12.20	6.200	10.200
2023-044	31	IMMUNOTURB		38	8.337	0.284	3.41	7.500	9.200
2023-044	40	SIEMENS DI		80	8.200	1.000	12.20	6.200	10.200
2023-044	40	SIEMENS DI		80	8.633	0.274	3.17	7.800	9.500
2023-044	46	ARCHITECT		19	8.232	0.281	3.41	7.400	9.100
146 GLYCOHEMOGLOBIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}					
2023-045	12	COBAS/INT.		29	6.107	0.330	5.40	5.100	7.100
2023-045	14	IMMUNOTUR.		14	6.250	0.304	4.87	5.300	7.200
2023-045	22	VITROS		48	5.911	0.102	1.72	5.600	6.200
2023-045	30	DAYTONA		11	6.800	0.453	6.67	5.400	8.200
2023-045	31	IMMUNOTURB		38	6.200	1.000	16.13	4.600	7.800
2023-045	31	IMMUNOTURB		38	5.870	0.307	5.24	4.900	6.800
2023-045	40	SIEMENS DI		80	6.188	0.244	3.95	5.500	6.900
2023-045	40	SIEMENS DI		80	6.200	1.000	16.13	4.600	7.800
2023-045	46	ARCHITECT		19	5.968	0.236	3.96	5.300	6.700

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
178 Vitamin D				EVALUATION CRITERIA: TARGET VALUE 20 %					
2023-261	3	VITROS		41	42.775	3.889	9.09	34.000	51.000
2023-261	5	ROCHE E		37	36.000	1.581	4.39	29.000	43.000
2023-261	5	ROCHE E		37	44.000	5.013	11.39	35.000	53.000
2023-261	9	BECK.COUL.		49	47.833	3.727	7.79	38.000	57.000
2023-261	11	ARC		19	45.684	2.514	5.50	37.000	55.000
2023-261	25	S. DIME		34	34.265	2.914	8.50	27.000	41.000

Participant Summary

MONTH 2 OF YEAR 2023

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
178 Vitamin D		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	20 %					
2023-262	3	VITROS		41	23.268	3.939	16.93	19.000	28.000
2023-262	5	ROCHE E		37	21.639	3.038	14.04	17.000	26.000
2023-262	5	ROCHE E		37	23.250	1.299	5.59	19.000	28.000
2023-262	9	BECK.COUL.		49	29.020	2.646	9.12	23.000	35.000
2023-262	11	ARC		19	27.579	1.311	4.75	22.000	33.000
2023-262	25	S. DIME		34	22.273	1.763	7.91	18.000	27.000
2023-263	3	VITROS		41	81.650	5.637	6.90	65.000	98.000
2023-263	5	ROCHE E		37	66.250	2.586	3.90	53.000	80.000
2023-263	5	ROCHE E		37	84.027	6.267	7.46	67.000	101.000
2023-263	9	BECK.COUL.		49	78.837	5.366	6.81	63.000	95.000
2023-263	11	ARC		19	74.053	3.300	4.46	59.000	89.000
2023-263	25	S. DIME		34	54.265	3.958	7.29	43.000	65.000
2023-264	3	VITROS		41	32.650	3.953	12.11	26.000	39.000
2023-264	5	ROCHE E		37	26.568	3.226	12.14	21.000	32.000
2023-264	5	ROCHE E		37	29.500	1.500	5.08	24.000	35.000
2023-264	9	BECK.COUL.		49	33.673	2.502	7.43	27.000	40.000
2023-264	11	ARC		19	31.737	1.445	4.55	25.000	38.000
2023-264	25	S. DIME		34	25.727	1.728	6.72	21.000	31.000
2023-265	3	VITROS		41	55.925	3.636	6.50	45.000	67.000
2023-265	5	ROCHE E		37	49.250	1.920	3.90	39.000	59.000
2023-265	5	ROCHE E		37	56.306	5.087	9.03	45.000	68.000
2023-265	9	BECK.COUL.		49	55.776	3.587	6.43	45.000	67.000
2023-265	11	ARC		19	54.526	1.957	3.59	44.000	65.000
2023-265	25	S. DIME		34	42.970	2.492	5.80	34.000	52.000